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Growth is the key characteristic that distinguishes children from adults. Growth of the long 
bones occurs at the growth plates, which are located at the distal ends of the bones, by a 
process called endochondral bone formation. This process is governed by a complex network 
of hormones. The mechanisms by which these hormones affect endochondral bone formation 
in the growth plate are not completely understood. One of the mechanisms could be by 
influencing the activity of locally produced growth factors. In this thesis we focus on the role 
of one of these growth factors, Parathyroid Hormone (PTH) related Peptide (PTHrP) and 
its receptor, the type I PTH/PTHrP receptor (PTHR1). The main objective of this study is to 
further elucidate the mechanisms of action of PTHrP and PTHR1 signalling in chondrocyte 
proliferation and differentiation in the epiphyseal growth plate. 
In the following chapter a short overview will be given about the formation of the growth 
plate and the process of endochondral bone formation. In addition, the involvement in this 
process of transcription factors is described. Subsequently, the regulation of endocrine and 
paracrine factors in endochondral bone formation is discussed, followed by a summary about 
PTHR1 signalling in chondrocytes. Finally, the outline of this thesis will be described. 
The growth plate
In the following section the formation and structure of the growth plate is described (fig. 1). 
During embryogenesis mesenchymal precursor cells reduce in size, become densely packed 
into condensations and differentiate into chondrocytes(1). Chondrocytes located at the ends 
of anlagen will eventually form the cartilage that covers the articular surface of the bone. In 
contrast, the chondrocytes beneath this zone of resting cells progress through a coordinated 
program of proliferation, differentiation, maturation and eventually apoptosis. The cartilage 
matrix is calcified, resorbed, and finally replaced by bone. This process is called endochondral 
bone formation and takes place in the primary ossification centre (fig. 1A). The primary 
ossification centre spreads outwards to the ends of the bone. Around birth, a secondary 
ossification centre is formed in the epiphyseal cartilage at the ends of the bone. The primary 
and secondary ossification centres remain separated by a layer of cartilage, the epiphyseal 
growth plate. Within the growth plate, chondrocyte proliferation, hypertrophy and matrix 
synthesis altogether contribute to longitudinal bone growth. The growth plate can be divided 
into four anatomic zones, the resting, proliferative, transition, and hypertrophic zone, that go 
through unique morphological and biochemical stages during the process of endochondral 
ossification (fig. 1B). 
Resting zone
The resting zone is located at the distal end of the growth plate and is characterized by a high 
ratio of extracellular matrix to cell volume. The resting cells are small, lie as single cells or in 
clusters, and are in a relatively quiescent state. The cells act as committed progenitor cells that 
are responsible for the generation of proliferating chondrocytes. This was shown by removal 
of the growth plate in vivo in rabbits, leaving only the resting zone, resulting in a complete 
regeneration of the growth plate(2). In addition, the same study showed that the resting zone 
directs the alignment of chondrocyte columns parallel to the long axis of the bone. Replacing 
Chapter 1
12
Figure 1. The formation and structure of the growth plate. 
A) During foetal development endochondral bone formation takes place in the primary ossification centre (P). Around birth a secon-
dary ossification centre (S) is formed. During childhood longitudinal bone growth increases and the growth plate decreases in size. 
At the end of puberty growth ceases, due to growth plate fusion. The early development is driven by locally produced growth factors 
(paracrine regulation). Around birth, when the secondary ossification centre is formed, the regulation switches in favour of endocrine 
regulation. B) The growth plate is divided into several zones, which are distinguished by biochemical and morphological differences. 
The resting zone contains stem cell-like chondrocytes. When these chondrocytes start proliferating they enter the proliferative zone. 
At a certain point, the chondrocyte stop proliferating and start to differentiate in the transition zone. They increase further in size 
in the hypertrophic zone. Finally, the fully mature chondrocytes go into apoptosis, leaving a scaffold for bone formation. Figure is 
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of the resting zone ectopically alongside the proliferative zone induced a 90-degree shift in the 
orientation of the nearby proliferating chondrocytes(2). Furthermore, the resting cells probably 
produce a morphogen that inhibits hypertrophy of nearby proliferating cells. In this way the 
resting zone may be partially responsible for the organization of the growth plate into distinct 




Upon an unknown trigger the resting chondrocytes enter into the proliferative zone. The 
proliferating chondrocytes display flattened shapes, divide, and become organized into 
longitudinal columns, a characteristic feature of the growth plate. The number of proliferating 
chondrocytes and thereby the length of the columns contributes to the increase in longitudinal 
bone growth(3). 
Transition zone
After a certain number of cell divisions the chondrocytes stop to divide and start to differentiate 
into pre-hypertrophic chondrocytes, thereby increasing in size. Both late-proliferative and 
pre-hypertrophic chondrocytes belong to the transition zone, also referred to as the pre-
hypertrophic zone. 
Hypertrophic zone
The pre-hypertrophic cells further increase in size to an enlargement of five to ten fold, 
which contributes to the increase of longitudinal bone growth(3). The longitudinal septa of 
cartilage matrix between the columns of hypertrophic chondrocytes eventually become 
calcified. The terminal differentiated chondrocytes go into apoptosis, leaving a scaffold for 
bone formation(4). Together with the invasion of blood vessels from the underlying primary 
spongiosum, osteoclasts enter and resorb the calcified cartilage matrix. At the same time, 
osteoblasts enter into the area and produce new metaphyseal trabecular bone. 
Extracellular matrix 
Within the zones of the growth plate the chondrocytes are embedded in an extracellular matrix, 
consisting predominantly of collagens and proteoglycans as well as other non-collageneous 
proteins, most of which are glycoproteins and phosphoproteins (reviewed in(5)). The primary 
collagen in the growth plate is collagen type 2, which represents 80 to 90% of the total collagen 
content and is predominantly expressed in the proliferative zone. Other collagens present 
in relatively small amounts in the cartilage matrix are collagen type 9, type 10 and type 11. 
Collagen type 9 and type 10 are specifically expressed by pre-hypertrophic and hypertrophic 
chondrocytes, respectively.
The other major cartilage matrix molecules, the proteoglycans, consist of a core protein to 
which glycosaminoglycans (GAG) side chains are attached(5). The GAG group in cartilage 
consists of chondroitin sulphate, dermatan sulphate, heparan sulphate, keratan sulphate, and 
hyaluronic acid. Five specific proteoglycans in cartilage are formed with the combinations 
of the different GAGs: aggrecan, decorin, biglycan, fibromodulin, and collagen type 9. The 
largest proteoglycan in size and most abundant by weight is aggrecan, a proteoglycan that 
possesses over 100 chondroitin sulfate and keratan sulfate chains(6). Together with collagen 
type 2, aggrecan makes up 90% of the organic matrix.
Degradation and remodelling of the cartilage matrix during endochondral bone formation 
is regulated by a group of remodelling enzymes, known as matrix metalloproteinases 
(MMPs) and their inhibitors (TIMPs) (reviewed in(7)). For instance, MMP13, expressed by 
hypertrophic chondrocytes, degrades preferentially collagen type 2(8). Furthermore, knockout 
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models emphasized the important role of MMPs in endochondral bone formation(8-10). 
Transcriptional control of growth plate formation and 
endochondral bone formation 
A complete overview of the transcriptional control of growth plate formation and chondrocyte 
development in the growth plate has recently been reviewed(11). Here, the actions of members 
of the Sox family and the runt related transcription factor (Runx) family on growth plate 
formation and chondrocyte development are discussed in more detail. 
The master transcription factor for chondrocyte development is Sox9, a member of the 
high-mobility-group (HMG)-box DNA-binding domain containing proteins. In the growth 
plate of long bones, Sox9 is expressed by proliferating chondrocytes, but its expression is 
completely shut off in hypertrophic chondrocytes. Its essential role in successive steps of the 
chondrocyte developmental pathway has been emphasized by several approaches in transgenic 
mouse, including gain as well as loss of function studies. These studies demonstrated that 
Sox9 positively regulates chondrocyte proliferation and negatively regulates chondrocyte 
hypertrophy(12-14). Inactivation of Sox9 in limb buds before mesenchymal condensations in 
the mouse embryo results in a complete absence of both cartilage and bone(12). In addition, 
inactivation of Sox9 after mesenchymal condensation in the mouse embryo results in arrest 
of condensed mesenchymal cells(12). In human, heterozygous missense mutations in the Sox9 
gene cause campomelic dysplasia, a rare disorder of skeletal development that results in 
deformities of most of the bones of the body(15). These malformations are comparable in mice 
with a haploinsufficiency of the Sox9 gene(14). Taken together, these data suggest that Sox9 
is the first transcription factor that is essential for chondrocyte development and cartilage 
formation.
Two other members of the Sox family, Sox5 and Sox6, are required for chondrocyte development 
as well. Both transcription factors are co-expressed with Sox9 during chondrogenesis. In 
addition, they are absent in limb buds with Sox9 inactivation, indicating that Sox9 is needed 
for Sox5 and Sox6 expression(12). Furthermore, like the expression of Sox9, the expression of 
Sox5 and Sox6 is excluded from hypertrophic chondrocytes. Although individual Sox5 and 
Sox6 knockout mice are born with mild skeletal abnormalities, double knockouts develop a 
severe, generalized chondrodysplasia, characterized by a virtual absence of cartilage, due to a 
defect in chondrocyte proliferation and impairment of cartilage matrix production(16). These 
data suggest that, similar to Sox9, Sox5 and Sox6 regulate sequential steps of chondrocyte 
development in the growth plate.
Other transcription factors regulating chondrogenesis are members of the family of the 
runt related transcription factors, Runx2 and Runx3. Both factors are expressed by pre-
hypertrophic and hypertrophic chondrocytes(17;18). Beside a transcription factor in chondrocyte 
hypertrophy, Runx2 is the key transcription factor in osteoblast differentiation. Runx2 
knockout mice show a complete arrest in osteoblast differentiation resulting in a total absence 
of skeletal ossification(19;20). Homozygous Runx2 mutants and Runx3 mutants as well, show 
disturbed chondrocyte maturation(17;18). Analysis of Runx2 and Runx3 double knockout mice 
demonstrated a complete lack of pre-hypertrophic and hypertrophic chondrocytes(17). This 
suggests that Runx2 and Runx3 play an essential role in terminal chondrocyte differentiation. 
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Furthermore, they partly compensate each other’s function in chondrogenesis.
Taken together, 2 families of transcription factors are most important in chondrogenesis. The 
Sox family of transcription factors regulates the formation of the growth plate and is involved 
in chondrocyte proliferation, whereas the Runt related family of transcription factors controls 
chondrocyte hypertrophy.
Endocrine regulation of endochondral bone formation
In contrast to foetal bone growth, which is predominantly regulated by locally produced 
growth factors and relatively independent of systemic hormones, postnatal bone growth 
is tightly regulated by systemic hormones (fig 1A), for instance Growth Hormone (GH), 
Insulin-like Growth Factor-1 (IGF-1), glucocorticoid, Thyroid Hormone, estrogen, androgen, 
vitamin D, and leptin (reviewed in(21)). From these hormones, GH is the dominant regulator. 
In addition, estrogen plays a crucial role during puberty. Therefore, the influence of these 
hormones in endochondral bone formation is discussed in more detail. 
Growth hormone and Insulin-like Growth Factor-1
GH is the most essential modulator of longitudinal bone growth after birth, whereas IGF-1 is 
important in the prenatal growth plate as well. Both are potent stimulators of endochondral 
bone formation, as shown by several human knockouts. For instance, GH insensitivity due to 
GH receptor mutations or defects in the GH receptor signalling pathway impairs postnatal 
growth(22-24). Severe postnatal growth retardation and delayed bone development are also 
found in GH knock out mice(25;26).
Homozygous mutations in the human IGF-1 gene or heterozygous mutations in the human 
IGF-1 receptor gene cause impaired growth in both the pre- and postnatal situation(27-29). 
In mice with IGF-1 deficiency, severe pre- and postnatal growth retardation is observed as 
well(30). A more severe phenotype is displayed by IGF-1 receptor knockout mice and these 
mice die early postnatally(30).
Many of GH’s actions on the growth plate are likely to be mediated through IGF-1(31). Systemic 
IGF-1, as well as locally produced IGF-1, contributes to longitudinal bone growth. However, 
locally produced IGF-1 has been argued to be of greater importance in the regulation of 
chondrocyte development than systemic levels of IGF-1(32). The so-called dual effector 
hypothesis states that GH acts locally on the growth plate to recruit resting chondrocytes into a 
proliferative state and thereby inducing the local production of IGF-1, which then stimulates 
proliferation of proliferating chondrocytes(31;33). The induction of IGF-1 after GH stimulation 
is mediated via the activation of signal transducer and activator of transcription 5b (Stat5b). 
Mutations in the Stat5b gene cause GH insensitivity and failure of IGF-1 production(23;24). 
Also other members of the Stat family, as Stat1, Stat3 and Stat5a, play a role in GH actions, but 
cannot compensate for lack of Stat5b (reviewed in(34;35)).
Estrogen
Estrogen is especially important in endochondral bone formation during puberty. The 
identification of an inactivating mutation in the estrogen receptor alpha (ERα) of a male 
patient revealed crucial insight in the role of estrogen during growth(36). This patient lacked 
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a growth spurt and growth plate fusion did not occur at the end of puberty. An almost 
identical phenotype was found in two male patients with a mutation in the gene coding for 
p450 aromatase, which is responsible for the conversion of androgen into estrogen(37;38). It 
is believed that low levels of estrogen initiate the pubertal growth spurt and high levels of 
estrogen causes growth plate fusion at the end of puberty(39). However, the mechanism of 
estrogen acting on growth plate chondrocytes remains largely unknown. 
Thus, GH regulates the expression of IGF-1 in the growth plate. It is likely, that GH also 
controls the expression of other locally produced growth factors, for instance components of 
the growth restraining Indian Hedgehog (IHh)/PTHrP feedback loop (discussed later). Since 
estrogen receptors are expressed in zones of the growth plate that also express components of 
the IHh/PTHrP feedback loop and since it has been shown that estrogen affects the expression 
of PTHrP and its receptor in the rat uterus, it seems possible that the expression of these genes 
may be regulated by estrogen(40;41).
Paracrine regulation of endochondral bone formation
Endochondral bone formation is not only regulated by endocrine factors, but is also controlled 
by locally produced growth factors. It is believed that prenatal growth is predominantly 
regulated by these locally produced growth factors and that it is relatively independent from 
systemic hormones (fig. 1A). Of the paracrine mechanisms, the IHh/PTHrP negative feedback 
loop is best studied. Beside this feedback loop other growth factors, like IGFs (discussed in the 
previous section), Fibroblast Growth Factors (FGFs), Bone Morphogenetic Proteins (BMPs), 
and members of the Wnt-family play important roles in chondrocyte proliferation and 
differentiation. Part of these growth factors interact with the IHh/PTHrP negative feedback 
loop, but can act independently of the feedback loop as well. First, PTHrP and the IHh/PTHrP 
negative feedback loop will be discussed, which will be followed by a short overview of the 
actions of other growth factors.
Parathyroid Hormone related Peptide
PTHrP was originally identified as the causative factor for Humoral Hypercalcemia of 
Malignancy(42). It shares significant homology with the calcium regulating Parathyroid 
Hormone (PTH). PTHrP and PTH act through a common receptor, the type 1 PTH/PTHrP 
receptor (PTHR1). PTHR1 signalling is involved in various phases of embryonic development, 
such as in the formation of the extra-embryonic endoderm of the parietal and visceral yolk 
sac, in skin and mammary duct development, in calcium homeostasis and in formation of the 
skeleton, including osteogenesis and chondrogenesis(43-45).
The crucial role for PTHrP in endochondral bone formation is underlined by a number of 
studies. Four human conditions exist, in which PTHR1 signalling is disturbed. Two arise 
from dominant mutations and two arise from recessive mutations in the PTHR1 gene. 
Dominant mutations have been found in Jansen’s type metaphyseal chondrodysplasia (JMC) 
and in enchondromatosis. Recessive mutations have been described in Eiken syndrome and 
Blomstrand lethal osteochondrodysplasia (BOCD)(46-54). BOCD is a lethal skeletal dysplasia 
and is characterized by skeletal malformations, leading to dwarfism(55-61). Patients with 
JMC and Eiken syndrome are viable and these diseases are also characterized by skeletal 
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malformations resulting in impaired growth(62;63). Ollier disease is one of the best known 
enchondromatosis syndromes and is characterized by multiple enchondromas, which are rare 
benign neoplasms(60;64).
In JMC, four heterozygous mutations have been identified, causing a constitutively 
activated PTHR1, resulting in decelerated chondrocyte differentiation, finally leading 
to dwarfism(47;49;54;65). In addition, a heterozygous mutation has been identified in 2 out of 
6 patients with enchondromatosis in one study(53). The mutation is thought to result in 
upregulation of the IHh/PTHrP pathway. However, in another study with a larger panel of 
patients, no mutations were identified in the PTHR1 gene, indicating that the PTHR1 gene is 
not the main culprit for enchondromatosis(66). 
The homozygous mutation identified in a unique family with Eiken syndrome results in a 
truncated PTHR1, causing abnormal PTHR1 signalling and retarded ossification(48). A similar 
phenotype has been identified in mice with a mutation in the C-terminal part of the PTHR1 
gene, which is responsible for the activation of the phospholipase C beta (PLCβ) / protein 
kinase C (PKC) signalling pathway(67). Finally, BOCD is a lethal skeletal dysplasia, which is 
caused by an inactivating mutation in the PTHR1 gene, resulting in accelerated chondrocyte 
maturation(46;50-52). In comparison with BOCD, striking similarities are found in PTHR1 
knockout mice. These mice die around birth and show accelerated chondrocyte maturation(43). 
A similar, although less severe, phenotype, perhaps because of the effects of maternal PTHrP 
or maternal or foetal PTH, is found in mice with homozygous ablation of the PTHrP gene. 
This also results in accelerated chondrocyte differentiation leading to dwarfism(68). In addition, 
ectopic expression of PTHrP causes a delay of chondrocytes differentiation, leading to a 
smaller cartilaginous skeleton(69). Until today, no humans lacking PTHrP production have 
been identified.
Taken together, these data underline the essential role of PTHrP in chondrocyte proliferation 
and differentiation. An excess of PTHrP, but also a deficiency of PTHrP result in growth 
plate abnormalities. Therefore, PTHrP expression must be tightly controlled. The protein 
regulating PTHrP expressing in the growth plate is IHh, together they form the IHh/PTHrP 
negative feedback loop.
IHh/PTHrP negative feedback loop
The pace of chondrocyte differentiation is regulated by a locally acting growth restraining 
feedback loop (fig. 2), consisting of IHh and PTHrP, which was first described in 1996, by 
studying bone explants of PTHrP and PTHR1 knockout mice(43;70). In the mouse embryonic 
growth plate pre-hypertrophic chondrocytes express IHh. The IHh signal acts on the 
perichondrium adjacent to the transition zone where it binds to its receptor complex, 
consisting of the membrane protein patched 1 (Ptch) and smoothened (Smo), and induces 
the expression of PTHrP in perichondrial cells and in round chondrocytes at the ends of the 
bones(71). PTHrP then binds to its receptor on the late-proliferating and pre-hypertrophic 
chondrocytes, preventing the transition from proliferating into hypertrophic chondrocytes, 
and thereby decreasing IHh expression. Further studies revealed that chondrocytes express 
PTHR1 before differentiating into IHh expressing cell type(70). The differentiation block induced 
by IHh appears to occur upstream of IHh expression, which is precisely the target cell type for 
the IHh/PTHrP negative feedback loop. Taken together, the IHh\PTHrP negative feedback 
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Figure 2. Interactions between growth factors with the IHh/PTHrP negative feedback loop in the embryonic growth plate.









loop controls the transition of proliferating chondrocytes into hypertrophic chondrocytes.
For many years it has been uncertain how IHh signal reaches the region in which it induces 
PTHrP expression. Initially it was thought that secondary factors, like Ext, BMPs or TGFβ, 
mediate the IHh signal. However, recent observations strongly support a model in which 
IHh acts as a long-range morphogen, directly inducing the expression of PTHrP(72). Recently, 
it has been shown that IHh induces PTHrP expression via alleviating the repression of the 
transcription factor Gli3(73).
After the identification of the IHh/PTHrP negative feedback loop, other growth factors, like 
BMPs and FGFs, have been implicated as interactors of this feedback loop (fig. 2). IHh induces 
BMP expression in the perichondrium and in proliferating chondrocytes(74). In addition, 
BMP signalling has been shown to regulate chondrocyte proliferation in parallel to IHh. 
Furthermore, BMPs induce IHh expression in cells that are released from the range of the 
PTHrP signal and BMPs delay the differentiation of terminal hypertrophic chondrocytes(74). 
Another study showed that FGF signalling seems to regulate the same phases of chondrocyte 
development as BMP signalling, however, with opposite effects(75). Therefore, it has been stated 
that BMPs and FGFs act in independent pathways having antagonistic effects on chondrocyte 
proliferation, IHh expression and chondrocyte hypertrophy(74;75). By simultaneously regulating 
proliferation, IHh expression, and terminal differentiation of chondrocytes, the balance of 
FGF and BMP signalling seem to adjust the process of hypertrophic differentiation to the 
proliferation rate. 




Figure 3. The IHh/PTHrP negative feedback loop in the postnatal growth plate. 
For details, see text.
formation the IHh/PTHrP negative feedback loop requires the presence of the perichondrium. 
During later stages, Ptch is expressed in chondrocytes themselves as well. Thus, in these 
stages no intermediate perichondrium is required. This is further emphasized in the postnatal 
growth plate, in which the IHh/PTHrP feedback loop is confined to the growth plate itself 
(fig. 3). Evidence for this hypothesis is found in the rat growth plate, where all members of the 
feedback loop are expressed in the transition zone, as well as in the stem cell zone(76). These 
data suggest the existence of a second PTHrP/IHh feedback loop in the postnatal growth 
plate. Beside the PTHrP/IHh negative feedback loop in the transition zone, another loop may 
be confined to the stem cell zone. It seems feasible that cross talks may occur between the two 
loops.
Indian Hegdehog
IHh is one of the key regulators of endochondral bone formation controlling at least three 
different steps. First, IHh regulates the onset of chondrocyte maturation by controlling 
the expression of PTHrP, which is described above. Second, IHh regulates chondrocyte 
proliferation by inducing proliferation of resting chondrocytes, which is independent from 
PTHrP(71;77). Third, IHh expression is essential for osteoblast development(77). This essential 
stimulatory role of IHh in endochondral bone formation is underscored by abnormalities 
arising from mutation in the mouse and human IHh gene and Gli genes, the downstream 
mediators of the Hh pathway(77-84). For instance, homozygous mutations in the IHh gene 
in mice result in severely reduced chondrocyte proliferation and accelerated chondrocyte 
differentiation(77;85). In addition, no bone collar is formed and no cortical and trabecular bone 








In the growth plate IHh is predominantly produced by pre-hypertrophic and hypertrophic 
chondrocytes. It binds to its receptor, Ptch, which suppresses the activity of Smo in the absence 
of IHh. Upon binding to Ptch, the inhibition on Smo is alleviated, resulting in activation of 
the IHh signalling pathway. Furthermore, IHh signalling is in vertebrates mediated through 
transcription regulation by the zinc-finger transcription factors, Gli1, Gli2 and Gli3. 
Fibroblast Growth Factors
The first functional link between FGF signalling and chondrocyte development was identified 
with the discovery that achondrodysplasia (ACH), the most common form of skeletal 
dwarfism in humans, was caused by a missense mutation in FGF receptor 3 (FGFR3)(86). This 
mutation resulted in constitutively activation of the FGFR3. Following this initial discovery 
hypochondrodysplasia (HCH), a milder form of dwarfism, and thanatophoric dysplasia (TD), 
a more severe form of dwarfism, were also found to result from mutations in FGFR3(87;88). 
Beside the chondrodysplasia syndromes, many other human skeletal dysplasias have been 
attributed to mutations in the three different FGF receptors, FGFR1, 2 and 3(89-91). 
FGFR3 and FGFR1 are expressed by proliferating chondrocytes. Pre-hypertrophic chondrocytes 
express FGFR3 and hypertrophic chondrocytes express FGFR1(92). FGFR1 and FGFR2 are 
both expressed by osteoblasts in the underlying trabeculae(92). Several FGFs are involved in 
chondrocyte differentiation, of which the role of FGF18, expressed in the perichondrium, is 
most clear. The phenotype of FGF18 knockout mice resembles that of FGFR3 knockout mice, 
indicating that FGFR3 acts as a receptor to FGF18 in chondrocyte differentiation(93). 
Two pathways are activated by FGFR signalling, the signal transducer and activator of 
transcription (STAT) pathway and the extracellular signal regulated kinase (ERK) pathway(94;95). 
The strong inhibition of chondrocyte proliferation and to a lesser extent the inhibition of 
chondrocyte differentiation is mediated via Stat1 and probably via other members of the Stat 
family of transcription factors. Activation of Stat1 leads to the upregulation of the cell cycle 
inhibitor p21waf1/cip1, thereby inhibiting chondrocyte proliferation(75;96;97). It has been postulated 
that the balance between ERK and Stat signalling after FGFR activation regulates the effect of 
FGF in chondrogenesis(98). 
Bone Morphogenetic Proteins
The Bone Morphogenetic Proteins are a group of at least 15 proteins and are part of the 
TGFβ superfamily. They were originally identified as inducers of ectopic bone formation(99). 
Nowadays, BMPs are recognized as important regulators of the development of a variety 
of tissues(100). Several BMPs and their receptors are expressed in the perichondrium and by 
chondrocytes in different zones of the growth plate(74;101;102). They regulate several aspects of 
chondrocyte development, like inducing chondrogenesis by promoting cell-cell interactions(103). 
Furthermore, continuous BMP signalling is required for chondrogenesis by maintaining Sox9 
expression(104;105). In addition, they promote chondrocyte proliferation(74;106-108) and terminal 
chondrocyte differentiation(107;109-112). By binding to their cell surface receptors, BMPs activate 




The Wnt-signalling pathway is a complex network of signalling molecules, receptors and 
downstream mediators, which has been described in detail elsewhere(113;114). In short, after 
binding of Wnt to its receptor, Frizzled, and its co-receptor, low-density lipoprotein receptor-
related proteins 5 (LRP5) and LRP6, the β-catenin pathway (canonical pathway) and the calcium 
pathway (non-canonical pathway) are activated. Activation of the canonical pathway leads to 
the release of β-catenin from a complex of proteins, including Adenomatous Polyposis Coli 
(APC), Glycogen Synthase Kinase 3β (GSK3β), and Axin. Stabilized β-catenin translocates to 
the nucleus where it forms a complex with transcription factors of the T-cell factor (TCF) / 
Leukocyte Enhancer Factor (LEF) family to activate transcription of target genes. Signalling 
via the non-canonical pathway results in activation of PLCβ and PKC (discussed later).
Wnt signalling is involved in all stages of chondrocyte development (reviewed in(115)). Activation 
of the canonical pathway prevents the differentiation of progenitor cells into chondrocytes, 
it inhibits chondrocyte proliferation, but it induces the differentiation of progenitor cells 
into osteoblasts(13;116). Furthermore, the canonical pathway is not active in differentiated 
chondrocytes in vitro. Therefore it has been hypothesized that the non-canonical pathway is 
the predominant pathway active during chondrocyte differentiation(115;117). Wnt5a and Wnt5b 
have been shown to control the pace of transition between different growth plate zones 
independently of the IHh/PTHrP negative feedback loop(118). Whether other Wnts influence 
chondrocyte proliferation and differentiation in association with the IHh/PTHrP negative 
feedback loop is unclear.
Neoplastic growth
Chondrocyte proliferation and differentiation in the normal growth plate is tightly regulated 
by several growth factors. Growth disorders, like various chondrodysplasias, are caused by 
disturbed signalling of these growth factors as described in the previous section. In addition, 
altered growth factor signalling is also considered to be the cause in neoplastic growth, like 
in chondrosarcomas and enchondromas. The parallels of growth factor signalling between 
chondrocyte proliferation and differentiation in the normal growth plate and in tumours have 
become obvious by the identification of various growth factors and their signalling pathways in 
normal as well as in neoplastic growth, like PTHrP and FGF and mediators of their signalling 
pathways(119-121). The elucidation of cartilaginous tumorigenesis requires understanding of the 
normal regulation of chondrocyte proliferation and differentiation. Vice versa, investigation 
of cartilaginous tumours could also provide insights into the biology of normal growth plate 
development(122). Since cartilaginous tumorigenesis is not the main subject of this thesis, it 
will not further be discussed.
Species differences
Many animal models are used to study the modulation and modification of endocrine and 
paracrine factors and the actions of these factors in several processes during development. The 
most studied organism in genetic and developmental biology is the drosophila melanogaster, 
for instance the actions of the Hh-, FGF-, TGFβ- and Wnt-signalling have extensively been 


















Figure 4. Schematic representation of the structure of the PTHR1. 
The PTHR1 consists of 593 amino acids and is encoded by 14 exons. S = signal peptide. E1-4 = extra cellular domain. M1-7 transmem-












between the actions of these factors in invertebrate and vertebrate models(127;128). To study the 
role of endocrine and paracrine factors in the regulation of chondrocyte proliferation and 
differentiation in the growth plate, many mouse models for these factors have been developed. 
Among them are mouse models to study the actions of PTHrP in chondrocyte proliferation 
and differentiation as described earlier in this chapter. Whereas in humans at the beginning of 
puberty an obvious growth spurt occurs and at the end of puberty growth plate fusion, mice 
do not clearly demonstrate these sexually maturating phenomena. Rabbits are a useful model 
for studying the actions of endocrine and paracrine factors in chondrocyte proliferation and 
differentiation in the growth plate, because rabbits demonstrate growth plate closure(129;130). 
Practical limitations, however, makes this specie less suitable.
PTHR1 signalling
The main topic of this thesis is the actions of PTHrP in chondrogenesis. Therefore, the 
characteristics of its receptor, the PTHR1, and the most important PTHR1 signalling pathways 
in chondrogenesis will be described in this section. The PTHR1 belongs to a distinct group 
of G protein-coupled receptors termed family B(131). The typical structure of these receptors is 
characterized by a relatively long extracellular N-terminus (approximately 160 amino acids), 
a seven membrane-spanning domain, and an intracellular C-terminus. About 45 amino 
acid residues, which are distributed throughout the transmembrane domains and in the N-
terminal extracellular domain, are conserved in all members of this receptor family, and are 
likely to have important functions in ligand binding, signal transduction, or both. The human 
PTHR1 consists of 593 amino acids, including a signal peptide of 25 amino acids, and is 
encoded by 14 exons (fig. 4)(131). It binds PTH and PTHrP with equal affinity.
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Upon binding of PTHrP or PTH, the receptor can activate adenylate cyclase (AC) through 
Gαs (fig. 5)(132). Subsequently, cyclic adenosine monophospate (cAMP) is produced by AC and 
adenosine triphosphate (ATP). cAMP binds then to the regulatory (R) subunits of the inactive 
protein kinase A (PKA), thereby releasing the catalytic (C) subunits. The free catalytic subunits 
of PKA can phosphorylate serine and threonine residues of transcription factors. 
The PTHR1 can also activate the PLCβ/PKC pathway via Gαq, although this signalling 
response is generally not as sensitive as the AC/PKA pathway (fig. 4). Activated Gαq stimulates 
PLCβ, which in turn cleaves phosphoinositol-4,5-biphosphate (PIP2) into inositol-1,4,5- 
triphosphate (IP3) and diacylglycerol (DAG). Subsequently, IP3 leaves the plasma membrane 
and diffuses rapidly through the cytosol, to release Ca(2+) from the endoplasmatic reticulum 
and DAG activates PKC. 
While the AC/PKA pathway after PTHR1 signalling is the dominant pathway in chondrogenesis, 
cells have a mechanism to redirect the PTHR1 signalling to the PLCβ\PKC pathway. This is 
achieved by direct binding of a scaffold protein, the Na+/H+ exchanger regulatory factor 
(Nherf), to the PTHR1, at least in kidney cells(133;134). Two Nherf proteins have been identified, 
Nherf1 and Nherf2. Binding of Nherf to the PTHR1 switches PTHR1 signalling from Gαs to 
Gαq, through a psd95, discs large protein, ZO1 (PDZ) domain interaction and by binding of 
Nherf through another PDZ domain interaction to PLCβ(133;134). Nherf proteins have also been 
identified to play a role in the regulation of sodium-hydrogen exchange, and phosphate and 
calcium transport in kidney cells(135-137).
Recently, chondrocyte specific knockout mice were generated, carrying a mutation in the 
Gαs(138). These mice displayed a phenotype comparable to the PTHrP knockout mice, like severe 
growth plate defects with shortening of the proliferative zone and accelerated chondrocyte 
differentiation(68). The opposite was found in mice carrying a mutant form of the PTHR1, 
which specifically interrupts signalling via the Gαq and signals normally via the Gαs(67). These 
mice showed an increase in chondrocyte proliferation and a delay in chondrocyte maturation. 
Taken together, this indicates that the two pathways have opposite effects on chondrocyte 
proliferation and differentiation. In addition, these results show that Gαs activation negatively 
regulates chondrocyte differentiation and that the critical signalling pathway of PTHR1 in 
growth plate chondrocytes is the AC/PKA pathway. 
Known targets of PKA after PTHR1 activation are the transcription factors cAMP responsive 
element binding protein (CREB) and AP-1, which is a complex formed through interactions 
between Fos and Jun family members (fig. 5)(132). CREB is rapidly activated via PKA and it 
subsequently activates or inhibits the transcription of PTHrP target genes(132;139-142). One of 
these targets is c-Fos, thereby enhancing the AP-1 signal(132;142). The direct activation of CREB 
and the activation of AP-1 thereafter were established by using dominant negative CREB and 
dominant negative c-Fos(132). Since transgenic mice with a dominant negative CREB display 
a different phenotype compared to PTHrP knockout mice, it is likely that not all the effects 
of PTHR1 signalling in chondrogenesis are mediated via CREB. PTHR1 signalling probably 
results in activation of other transcription factors as well. One of these candidates could be 
the master transcription factor for chondrocyte development, Sox9, which is phosporylated 
by PKA upon PTHR1 activation(143). Since Sox9 stimulates chondrocyte proliferation and 




Figure 5. Schematic representation of the PTHR1 signalling pathway. 
Upon ligand binding Gαs activates AC, which in turn generates cAMP from ATP. cAMP releases the catalytic subunits (C) from inac-
tive PKA. These catalytic subunits stimulate CREB, which is required for the transcription of c-Fos and c-Jun. These proteins form a 
complex, AP-1, which activates the transcription of more PTHrP target genes. PLCβ is activated via Gαq and it cleaves PIP2 into DAG 
and IP3. Subsequently, DAG stimulates PKC and IP3 releases Ca2+ ions from the endoplasmatic reticulum (ER). The combination of 



























Upon PTHrP binding, PTHR1 signalling leads to the induction or suppression of mRNA 
expression of PTHrP target genes, together regulating the biological response to PTHrP. For 
instance, it has been shown that p57, a member of the CIP/KIP family of inhibitors of cyclin-
dependent kinases, is a target gene of PTHrP(144). Knockout studies with p57 null mice and 
studies with mice missing both the PTHrP and the p57 gene indicated that suppression of 
p57 expression is a major mechanism used by PTHrP to maintain chondrocyte proliferation 
and delay chondrocyte differentiation(144;145). In addition, PTHrP inhibits the synthesis of the 
transcription factor Runx2 in chondrocytes(141). Since Runx2 is a stimulator of chondrocyte 
differentiation, the suppression of Runx2 mRNA production by PTHrP probably contributes 
to the delayed differentiation of chondrocytes. 
In vitro studies 
In this study two in vitro models representing endochondral bone formation were used, 
namely the mouse pre-chondrogenic ATDC5 cell line and the mouse mesenchymal KS483 
cell line. ATDC cells are derived from a differentiating culture of the AT805 teratocarcinoma 
cells(146). During monolayer culture the cells reproducibly differentiate into chondrocytes 
in four weeks and they start to produce chondrocyte markers, like collagen type 2, type 9 
and type 10(147). In addition, ATDC5 cells express the PTHR1, however the responsiveness 
during the first week of culture is low. During differentiation the responsiveness to PTHrP 
increases(148). Furthermore, in agreement with in vivo studies PTHrP inhibits hypertrophic 
chondrocyte differentiation(109).
The mesenchymal stem cell line KS483 is a subclone of the KS4 cell line, which is derived 
from mouse calvariae(149). Depending on the right culture conditions, the KS483 cells can 
differentiate into mineralizing osteoblasts, lipid droplets containing adipocytes and into 
chondrocytes depositing a cartilaginous matrix(150). The PTHR1 becomes expressed during 
KS483 osteoblast differentiation. In addition, PTHrP treatment results in inhibition of early 
and late osteoblast differentiation markers, which is in agreement with in vivo studies(151).
Aim and outline of this thesis
The regulation of the development from early chondrocytes into mature chondrocytes has 
not been fully understood yet. For a complete understanding of the complex regulation of 
this process, more information is needed on the actions and interactions of endocrine and 
paracrine regulators. Since PTHrP and its receptor, PTHR1, are key regulators of chondrocyte 
differentiation, we have focused on the actions of PTHR1 signalling during endochondral 
bone formation. Therefore, in this thesis the consequences of disturbed PTHR1 signalling were 
investigated. In addition, to study how PTHrP exert its effect on chondrocyte proliferation 
and differentiation, in vitro models representing endochondral bone formation were used. 
In chapter 2 the underlying causative factors for the heterogeneity in the clinical presentation 
of BOCD is addressed. The aim of chapter 3 was first to investigate whether Nherf1 and 
Nherf2 are expressed during endochondral bone formation, second to elucidate whether 
Nherf1 or Nherf2 overexpression affects chondrocyte and osteoblast differentiation, and 
third whether Nherf1 or Nherf2 overexpression influence the effect of PTHR1 signalling 
in chondrocyte and osteoblasts differentiation. To identify PTHrP early and late response 
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genes in chondrocytes and to recognize interactions with other regulatory factors, we used 
the ATDC5 cell line and performed microarray analysis in chapters 4 and 5. To calculate p-
values and confidence bands in data derived from qPCR analysis, when using many samples, 
we developed the Double Delta Model (DDM), described in Chapter 6. Finally, general 
conclusions and discussions are described in chapter 7.
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Context: The parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor type 
1 (PTHR1) plays a key role in endochondral ossification, which is emphasized by diseases 
resulting from mutations in the PTHR1 gene. Among these diseases is the human variant of 
the PTHR1 knockout mice, Blomstrand osteochondrodysplasia (BOCD).
Objective: BOCD can be divided into two types, depending on the severity of the skeletal 
abnormalities. The molecular basis for this heterogenic presentation is unknown.
Design and patients: We performed mutation analysis in 2 families with type I BOCD and in 
3 families with the less severe form, type II BOCD. The latter include 1 case that has not been 
described before. 
Results: In one of the type I BOCD cases a nonsense mutation (R104X) was found, resulting 
in a truncated PTHR1, while in the second type I BOCD case no receptor mutation was 
identified. A splicing defect (intronM4+27C>T) was demonstrated in one of the type II BOCD 
cases. The use of the aberrant splice site resulted in a truncated protein. Although at low 
levels, the wild type transcript remained present. In the other 2 families with type II BOCD a 
previously identified missense P132L mutation was found. Functional analysis demonstrated 
a near complete inactivation of the PTHR1 with low residual activity.
Conclusions: In combination with data presented in literature, we conclude that type I BOCD 
is caused by a complete inactivation of the PTHR1, whereas low levels of residual activity due 
to a near complete inactivation of the PTHR1 result in the relatively milder presentation of 
type II BOCD.
Introduction
The parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor type 1 (PTHR1) 
is a member of a subclass of the G-protein-coupled receptor family. The typical structure 
of these receptors is characterized by an extracellular N-terminus for ligand binding, a 
seven-transmembrane domain, and an intracellular C-terminus. The intracellular parts of 
the transmembrane domains and the C-terminus are responsible for the activation of the 
two dominant signalling cascades, the adenylate (AC) / protein kinase A (PKA) and the 
phospholipase C beta (PLCβ) / protein kinase C (PKC) pathways. 
Signalling through the PTHR1 plays a key role in calcium and phosphorus homeostasis in 
foetal and adult life(1). Recent studies have demonstrated the essential role of PTHR1 signalling 
in cartilage and bone development in mice. Mice lacking the PTHrP gene die perinatally 
and show accelerated chondrocyte differentiation, leading to dwarfism(2). A more severe bone 
phenotype is caused by loss of the PTHR1 gene. Depending on the genetic background these 
mice die at various embryonic ages(3). 
The essential role for PTHR1 signalling in bone and cartilage development has also been 
shown in human diseases. Mutations in the PTHR1 can be divided into dominant and recessive 
mutations. Dominant mutations are found in Jansen´s metaphyseal chondrodysplasia (JMC) 
and Ollier disease(4;5). Four different heterozygous mutations have been identified in JMC 
patients, causing a constitutively activation of the PTHR1, leading to skeletal malformations 
and dwarfism(4;6-8). In a paper by Hopyan et al. in two out of 6 patients with enchondromatosis 
(Ollier and Maffucci diseases), which are common benign tumours of cartilage and bone, a 
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heterozygous mutation in the PTHR1 gene was identified(5). The mutation is thought to result 
in upregulation of the Indian Hedgehog/PTHrP pathway(5). However, in another study with a 
larger panel of patients, no mutations were identified in the PTHR1 gene, suggesting that the 
PTHR1 gene is not the main culprit for enchondromatosis(9). 
Recessive mutations have been identified in Eiken syndrome and in Blomstrand 
osteochondrodysplasia (BOCD)(10-14). Eiken syndrome, an extremely rare syndrome presently 
reported in only 1 family, is caused by a homozygous nonsense mutation. This mutation 
resulted in a truncated protein, only missing a small part of the C-terminus, possibly 
leading to a disbalance between the activation of the AC/PKA and the PLCβ/PKC signalling 
pathways(10;15). BOCD is a rare autosomal recessive disorder characterized by advanced skeletal 
maturation and premature ossification. In addition, BOCD is also characterized by extra-
skeletal manifestations, like hypoplastic lungs, tooth abnormalities, aortic coarctation, and 
absence of breast development(16;17). The skeletal and extra-skeletal abnormalities resemble 
the defects observed in PTHR1 knockout mice(3;18). It has been proposed, that BOCD presents 
in two forms, type I and type II(16). Type I BOCD is the classical and most severe form, 
characterized by extremely short and malformed bones. Although also lethal, the skeletal 
manifestations in type II BOCD are less severe compared to type I.
The first case of BOCD was described by Blomstrand et al. in 1985(19). Until now, 10 other 
families have been described with the same disorder(16;20-26). In the majority of the cases 
parental consanguinity was noted. Only 2 reports have been published in which the affected 
foetuses were born to non-consanguineous parents(16;23). In three BOCD cases a mutation 
in the PTHR1 gene has been described. Jobert et al. reported in 1998 for the first time an 
inactivating mutation in the PTHR1 gene(13). In the same year a missense mutation in another 
BOCD case was reported(11;12). Thereafter, another study revealed that a frame shift mutation 
in the PTHR1 gene, resulting in a truncated protein, was the cause of BOCD in the case 
described by Den Hollander et al.(14;21). 
In this study, we address the molecular basis for the heterogenic presentation of BOCD by 
performing mutation analysis in 2 type I and 3 type II BOCD cases. 
Materials and Methods
Cases included in this study
Case 1 is a type I BOCD and was the first reported case of BOCD described in detail by 
Blomstrand et al.(19). The female foetus was born after 29 weeks of gestation to consanguineous 
parents. The second case, a female foetus born to consanguineous Caucasian parents at 32 
weeks of gestation, is described in detail elsewhere and is classified as type I BOCD (case 
I in(16)). Case 3, classified as a type II BOCD, is described for the first time in the present 
study (for detailed description see next paragraph). Case 4 is one of the three affected siblings 
born to Asian parents who where first-degree cousins and who had no family history of 
skeletal dysplasia (case II in(16)). The first two foetuses were described in detail before(16). 
Another pregnancy of the same parents resulted in a third affected foetus, showing the same 
characteristics as its sibs. All three foetuses were classified as type II BOCD. In the fifth case 
the foetus was obtained from a terminated pregnancy at 26 weeks of gestation (case III in(16)). 
The Asian parents were non-consanguineous. Post-mortem radiography and osteochondral 
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histopathology classified the skeletal dysplasia as type II BOCD. Parental consent was obtained 
for this study.
Case 3 Clinical report and family history
Case 3 was a male infant whose mother presented with polyhydramnion at 32 weeks. Foetal 
ultrasound at 32 weeks revealed furthermore a relatively large head, a small thorax, lung 
hypoplasia and very short dense tubular bones. Because of the gross polyhydramnion and the 
probable lethal prognosis labour was initiated. At birth the infant did not breathe and died 
within minutes. Birth weight was 1800 gram. The boy showed a short stature (Crown-Rump 
Length (CRL) 28.5 cm), a large head (Head Circumference (HC) 32 cm) and a hypoplastic 
viscerocranium (fig. 1A). The face showed typical abnormalities: severe micrognathia with 
a protruding tongue, a hypoplastic nose, and low-set ears were noted. The infant also had a 
narrow thorax and no nipples. The limbs were symmetrically shortened. Autopsy revealed 
hypoplastic lungs and a pre-ductal aortic coarctation. Abdominal and pelvic organs showed 
no abnormalities. Radiography showed generalised osteosclerosis and advanced skeletal 
maturation, a small viscerocranium, short ribs, ossification of laryngeal cartilage and patella 
(fig. 1A). The tubular bones were short with metaphyseal broadening. Most carpal and 
tarsal bones were ossified. Histology of tubular bones showed a reduction of the resting and 
proliferative zone of the growth plates (fig.1B). The epiphysis showed irregular columnization 
of the hypertrophic chondrocytes. The overall picture resembles the clinical manifestations of 
BOCD. Given the relatively well-developed long bones, a recognizable epiphysis and a normal 
diaphyseal bone marrow space this case was classified as type II BOCD.
The parents both originated from a 250-person village in Turkey, but they deny any 
consanguinity. This foetus was the 7th pregnancy of these parents. Two sons are healthy, one 
child died one week old of unknown cause, one child had been healthy until the age of death 
at 11 months of unknown cause, one earlier pregnancy had ended in the birth of a stillborn 
boy at 28 weeks pregnancy and one pregnancy ended in a spontaneous miscarriage at 12 
weeks. No medical information on these deceased children is available.
Sequence analysis and site-directed mutagenesis
From cases 1 and 2 only tissue blocks embedded in paraffin were present. Sections from 
these blocks were deparaffined and hydrated through graded ethanols. Subsequently, DNA 
was extracted by proteinase K (Invitrogen) digestion and ethanol precipitation. From cases 
3, 4 and 5 genomic DNA was isolated from cultured fibroblasts by sequential proteinase K 
treatment and high salt precipitation.
Primer sets used for the amplification of the coding exons of hPTHR1 were previously 
described(14;27). PCR products were sequence verified using an ABI thermal sequencer (PE 
Applied Biosystems, Foster City, CA, USA).
A mutant PTHR1 receptor cDNA was created by PCR based site directed mutagenesis, using 
the wild type receptor as a template. The mutant construct was sequence verified and cloned 
in the pcDNA3.1 expression vector. Primer sets to check for the expression of wild type and 
mutant PTHR1 transcripts in case 3 are indicated in table 1.
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Cell culture, transient transfection assays and cAMP production
At autopsy of cases 3, 4, and 5 a skin biopsy was taken and dermal fibroblast were cultured 
in αMEM, containing 100 U/ml penicillin (Invitrogen, Breda, The Netherlands), 100 U/
ml streptomycin (Invitrogen), and 10 % fetal calf serum (FCS; Integro BV, Zaandam, The 
Netherlands). Cells were seeded at a density of 15000 cells/cm2 in a 24-wells tissue culture 
plate. After 4 days cells were used for intracellular cAMP determination after a challenge with 
Figure 1. Case 3: phenotypic presentation of type II BOCD. 
A) Left panel: external view of a foetus delivered 32 week after gestation, showing short stature and micromelia.  Right panel: whole 
body radiograph, showing advanced skeletal maturation, a small viscerocranium, short ribs, ossification of laryngeal cartilage and 
patella. The tubular bones are short with metaphyseal broadening. Most carpal and tarsal bones are ossified. B) Histology of a femoral 
head, showing a reduction in size of the epiphysis. High magnification shows a decrease in resting chondrocytes (R) and a near com-
plete absence of column-wise orientated proliferating chondrocytes (P). Note the irregular border between the growth plate and the 












Table 1: Primer sets used for PCR analysis in case 3.
hPTHrP(1-34) or bNle8,18PTH(1-34) (Bachum Holding AG, Bubendorf, Switzerland), using 
an enzymimmunoassay (Amersham, Freiburg, Germany), according to the manufacturers 
protocol, as described before(14). COS-7 cells were cultured in bicarbonate-buffered DMEM, 
containing 7.5 % FCS, 100 U/ml penicillin, and 100 U/ml streptomycin. For transient 
transfection assays, cells were seeded in a 75 cm2-disk. At 80 % confluence, cells were overnight 
transfected with 6 µg of the pcDNA3.1 expression vector (Invitrogen), containing either the 
wild type or mutant human PTHR1 cDNA or no insert (mock) using Fugene-6 (Roche, 
Indianapolis, IN). The following day, cells were trypsinized and seeded at a density of 15000 
cells/cm2 in a 24-wells tissue culture plate. After 2 days cells were used for determination of 
intracellular cAMP as described before(14). 
RT-PCR analysis
Dermal fibroblasts were cultured as described above. Cells were seeded at a density of 15000 
cells/cm2 in a 56 cm2 tissue culture disk. After confluence, total RNA was isolated according 
to the method of Chomczinksy and Sacchi(28). Next, total RNA was reverse transcribed into 
cDNA using random hexamer primers (Amersham, Freiburg, Germany). To correct for 
variations in RNA content and cDNA synthesis between the different samples, cDNAs were 
equalized on the basis of their content of the housekeeping gene beta-2-microglobulin as 
described in detail elsewhere(29). Semi-quantitative PCR was performed for the PTHR1 or for 
various parts of the PTHR1 under the following conditions: cDNA was denatured at 94ºC for 
5 minutes, followed by cycles of 30 s at 94ºC, 30 s at 56ºC, and 30 s at 72ºC, and final extension 
at 72ºC for 10 minutes.
Results
Case 1
Sequence analysis of the coding exons and the flanking exon-intron boundaries of the PTHR1 
gene revealed a homozygous point mutation (338C>T), causing a premature stop codon at 
position 104 (R104X) (fig. 2A). The presence of the mutation was verified by restriction 
fragment length analysis (fig. 2B). DNA corresponding to exon 1 from the foetus was amplified 
by PCR and was, as expected, resistant to KpnI restriction. Due to the substitution a truncated 
protein was formed, only consisting of the signal peptide and the first 79 amino acids. This 
mutant protein lacks all functional domains of the PTHR1, including a large part of the 
extracellular N-terminus, the transmembrane domains and the intracellular C-terminus, and 




Sequence analysis of the PTHR1 gene did not reveal a mutation in the coding exons and 
flanking exon-intron boundaries (data not shown).
Case 3
The dermal fibroblast of the affected foetus showed no cAMP accumulation after a challenge 
with a high dose of PTH or PTHrP (fig. 3A). To establish whether the abnormalities were 
indeed caused by a mutation in the PTHR1, all coding exons and flanking exon-intron 
boundaries of the PTHR1 gene were sequenced. In none of the coding exons a mutation was 
found. However, a homozygous point mutation was identified in the intron between exon M4 
and exon EL2 (intronM4+27C>T) (fig. 3B). This mutation creates a perfect match with the 
consensus sequence of an exon-intron boundary with higher homology than the native splice 
site. RT-PCR analysis of the PTHR1 gene revealed decreased expression and a larger transcript 
in the fibroblasts from the patient compared to control samples (fig. 3C). To test whether or 
not the splicing machinery can still use the native splice site, RT-PCR was performed using 
a reverse primer, spanning the wild type exon M4 and EL2 splice site. This primer can only 
result in amplification of wild type, but not in mutant transcripts. As shown in figure 3D 
still a small amount of wild type PTHR1 mRNA was expressed in fibroblasts of the patient 
compared to control samples, indicating the preferential but not exclusive use of the aberrant 
splice site. The formation of an aberrant splice site and subsequently the extension of exon M4 
resulted in a premature stop codon, thereby creating a truncated protein, lacking the 5th, 6th, 
and 7th transmembrane domains, the intervening intra- and extracellular domains, as well as 
the cytoplasmatic tail (fig. 3E). 
Figure 2. Case 1: premature stopcodon in PTHR1.
A) Comparison of the DNA and amino acid sequences of the wild type (wt) and the mutant (mt) receptors. Sequence analysis of 
PTHR1 gene revealed a 338C>T substitution (capital and bold), resulting in a premature stop codon in the extracellular part of the 
receptor. The position of the mutation is shown in a schematic representation of the structure of the PTHR1. B) Exon E2 was amplified 
and subjected to restriction enzyme analysis. The PCR product of the patient but not of a control was resistant to KpnI restriction.
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Figure 3. Case 3: Introduction of a novel splice site.
A) Dermal fibroblast of the affected foetus and control dermal fibroblasts were treated with a high dose (10-7 M) PTH(1-34) or 
PTHrP(1-34) and cAMP accumulation was measured. In contrast to control, dermal fibroblasts of the affected foetus showed no 
cAMP accumulation. B) A homozygous point mutation was identified 27 bp downstream of exon M4 (intronM4+27C>T), creating 
a new exon-intron boundary with higher homology to the consensus sequence than the wild type splice site. Native and mutated 
exon/intron boundaries are underlined. C) RT-PCR of the PTHR1 using a sense primer (S8) located in exon M4 and an antisense 
primer (AS9) located in the downstream exon EL2 revealed a bigger transcript in case 3 compared to control samples, which is indi-
cative for aberrant splicing. M is marker. D) RT-PCR was performed with a sense primer (S8) specific for exon M4 and an antisense 
primer (AS8) overlapping the wild type exon-exon boundary of exon M4 and EL2. Only in the case of wild type mRNA this primer 
combination results in an amplicon. A small amount of wild type PTHR1 mRNA was expressed in the affected sample compared to 
control samples, indicating the preferential but not exclusive use of the aberrant splice site. E) Comparison of the DNA and amino 
acid sequences of the wild type (wt) and the mutant (mt) receptors. When the alternative splice site is used, the last amino acid of 
exon M4 will be followed by a stop codon. This results in a truncated protein, lacking the transmembrane domains 5, 6 and 7 and the 




Dermal fibroblasts of case 4 showed no cAMP accumulation after a challenge with a high 
dose of PTH or PTHrP (fig. 4A), indicating abrogated PTHR1 signalling. We subsequently 
sequenced the coding exons and flanking exon-intron boundaries of the PTHR1 gene. A 
homozygous point mutation (423C>T) in exon E3 was identified, resulting in a missense 
mutation at position 132 (P132L) (fig. 4B). The presence of the mutation was verified by 
restriction fragment length analysis (fig. 4C). DNA corresponding to exon 3 from the foetus 
was amplified by PCR and was, as expected, resistant to MspI enzymatic activity. The same 
mutation was identified in the two other sibs with BOCD. Functional analysis by transient 
transfections of wild type and mutant receptors in COS-7 cells revealed that the mutant 
receptor could still accumulate cAMP after receptor activation, although to a lesser extent 
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Figure 4. Case 4 and 5: P132L missense mutation.
A) Dermal fibroblast of case 4 and control dermal fibroblasts were treated with a high dose (10-7 M) PTH(1-34) or PTHrP(1-34) 
and cAMP accumulation was measured. Dermal fibroblasts of the affected foetus showed no cAMP accumulation, whereas in control 
fibroblasts cAMP accumulation was induced. B) Comparison of the DNA and amino acid sequences of the wild type (wt) and the 
mutant (mt) receptors. Sequence analysis of PTHR1 gene revealed a homozygous 423C>T substitution (capital and bold), resulting in 
an amino acid change in the extracellular part of the receptor (P132L). The position of the mutation is shown in a schematic represen-
tation of the PTHR1. C) Exon E3 was PCR amplified and subjected to restriction enzyme analysis. The mutation resulted in a loss of 
an MspI restriction site in case 4 and 5. M is marker. D) COS-7 cells were transiently transfected with an expression vector encoding 
wild type PTHR1 (wt), mutant P132L PTHR1 or an empty expression vector (mock). Subsequently, cells were treated with a dose 


























Sequence analysis also revealed the homozygous mutation 423C>T in the PTHR1 gene as 
described for case 4, resulting in a P132L substitution. The presence of the mutation was 
verified by restriction fragment length analysis (fig 4C).
Discussion
In the present study we have performed mutation and functional analysis in 5 cases with 
BOCD. The presence of inactivating mutations in 4 out of 5 cases further confirms the causative 
role of the PTHR in BOCD. In one patient (case 2 in this study) we did not identify a mutation 
in the coding exons and flanking exon-intron boundaries of the PTHR1 gene. Possibly, a 
mutation is present in an intron or in the promoter region, which inhibits the expression 
of the PTHR1 gene. Such a mutation probably also underlies the absence of expression of 
the paternal allele in the case described by Jobert et al.(13). Another explanation could be the 
presence of a mutation in another gene, like PTHrP. Unfortunately, we were unable to test this 
hypothesis, since only a small amount of DNA of poor quality could be isolated from a limited 
number of paraffin blocks.
Including this study, 5 different mutations have been described in the PTHR1 causing 
BOCD(11-14, this study). Each family had its own mutation, with exception of the P132L. This data 
suggests that this conserved proline residue serves as a hotspot for mutations. Hotspots have 
already been described in other chondrodysplasias, like the H223R mutation in the PTHR1 
causing JMC, and the A380G mutation in the FGFR3 causing achondrodysplasia (4;30). Another 
explanation for the relatively high frequency of the P132L mutation could be that the patients 
originate from the same ancestor. Pedigree analysis revealed no indications for this. However, 
since the 3 families with P132L live in the same region of England and originate from the 
same ethnic population, such a founder effect cannot be ruled out.
The topic we addressed was the difference between type I and type II BOCD. Oostra et al. 
postulated that type I BOCD is caused by a completely inactivating mutation in the PTHR1 
gene(16), while the less severe abnormalities in type II BOCD are caused by incomplete 
inactivation of the PTHR1. We present evidence in concordance with this hypothesis. The 
mutations in the type I BOCD cases described in this study and in previous studies are all 
completely inactivating mutations(13;14). In the three families classified by Oostra et al. as 
type II BOCD, the P132L mutation was found(11;12;16, this study). Functional analysis of the P132L 
mutation, after transient transfections in COS-7 cells, revealed residual activity. Also in the 
study of Zhang et al. some residual activity was present with respect to activation of the 
cAMP/PKA pathway, but not to activation of the PLCβ/PKC pathway(12). 
The residual activity of the P132L mutation in COS-7 cells contrasts our observation in dermal 
fibroblasts of case 4, in which no cAMP accumulation was found after stimulation with PTH 
or PTHrP (not shown). This discrepancy is most likely explained by a substantial difference in 
the number of receptors present in dermal fibroblasts and transiently transfected COS-7 cells. 
Only in the presence of high receptor numbers residual activity might become evident. Since 
chondrocytes and osteoblasts express higher levels of PTHR1 mRNA and, therefore, are more 
responsive than dermal fibroblasts, the residual activity of the P132L mutation in vivo may 
only become evident in the developing skeleton, resulting in a milder clinical presentation. 
Chapter 2
48
An alternative explanation is that the milder phenotype in the three type II BOCD cases is 
associated with the same ethnic background. It has been described that the phenotype of 
PTHR1 knock out mice strongly depends on this genetic composition(3). This latter explanation 
seems, however, unlikely, since we have identified in this study a new type II BOCD case of 
distinct ethnic background, caused by a novel mutation (intronM4+27C>T). Like in case 4, 
dermal fibroblasts of this patient did not reveal any responsiveness to PTH or PTHrP, using 
intracellular cAMP accumulation as a read out. However, by sensitive RT-PCR we show that 
the native splice site is also used, although at very low levels. This will result in the presence of 
low levels of wild type mRNAs. Apparently, in dermal fibroblasts, a cell type with low levels of 
PTHR1 transcripts, this expression is too low to result in a measurable functional response. 
In skeletal cells with high levels of mRNA and high responsiveness, low residual activity due 
to native splicing may become evident, resulting in the milder skeletal manifestations. Taken 
together, the relatively milder presentation of BOCD type II, particularly in the skeleton, is 
most likely caused by a partial inactivating mutation of the PTHR1 gene, resulting in low 
amounts of residual activity during endochondral bone formation.
The heterogeneity in clinical manifestations, depending on the kind of mutation, is not 
only shown by differences in skeletal abnormalities, but also by differences in extra-skeletal 
abnormalities. A characteristic of PTHR1 knockout mice is the absence of breast and nipple 
formation(18). This finding is confirmed in a patient with BOCD(17). Also in case 3 reported in 
this study, absence of nipple formation was noted during obduction. However, in one case 
(specimen M684 in the study by Oostra et al.), having the typical skeletal characteristics of 
BOCD, nipple formation is clearly visible (see figure 4 in(20)). We postulate that the presence 
or absence of nipple formation may also depend on the nature of the mutation in the PTHR1, 
affecting skeletal development but not nipple formation. Unfortunately, because of long-term 
preservation (over 100 years in formalin), DNA isolation from this case for sequence analysis 
was not possible to test this hypothesis.
Heterogeneity in clinical manifestations due to the nature of the mutation in the PTHR1 is 
not only shown in BOCD families, but also in JMC families. Two missense mutations at the 
same amino acid position in the PTHR1 (T140P and T140R) have distinct effects on receptor 
activity. Compared to T140P, the T140R substitution resulted in a less severe form of ligand 
dependent activation of the AC/PKA pathway(7). This became clinically evident in a less severe 
presentation of JMC(8). The impact of a mutation on receptor function critically determines 
the clinical presentation.
The mutations in the PTHR1 gene identified in this study and in previous studies are shown in 
table 2. It summarizes the type and position of the mutations identified in 4 disorders, caused 
by defective PTHR1 signalling. They are divided into dominant and recessive disorders. Not 
only the type of the mutation, but also the position of the mutation influences the kind and the 
severity of the disease. The mutations are evenly distributed over the open reading frame. The 
striking differences in clinical presentations caused by distinct mutations further underscores 
the critical role of the PTHR1 in normal endochondral bone formation. Multiple signalling 
pathways are activated by the PTHR1. It seems feasible that distinct mutations affect only 
subsets of these pathways, resulting in differences in signalling properties and hence in clinical 
manifestations. Detailed functional analysis of mutations in the PTHR1 identified in human 
patients may, therefore, provide novel insights in the role of each of these signalling pathways 
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in the biological effects of PTHR1.
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mutation Impact on receptor reference
dominant JMC 696A>G H223R missense constitutively activating (6)
1401T>G I458R missense constitutively activating (4)
1256A>C T410P missense constitutively activating (7)
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report
1122delG V365fsX505 frameshift Inactivating (14)
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Abstract
The PDZ domain containing proteins Na+/H+ exchanger regulatory factor 1 (Nherf1) and 
Nherf2 redirect type 1 Parathyroid Hormone (PTH)/PTH related Peptide (PTHrP) receptor 
(PTHR1) signalling in renal tubuli. Whether Nherf1 and Nherf2 are also expressed during 
endochondral bone formation and whether they play a role in osteoblast and chondrocyte 
differentiation is not known. Furthermore, it is not known whether they modulate PTHR1 
signalling in these cells. 
We showed that Nherf1 and Nherf2 are expressed by growth plate chondrocytes and by 
osteoblasts in the bone collar using in situ hybridization. In addition, overexpression of Nherf1 
and Nherf2 in KS483 mesenchymal progenitor cells resulted in opposite effects on terminal 
osteoblast differentiation. Nherf1 overexpression inhibited, while Nherf2 overexpression 
stimulated matrix mineralization. Cartilage matrix mineralization was increased in the 
Nherf2, but not in the Nherf1 overexpressing cell line. Overexpression of Nherf1 or Nherf2 
had no effect on the production of the early chondrocyte marker, the glycosaminoglycans. 
PTHrP inhibited osteoblastic matrix mineralization and GAG production in chondrocytes. 
Overexpression of Nherf1 or Nherf2 did not change the effect of PTHrP treatment on 
osteoblast and chondrocyte differentiation.
The distinct actions of Nherf1 and Nherf2 are probably due to the recruitment of different 
target molecules, like transcription factors, receptors and signalling molecules.
Introduction
The Na+/H+ exchanger regulatory factor 1 (Nherf1) and Nherf2 form a family of adaptor 
proteins and are characterized by the presence of two tandem psd95, discs large protein, 
ZO1 (PDZ) protein interaction domains. They were first found in the apical membranes of 
renal epithelial cells, where they are involved in regulating the sodium-hydrogen exchange(1). 
Other studies revealed that Nherf proteins also play a role in the regulation of phosphate and 
calcium transport in kidney cells(2;3). Beside interaction with ion channels, Nherf1 and Nherf2 
also cooperate with transcription factors, signalling proteins, structural proteins, and with 
G-protein coupled receptors, including the type 1 Parathyroid Hormone (PTH)/PTH related 
Peptide (PTHrP) receptor (PTHR1)(4;5).
The interactions of Nherf1 and Nherf2 with the PTHR1 are best studied in kidney cells. 
Immunohistochemical analysis suggests that the PTHR1 co-localizes with Nherf1 and Nherf2 
in the tubuli. Binding of PTHR1 to Nherf1 occurs through the PDZ1 domain and binding 
to Nherf2 through the PDZ2 domain(4;6;7). Both adaptor proteins bind, beside to the PTHR1, 
also to the intracellular signalling mediator phospholipase C beta (PLCβ), which results in a 
switch of PTHR1 signalling from the adenylate cyclase (AC)/protein kinase A (PKA) pathway 
to the PLCβ/protein kinase C (PKC) pathway(4;6). It is unclear whether Nherf1 or Nherf2 are 
also expressed in osteoblasts and chondrocytes, the other main targets of PTH and PTHrP 
signalling, and whether they play a comparable role in redirecting PTHR1 signalling in these 
cells.
In chondrocytes and osteoblasts PTHR1 signalling results in the activation of two main 
pathways, the AC/PKA pathway via the Gαs-protein and PLCβ/ PKC pathway via the Gαq-
protein. Activation of the Gαs-protein results in phosphorylation of the plasma membrane 
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bound enzyme AC, which synthesizes cyclic AMP (cAMP) from ATP. Subsequently, cAMP 
exerts its effects by activating the enzyme PKA, which finally leads to the activation of 
cAMP response element binding protein (CREB). In addition, Gαq-protein activates PLCβ, 
which in turn cleaves phosphatidylinositol 4,5-biphosphate (PIP2) to generate two products: 
diacylglycerol (DAG) and inositol 1,4,5-triphosphate 3 (IP3). At this step the signalling pathway 
splits in two branches. First, IP3 leaves the plasma membrane and diffuses rapidly through 
the cytosol, to release Ca(2+) from the endoplasmatic reticulum. Second, DAG activates PKC, 
which in turn activates downstream mediators, resulting in genomic responses. 
Both pathways are essential in the regulation of chondrocyte proliferation and differentiation. 
This can be deduced from comparing the bone phenotypes of transgenic mice. PTHR1 
knockout mice show a severe inhibition of chondrocyte proliferation and premature 
maturation of chondrocytes(8). A similar, but less severe phenotype is observed in PTHrP 
knockout mice(9). Chondrocyte specific knockout mice, carrying a mutation in the Gαs-
protein, leading to disruption of the AC/PKA pathway, displayed a comparable phenotype 
to the growth plate phenotype observed in PTHrP knockout mice(9;10). The opposite was 
found in mice carrying a mutant form of the PTHR1, which specifically interrupts signalling 
via the PLCβ/PKC pathway and signals normally via the AC/PKA pathway(11). These mice 
showed an increase in chondrocyte proliferation and a delay in chondrocyte hypertrophy and 
vascular invasion. These data indicate that the PLCβ/PKC pathway regulates the transition 
from proliferating into hypertrophic chondrocytes. In addition, it suggest that the AC/PKA 
pathway is the dominant pathway after PTHR1 signalling in chondrogenesis and that PLCβ/
PKC signalling opposes the effects of the AC/PKA pathway(11). 
Whether Nherf1 and Nherf2 are involved in directing PTHR1 signalling towards the PLCβ/
PKC pathway in chondrocytes and osteoblasts is unclear. Therefore, in this study we first 
addressed whether Nherf1 and Nherf2 are expressed during endochondral bone formation 
in vivo. In addition, the actions of Nherf1 and Nherf2 overexpression on chondrocyte and 
osteoblast differentiation in vitro were examined. Finally, the influence of Nherf1 and Nherf2 
overexpression on the effect of PTHR1 signalling in vitro was investigated.
Materials and Methods
In situ hybridization
Nherf1 and Nherf2 full-length cDNA were obtained from Image Consortium and they were 
sequence verified. For in situ hybridizations, plasmids were linearized with the appropriate 
restriction enzymes and antisense and sense cRNA probes were generated using T7 or 
Sp6 RNA polymerase, respectively. The probes were labelled and in situ hybridization was 
performed as previously described(12). 
Generation of stable cell lines
Stable cell lines were generated using the Flp-In system (Invitrogen) according to the 
manufacturer’s protocol. In short, first a KS483 Flp-in host cell line was generated by stable 
introduction of a single copy of an Flp-Recombinase target (FRT) site as an integral part of 
an antibiotic resistancy gene in the genome of KS483. One clone, KSfrt 4D3, was selected 
that was comparable to the parental KS483 cells in differentiation characteristics and retained 
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full capacity to differentiate into osteoblasts and chondrocytes. This clone was used for the 
generation of isogenic stable cell lines by transient co-transfection of an FRT-targeting vector 
and an Flp-recombinase expression vector. FRT-targeting vectors were a derivation of the 
pEF5/FRT/V5-DEST vector (Invitrogen), containing either luciferase cDNA as a control or 
full length human Nherf1 or human Nherf2 cDNAs, under the control of the EF1α promoter. 
Due to Flp-mediated recombination at the genomic FRT-site, this targeting vector was 
incorporated in the genome. Simultaneously, a shift in antibiotic resistancy was introduced 
allowing positive selection for integrants in the genomic FRT-site only and negative selection 
for random integrants in one single step. This method allows the generation of isogenic stable 
cell lines after a single transfection by eliminating variability of multiple integrated copies and 
results in consistent long-term stable expression of the transgene(13).
Cell culture
For osteoblast differentiation KS483 cells were seeded at a density of 12000 cells/cm2 as 
described previously(14). Medium was changed every 3 to 4 days. At confluence (from day 4 of 
culture onward), ascorbic acid (50 µg/ml. Merck Inc., NY, USA) and when nodules appeared 
(from day 11 of culture onward) β-glycerol phosphate (5mM, Sigma Chemical Co., St Louis, 
MO, USA) were added. From day 11 the cells were cultured in the absence or presence of 
10-7 M PTHrP (1-34) (Bachem, PA, USA), stained at day 18 for matrix mineralization with 
alizarin and alizarin was subsequently measured as described before(14).
For chondrocyte differentiation KS483 cells were cultured as pellets. For this, 300000 cells were 
seeded in a 96 wells plate (Greiner, Alphen a/d Rijn, The Netherlands) in high glucose DMEM 
(Invitrogen, Breda, The Netherlands), containing 40 µg/ml proline (Sigma, Zwijndrecht, The 
Netherlands), 100 µg/ml pyruvate (Sigma), 50 mg/ml ITS + premix (BD Biosciences, San 
Jose, USA), and 50 µg/ml ascorbic acid and centrifuged for 5 min at 1238 rpm. Medium 
was changed every 3 to 4 days. From day 1 to 14 medium was supplemented with 10-7 M 
dexamethasone (Sigma), and 10 ng/ml TGFβ3 (R&D systems, Minneapolis, USA). From day 
14 to 28 medium was supplemented with 5mM β-glycerol phosphate and 500 ng/ml BMP6 
(kindly provided by dr. S. Vukicevic, University of Zagreb, Croatia). At day 28 pellets were 
used for glycosaminoglycan (GAG) analysis or used for histology.
Glycosaminoglycan assay
After 28 days 3 to 4 pellets were washed with PBS and incubated overnight in 0.1 mM EDTA, 
containing 40 µg/ml proteinase K (Invitrogen) at 56ºC. From each sample 50 µl was used for 
GAG analysis and 10 µl was used for DNA measurements. For GAG analysis, 50 µl sample was 
calibrated against a GAG standard (0,1,2,3, and 5 µg) using the Blyscan sulphated GAG assay 
(Biocolor, Krimpen a/d IJssel, The Netherlands) according to the manufacturers protocol, 
with small modifications. In short, each sample was diluted 1:1 in 0.1 mM EDTA/40 µg/ml 
proteinase K and 500 µl Blyscan dye reagent was added. Next, the samples were mixed for 30 
minutes and centrifuged for 10 minutes at 13000 rpm. Then, pellets were dissolved in 200 µl 
dye dissociation reagent and mixed for 15 minutes. Absorbance was measured at 650 nm. For 





At day 28, two pellets were fixed in 10% formalin for 1 hour and embedded in paraffin. Section 
of 5 µm were deparaffined and hydrated through graded ethanol steps and rinsed with bidest. 
Subsequently, they were incubated in 1% AgNO3 for 30 seconds and rinsed with bidest. Next, 
sections were treated for 3 minutes in 0.01% pyrogallol and rinsed with bidest. Then, they 
were incubated in 5% Nathiosulfate and rinsed with bidest. Sections were counterstained with 
light green and afterwards rinsed three times with bidest. Finally, the sections were air dried 
and embedded in histomount-diluted 1:1 in xylene. 
RNA isolation
Cells were cultured under osteoblastic conditions as described before(14), for 4, 7, 11, 14, 18 
days and RNA was isolated using Trizol LS reagent (Invitrogen) and reverse transcribed into 
cDNA using random hexamer primers (Amersham).
Quantitative PCR
Quantitative PCR (qPCR) was performed using the BioRad iCycler (Biorad, Veenendaal, The 
Netherlands). For each gene a set of primers was designed (table 1), which spanned at least 
1 intron-exon boundary and had an optimal annealing temperature of 60˚C, using Beacon 
designer (United Bioinformatica Inc., Calgary, Canada). cDNA (5 ng) was amplified in triplicate 
using the qPCR core kit for SYBR green 1 (Eurogentec, Maastricht, The Netherlands), under 
the following conditions: cDNA was denatured for 10 minutes at 95˚C, followed by 40 cycles, 
consisting of 15 s at 95˚C, 20 s at 60˚C, and 40 s at 72˚C. From each sample a melting curve 
was generated to test for the absence of primer dimer formation and DNA contamination. 
Each reaction contained 5 µl cDNA (1 ng/µl), 10x reaction buffer, 3 or 4 mM MgCl2 (table 1), 
40 µM dNTP's, 300 nM primer, 0,75 µl SYBR green, and 0,1 µl HotGoldStar polymerase in a 
total volume of 25 µl. Fold changes, adjusted for the expression of β2m, were calculated and 
log transformed using the comparative method(15). Significant changes were calculated using 
the Double Delta Model (DDM) (J. Hoogendam et al., Chapter 6).
Name  F/R Primer     MgCl
β2µ  F CACTGACCGGCCTGTATGC  3 mM
  R GAATTCAGTGTGAGCCAGGATATAGA 
mouse nherf1 F CCAGCGATACCAGTGAGGAGC  3 mM
  R GAGGAGGAGGAGGAGGTAGATGAG 
mouse nherf2 F GCTCTCCTGCTTCTCACTCTGG  3 mM
  R TCGTCCTCCTGTGCCTTGATTC 
human nherf1 F TACAGAAGGAGAACAGTCGTGAAGC 4 mM
  R GCCAGGGAGATGTTGAAGTCTAGG 
human nherf2 F CCGACAAGGACACTGAGGATGG  4 mM
  R CGCTTGTTGACTCGCATGGC 
Table 1: quantitative PCR primer sets.
F: forward primer, R: reverse primer.
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Statistics
Values represent mean ± SEM. Differences were examined by analysis of variance (ANOVA) 
followed by the post-hoc least significant difference test (LSD). Results were considered 
significant at p<0.05.
Results
Nherf1 and Nherf2 mRNA expression during endochondral bone formation 
in vivo
In order to establish whether Nherf1 and Nherf2 mRNAs are expressed by chondrocytes and 
osteoblasts during endochondral bone formation, in situ hybridizations were performed on 
18-days old mouse embryos and on hind paws of 17-days old mouse embryos. Nherf1 (fig. 
1 A-D) and Nherf2 (fig. 1 E-H) showed a similar expression pattern in kidney, vertebrae, as 
well as in metatarsals. The negative controls are shown in figure 1A (Nherf1) and 1E (Nherf2). 
In kidney Nherf1 and Nherf2 mRNAs were expressed in the tubuli, whereas no expression 
was found in the glomeruli (fig. 1B and 1F). Nherf1 and Nherf2 mRNAs were expressed 
by chondrocytes throughout the growth plate and by the osteoblasts in the bone collar (fig. 
1C and 1G). In addition, the chondrocytes in vertebrae showed Nherf1 and Nherf2 mRNA 
expression as well (fig. 1D and 1H). Remarkably, the pre-chondrocytes in the intervertebrae 
region and the pre-osteoblasts in the perichondrium showed no Nherf1 and Nherf2 mRNA 
expression. Taken together, Nherf1 and Nherf2 mRNAs are co-expressed by chondrocytes 
and osteoblasts during endochondral bone formation. 
The effect of Nherf1 and Nherf2 overexpression on chondrocyte and osteoblast 
differentiation in vitro
We subsequently studied Nherf1 and Nherf2 mRNA expression during osteoblast differentiation 
in vitro using KS483 cells. In agreement with the results of the in situ hybridization, we found 
stable Nherf1 (fig. 2A) and Nherf2 (fig. 2B) mRNA expression during KS483 osteoblast 
differentiation. In order to investigate the role of Nherf1 and Nherf2 in osteoblast and 
chondrocyte differentiation, we generated human Nherf1 and Nherf2 overexpressing KS483 
cell lines using the Flp-In system. As a control cell line, cells were stably transfected with the 
luciferase gene. 
The Nherf1 and Nherf2 overexpressing cell lines showed stable overexpression of about 10-
fold of human Nherf1 and human Nherf2 mRNA compared to endogenous (mouse) Nherf1 
and endogenous (mouse) Nherf2 mRNA (fig. 3). In addition, the expression of endogenous 
Nherf1 and Nherf2 mRNA at the end of culture (day 18) was not different from the expression 
at the beginning of culture (day 4) in both overexpressing cell lines, which is comparable to 
Nherf1 and Nherf2 mRNA expression in the control cell line. 
To establish whether Nherf1 and Nherf2 overexpression influences osteoblast differentiation 
of KS483 cells, the cells were cultured in monolayer for 18 days under osteoblastic conditions. 
At the end of culture the mineralized osteoblastic matrix was stained with alizarin red 
(fig. 4A) and alizarin red was quantified (fig. 4B). Nherf2 overexpression stimulated the 





Figure 1: Nherf 1 and Nherf2 mRNA expression in mouse embryo
Nherf1 and Nherf2 mRNA expression were established by performing in situ hybridizations on parasagital sections of 18-days 
old mouse embryos and on hind paws of 17-days old mouse embryos. A) The negative control (sense probe) for Nherf1 and E) 
the control for Nherf2 were not stained. In the kidney B) Nherf1 and F) Nherf2 mRNA were expressed in tubuli (t), but not in 
the glomeruli (g). In the growth plate C) Nherf1 and G) Nherf2 mRNA was expressed throughout the growth plate by resting (r), 
proliferating (pr), and hypertrophic (h) chondrocytes. Both mRNAs were also expressed by osteoblasts in the bone collar (b) but 
not by pre-osteoblasts in the perichondrium (p). In vertebrae D) Nherf1 and H) Nherf2 were expressed throughout the growth 
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Figure 2: Expression Nherf1 and Nherf2 during KS483 osteoblast differentiation
The mRNA expression of Nherf1 and Nherf2 during KS483 osteoblast differentiation was established using qPCR analysis. Both 

































Figure 3: Overexpression of Nherf1 and Nherf2 in KS483 cells
Full length human Nherf1 and human Nherf2 cDNAs were stably transfected in the KS483 cell line. Using qPCR, the mRNA expres-
sions of mouse and human were measured at day 4 and day 18 of osteoblast culture. Mouse mRNAs were continuously expressed 




of the mineralized matrix by Nherf1 overexpressing cell line, in which the mineralization was 
decreased, compared to the control cell line.
To examine whether Nherf1 or Nherf2 overexpression affected chondrocyte differentiation 
as well, cells were cultured as pellets for 4 weeks under chondrogenic conditions. At the end 
of culture the GAG production was measured (fig. 5) and the mineralized cartilage matrix 
was stained with von Kossa (fig. 6). While the production of GAGs in the Nherf1 and Nherf2 
overexpressing cell lines was comparable to the GAG production in the control cell line (fig. 5), 
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Figure 4: The effects of Nherf overexpression and PTHrP treatment on osteoblastic matrix mineralization
Cells were cultured under osteoblastic conditions for 18 days. From day 11-18, cells were treated with a dose range of PTHrP (10-11, 
10-9, 10-7 M). After 18 days the mineralized osteoblastic matrix was stained with alizarin Red (A) and the amount of alizarin Red 
was measured (B). Nherf1 overexpression inhibited, while Nherf2 overexpression stimulated matrix mineralization. In the control 
cell line, PTHrP dose dependently inhibited matrix mineralization. The highest dose completely inhibited mineralization. In ad-
dition, the highest dose of PTHrP also completely inhibited mineralization of the Nherf1 overexpressing cell line, this was, however, 
not significant. Matrix mineralization of the Nherf2 cell line was inhibited, although not completely by 10-7 M PTHrP. *Significant 
p<0.05 compared to untreated cultures.
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mineralization of the cartilage matrix was not similar (fig. 6). Nherf2 induced mineralization 
of the cartilage matrix, whereas the Nherf1 overexpressing cell line, like the control cell line, 
had not produced a mineralized cartilage matrix. 
Thus, Nherf1 and Nherf2 overexpression have distinct effects on terminal chondrocyte and 
osteoblast differentiation of KS483 cells.
The effect of PTHrP treatment in Nherf1 and Nherf2 overexpressing cell 
lines
In order to investigate whether Nherf1 and Nherf2 overexpression changed the biological 
response to PTHrP treatment in osteoblast differentiation, monolayer cultures were treated 
with a dose range of PTHrP from day 11-18. The osteoblastic matrix was stained with alizarin 
red (fig. 4A) and afterwards alizarin red was measured (fig. 4B). PTHrP inhibited the production 
of a mineralized matrix in the control cell line dose dependently. Nherf2 overexpression 
partly reversed this inhibition. Only the highest concentration (10-7 M) inhibited matrix 
mineralization in the Nherf2 overexpressing cell line, whereas all doses of PTHrP inhibited in 
the control cell line. Treatment with the highest dose of PTHrP also inhibited mineralization 






































Figure 5: The effects of Nherf overexpression and PTHrP treatment on GAG production
Cells were cultured as pellets, to stimulate chondrocyte differentiation. Pellets were treated from week 2 to 4 with a dose range of 
PTHrP (10-11, 10-9, 10-7 M). After 4 weeks the GAG production corrected for DNA was determined. The GAG production was 
not affected by Nherf overexpression. In all cell lines PTHrP inhibited dose dependently the GAG production. *Significant p<0.05 




To examine whether Nherf1 and Nherf2 overexpression altered the biological response to 
PTHrP treatment in chondrocyte differentiation, pellets were treated with a dose range 
of PTHrP from week 2-4. After 4 weeks, the GAG production was measured and the 
mineralized cartilage matrix was stained with von Kossa. In all cell lines, PTHrP treatment 
resulted in a dose dependent decrease of GAG production (fig. 5). In the control and Nherf1 
overexpressing cell lines, a dose of 10-9 M PTHrP inhibited GAG production, while in the 
Nherf2 overexpressing cell line a dose of 10-11 M PTHrP already inhibited GAG production. 
Only the Nherf2 overexpressing cell line had produced a mineralized cartilage matrix and the 
highest dose of PTHrP (10-7 M) inhibited the production of mineral (fig. 6).
Thus, overexpression of Nherf1 or Nherf2 had only minor consequences for the biological 
actions of PTHrP.
Control





Figure 6: The effects of Nherf overexpression and PTHrP treatment on cartilage matrix mineralization
Cells were cultured as pellets, to stimulate chondrocyte differentiation. Pellets were treated from week 2 to 4 with a dose range of 
PTHrP (10-11, 10-9, 10-7 M). After 4 weeks the matrix was coloured with von Kossa to stain the mineralized matrix. The control 
and Nherf1 overexpressing cell line had not produced a mineralized cartilage matrix after 4 weeks. Nherf2 overexpression induced 
mineralization of the cartilage matrix. The highest dose of PTHrP inhibited the mineralization.
Discussion
Nherf has first been found in renal tubular cells as a regulator of the Na+/H+ exchanger(1). The 
two isoforms of Nherf, Nherf1 and Nherf2, have not only been associated with the regulation 
of ion channels, but they also bind to other proteins, like transcription factors, signalling 
molecules and receptors, including the PTHR1(4;5). The interactions of the Nherf proteins 
and PTHR1 are best studied in renal tubuli, where they redirect signalling from the AC/PKA 
pathway to the PLCβ/PKC pathway(4). In this study we examined whether Nherf1 and Nherf2 
mRNAs are also expressed by chondrocytes and osteoblasts in vivo. In addition, we investigated 
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the effects of Nherf1 and Nherf2 overexpression on chondrocyte and osteoblast differentiation 
in vitro. Furthermore, we examined whether Nherf1 and Nherf2 overexpression alters the 
biological response to PTHR1 signalling in chondrocyte and osteoblast differentiation.
To address the first question, whether Nherf1 and Nherf2 are expressed during endochondral 
bone formation, we performed in situ hybridizations for Nherf1 and Nherf2 on 18-days 
old mouse embryos and hind paws of 17-days old mouse embryos. We found a widespread 
expression of Nherf mRNAs, including expression in renal tubuli, which is line with other 
studies(16;17). During endochondral bone formation, both Nherf1 and Nherf2 mRNAs were 
expressed by chondrocytes and by osteoblasts in the bone collar. However, no expression 
was found in pre-chondrocytes and pre-osteoblasts, suggesting that Nherf1 and Nherf2 exert 
their actions during later stages of chondrocyte and osteoblast differentiation and have no 
effect on progenitor cells. In line with the in vivo data, we detected Nherf1 and Nherf2 mRNA 
expression during osteoblast differentiation in vitro using KS483 progenitor cells.
The second question we addressed was whether Nherf1 and Nherf2 overexpression altered 
chondrocyte and osteoblast differentiation of KS483 progenitor cells. Generation of Nherf1 
and Nherf2 overexpressing cell lines resulted in stable overexpression of Nherf1 and Nherf2 
mRNA of about 10 fold during culture. No data about overexpression of Nherf1 and Nherf2 
protein have been collected. Since overexpression of Nherf1 and Nherf2 resulted in biological 
responses, it is likely that Nherf1 and Nherf2 protein are overexpressed as well. This needs to 
be confirmed.
Overexpression of Nherf1 and Nherf2 had distinct effects on osteoblast differentiation. 
Overexpression of Nherf2 resulted in an increase in matrix mineralization. Probably, 
Nherf2 overexpression results in the recruitment of signalling mediators, as receptors and 
signalling molecules, involved in mineralization and thereby inducing the mineralization of 
the osteoblastic matrix. Since Nherf2 overexpression induced cartilage matrix mineralization 
as well, this mechanism is perhaps also operational in chondrocyte differentiation. In 
contrast to overexpression of Nherf2, overexpression of Nherf1 inhibited osteoblastic matrix 
mineralization. The negative effect of Nherf1 in bone formation has been demonstrated 
before in Nherf1 knockout mice(17). Some, but not all female Nherf1 knockout mice, showed 
dwarfism and displayed severe osteoporosis and bone fractures. This is presumably a secondary 
effect of the mild hypophosphatemia due to ablation of Nherf1, since Nherf1 regulates the 
phosphate transport by binding to the sodium/phosphate co-transporter type IIa (Npt2a). 
However, our data suggests that the bone phenotype may also be explained partly by direct 
effects on osteoblastic matrix mineralization. The effect of Nherf1 overexpression on cartilage 
matrix mineralization was less clear. However, the control cell line had not yet produced a 
mineralized cartilage matrix after a culture period of 4 weeks as well. 
Distinct functions for Nherf1 and Nherf2 have been reported in the kidney, in the regulation 
of ion channels(17-19). Our results also suggest diverse functions in osteoblast and chondrocyte 
differentiation for Nherf1 and Nherf2. This might be explained by their distinct construction, 
which consists of several functional domains. Therefore, Nherf1 and Nherf2 may have a 
preference for binding to different sets of other PDZ proteins, like receptors, ion channels, 
signalling proteins, transcription factors and cellular structural proteins(2;3;16;20).
The third aim was whether Nherf overexpression alters the biological effect of PTHR1 signalling 
on osteoblast and chondrocyte differentiation. We have shown earlier that the PTHR1 is 
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expressed during KS483 osteoblastic differentiation and that PTHR1 signalling inhibits the 
mineralization of the osteoblastic matrix via various mechanisms(13). Despite overexpression of 
Nherf1 and Nherf2, the highest dose of PTHrP inhibited matrix mineralization. Thus, Nherf1 
and Nherf2 had only minor effects on the biological effects of PTHrP in this cell model.
Remarkably, while the lowest dose of PTHrP already inhibited osteoblastic matrix 
mineralization in the control cell line, only a high dose of PTHrP inhibited osteoblastic 
mineralization in Nherf2 overexpressing cell line. This discrepancy could be a direct effect of 
Nherf2, but we hypothesize that it is an indirect effect, through the presumably larger amount 
of mineralization at the time point of PTHrP treatment compared to the control cell line. For 
complete inhibition of the mineralization of the osteoblastic matrix, PTHrP treatment should 
start earlier during differentiation. Comparable to the control cell line, PTHrP treatment 
completely inhibited osteoblastic matrix mineralization in the Nherf1 overexpressing cell 
line. This inhibition was, however, not significant, because of the already low amount of 
mineralization in the untreated cells.
The effects of PTHrP on chondrocyte proliferation and differentiation in the growth plate 
have been studied extensively(8;21;22). In agreement with these studies, we found an inhibition 
of PTHrP treatment on cartilage matrix mineralization in the Nherf2 overexpressing cell line. 
The effects of PTHrP treatment on cartilage matrix mineralization in the control and Nherf1 
cell lines were less clear, due to the lack of mineralization in these pellets. Nherf1 and Nherf2 
overexpression did not alter the effect of PTHrP treatment on GAG production. PTHrP dose 
dependently inhibited GAG production with only small differences, irrespective of Nherf 
overexpression.
Despite overexpression of Nherf1 or Nherf2 mRNA, overexpression did not result in major 
changes on biological actions of PTHrP. This may be explained by a lack of translation from 
Nherf mRNA into protein. However, it is likely that Nherf2 protein is overexpressed, since the 
Nherf2 overexpressing cell line induced biological responses in osteoblast and chondrocyte 
differentiation. In addition, the Nherf1 overexpressing cell line altered the biological response 
in osteoblast differentiation, indicating that Nherf1 protein is overexpressed as well. Another 
explanation could be the inefficient coupling of Nherf1 and Nherf2 to the PTHR1 in osteoblasts 
and chondrocytes, in contrast to renal kidney cells. In addition, levels of PLCβ could be too 
low to affect the dominant AC/PKA pathway. The measurements of the activation of the AC/
PKA pathway and the PLCβ/PKC pathway are currently underway. 
In summary, we showed that Nherf1 and Nherf2 are expressed during endochondral 
bone formation by chondrocytes and osteoblasts. In addition, our data suggest that Nherf 
predominantly alters the matrix mineralization of KS483 osteoblasts and chondrocytes. 
Finally, in our study Nherf overexpressing did not alter the biological response to PTHR1 
signalling.
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Abstract
We have performed microarray analysis to identify PTHrP target genes in chondrocytes. 
ATDC5 cells were cultured as micromasses to induce chondrocyte differentiation. At day 8 of 
culture the cells had a pre-hypertrophic appearance. This time point was chosen for isolation 
of RNA at 0h, 1h, 2h, and 4h after a challenge with 10-7 M PTHrP. Samples were subjected to 
a cDNA microarray using competition hybridization. 
A list of 12 genes (p< 10-3), of which the expression regulation by PTHrP was confirmed by 
qPCR analysis, was generated. This included 7 upregulated and 5 downregulated genes. Three 
genes were known to be involved in PTHrP regulation and 6 were previously found in growth 
plate chondrocytes. Most of the genes (10 out of 12) were implicated in signal transduction and 
regulation. PTHrP also induced the expression of the upregulated genes in KS483 osteoblasts, 
suggesting involvement in a more generalized response to PTHrP. The vast majority of the 
upregulated genes (6 out of 7) contained CREB and/or AP-1 transcription factor binding 
sites in their promoter regions. Remarkably, a number of PTHrP regulated genes contained 
Stat transcription factor binding sites in their promoters. In transient transfection assays we 
show that PTHrP is able to positively regulate the activity of Stat3- and negatively regulate 
the activity of Stat5-specific promoter-reporter constructs in ATDC5 and UMR106 cells. 
In combination with the expression regulation of genes involved in Jak/Stat signalling, this 
data is suggestive for a previously not recognized interaction between PTHrP and Jak/Stat 
signalling.
Introduction
Longitudinal growth results from chondrocyte proliferation and subsequent differentiation 
in the epiphyseal growth plate, by a process called endochondral ossification. During this 
process resting chondrocytes in the stem cell zone enter the proliferative zone, start dividing 
and arrange in typical columns. These cells are characterized by secreting high amounts 
of collagen II. Subsequently, cells stop proliferating and start to differentiate into pre-
hypertrophic chondrocytes, secreting collagen IX. Pre-hypertrophic cells further increase in 
size and become hypertrophic chondrocytes, which secrete high amounts of collagen X. The 
extracellular matrix becomes calcified and finally, mature chondrocytes undergo apoptosis, 
leaving a scaffold for bone formation. 
Systemic hormones regulate longitudinal growth, partly via direct actions on growth 
plate chondrocytes through their receptors(1-3). The direct and indirect actions of systemic 
hormones on growth plate chondrocytes were recently reviewed by Van der Eerden et al.(4). 
The mechanism of action of the various factors involved in regulating the proliferation and 
differentiation of chondrocytes within the growth plate is still largely unknown. Systemic 
hormones probably interact with locally acting growth factors present in the growth plate, 
such as the Fibroblast Growth Factors (FGFs) or the members of the Indian Hedgehog (IHh)/
Parathyroid Hormone related Peptide (PTHrP) negative feedback loop, which is described to 
control the pace of chondrocyte differentiation(5;6). 
In this study we have focused on the actions of PTHrP on growth plate chondrocytes. PTHrP 
plays a crucial role in controlling the pace of chondrocyte proliferation and differentiation 
in the growth plate, which is recognized by a number of studies. Knockout mice for PTHrP 
Chapter 4
72
show accelerated chondrocyte differentiation leading to dwarfism(7), while ectopic expression 
of PTHrP in chondrocytes inhibited their differentiation leading to a smaller cartilaginous 
skeleton(8). In addition, PTHrP, the expression of which is tightly controlled by IHh(5), regulates 
both the rate and extent of chondrocyte proliferation by directly regulating the cell cycle 
machinery, partly by down regulation of the cyclin-dependent kinase inhibitor p57Kip2(9). 
PTHrP signals through the PTH/PTHrP Receptor 1 (PTHR1), which is predominantly 
expressed in pre-hypertrophic chondrocytes in the transition zone of the growth plate(10). 
Binding of PTHrP to its receptor activates various signal transduction pathways. The 
dominant pathways result in activation of adenylate cyclase/protein kinase A (AC/PKA) and 
phospholipase C/protein kinase C (PLC/PKC)(11). Downstream targets of PTH-signalling 
include the transcription factors cAMP response element-binding protein (CREB) and 
members of the AP-1 family, which are responsible, at least partly, for the genomic response. 
Indeed various PTH response genes have binding sites for these transcription factors in their 
promoters(12;13). Recently, early response genes of Parathyroid Hormone (PTH) in osteoblasts 
were identified by microarray analysis(14).
In this study the chondrogenic ATDC5 cell line was used to identify PTHrP target genes in pre 
hypertrophic-like chondrocytes(15). ATDC5 cells reproducibly differentiate into chondrocytes 
in four weeks in a monolayer culture(16). This cell line is a representative model for studying 
the actions of PTHrP on chondrogenesis. During this process cells become responsive to 
PTHrP and in agreement with in vivo studies PTHrP inhibits hypertrophic chondrocyte 
differentiation(17;18).
We selected this cell line for the identification of early response genes of PTHrP. Using cDNA 
microarray analysis we identified 12 early response genes and confirmed their regulation by 
PTHrP using quantitative PCR in different cell culture models. Bio-informatic and functional 
analysis of a subset of these response genes, using transient transfection assays, revealed a 
previously not recognized level of interaction between PTHrP and Jak/Stat signalling.
Materials and Methods
Cell culture
ATDC5 cells were grown in Dulbecco’s modified Eagle’s medium /F-12 (DMEM/F12) 
(Invitrogen, Breda, The Netherlands) containing 100 U/ml penicillin (Invitrogen), 100 U/
ml streptomycin (Invitrogen), 10% charcoal stripped foetal calf serum (FCS; Integro BV, 
Zaandam, The Netherlands), 10 µg/ml insulin (Sigma Chemical Co., St Louis, MO, USA), 10 
µg/ml bovine transferrin (Roche, Almere, The Netherlands), and 3 x 10-8 M sodium selenite 
(Roche), in a humidified atmosphere of 5% CO2 and 95% O2 at 37ºC. The micromass culture 
technique was modified from Ahrens et al.(19). Trypsinized cells were resuspended in medium 
at a concentration of 2 x 107 cells/ml, and 3 drops of 10 µl of this cell suspension were placed 
in a well of a standard 12 wells culture plate. The cells were allowed to adhere for 2 hours at 
37ºC and 5% CO2, and then 1 ml medium was added to each well. The medium was replaced 
every other day. KS483 mesenchymal progenitor cells were differentiated into osteoblasts as 
described previously(20). UMR106 cells were cultured in DMEM (Invitrogen) containing 100 
U/ml penicillin (Invitrogen), 100 U/ml streptomycin (Invitrogen), 10% FCS (Integro BV).
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cAMP enzymimmunoassay
To establish the responsiveness of ATDC5 cells to PTHrP, intracellular cAMP accumulation 
was measured as previously described(21), using an enzymimmunoassay (Amersham, Freiburg, 
Germany), according to the manufacturers protocol. For this purpose, ATDC5 micromasses 
were challenged with a dose range of PTHrP(1-34) at day 7 and 14 of culture.
RNA isolation and amplification
Medium was refreshed after 7 days and the ATDC5 micromasses were challenged with 10-7 
M PTHrP(1-34) at day 8 of culture (time point 0h) and total RNA was extracted at different 
time points in triplicate by using Trizol LS Reagent (Invitrogen), followed by RNA cleanup 
with RNeasy mini kit (Qiagen, Maryland, USA). RNA concentrations were determined by 
measuring the absorbance at 260 nm. Next, RNA samples were pooled and time point 0h was 
chosen as reference sample. Total RNA (3 µg/reaction) was amplified as described before(22), 
with slight modifications. In short, first strand cDNA was synthesized by adding 500 ng T7-
oligodT primer (5’-TCTAGTCGACGGCCAGTGAATTGTAATACGACTCACTATAGGGC
G(T)21-3’) to 10 µl RNA sample. Samples were incubated for 10 minutes at 70ºC, followed by 
60 minutes at 42ºC in a total volume of 20 µl, containing 5x first strand buffer, 10 mM DTT, 
0.5 mM dNTPs, 2U Rnasin (Promega, Leiden, The Netherlands), and 200U Superscript II RT 
(Invitrogen). Next, second strand cDNA was synthesized for 2 hours at 16ºC in a total volume 
of 150 µl, containing 5x second strand buffer, 0.2 mM dNTP's, 10U DNA Ligase (Invitrogen), 
40U DNA polymerase I (Invitrogen), and 2U Rnase H (Invitrogen). This was followed by 
addition 2 µl T4 polymerase (5 U/µl) (Invitrogen) and incubation for 5 minutes at 16ºC. 
The double-stranded cDNA reaction was stopped and the remaining RNA in the mixture 
was degraded by addition of 7.5 µl of 1 M NaOH, 2 mM EDTA by incubation at 65ºC for 10 
minutes. Samples were purified by phenol/chloroform/isoamylalcohol (25:24:1) extraction. 
The volume of the aqueous phase was increased to 450 µl using H2O. For further purification, 
samples were transferred to a Centricon-100 microconcentrator column (Millipore, 
Amsterdam, The Netherlands) (pre-spinned with 450 µl H2O) and centrifuged for 12 minutes 
at 2500 rpm. After 3 wash steps with 450 µl H2O, cDNA was collected in a total volume of 7 µl 
by inverting the column and by centrifuging for 30 s at 13000 rpm. Subsequently, cDNA was 
transcribed into cRNA using the T7 high yield transcription kit (Epicentre, Madison, USA). 
The cDNA solution was incubated at 42ºC for 3 hours in a total volume of 20 µl, containing 
10x T7 reaction buffer, 7.5 mM ATP, CTP, GTP, and UTP, 10 mM DTT, 2U Rnasin, and 2 
µl Ampliscribe T7 enzyme solution, followed by sample concentration using centricon-100 
microconcentrator columns. This method was based on the original protocol of Van Gelder et 
al.(23). Finally, cRNA concentration was determined by measuring the absorbance at 260 nm.
Probe labelling 
cRNA (1.2 µg) was reverse transcribed with random hexamer primers, and labelled by 
incorporation of cyanine 5-dUTP (Cy5) or cyanine 3-dUTP (Cy3) (NEN, Boston, USA) 
according to the protocols of Ross et al.(24), with slight modifications. In short, cRNA and 
8 µg random primers (Roche) in a total volume of 15 µl was incubated for 10 minutes at 
70ºC. Subsequently, 6 µl 5x first strand buffer, 3 µl 0.1 M DTT, 0.6 µl low-T dNTPs, 3 µl Cy3 
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dUTP (time point 0h) or Cy5-dUTP (other time points), and 1 µl Superscript II RT (200 
U/µl) were added, incubated for 10 minutes at room temperature, followed by incubation at 
42ºC for 90 minutes. After 60 minutes fresh Superscript II RT (1 µl) was added. Next, RNA 
was degraded, by addition of 15 µl 0.1 M NaOH and incubation for 10 minutes at 70ºC, after 
which the solution was neutralized by addition of 15 µl 0.1 M HCl. The labelled samples, 
supplemented with 180 µl 10 mM Tris, 1mM EDTA, pH 8 (TE) and 10 µl mouse Cot-1 DNA 
(10 mg/ml) (Invitrogen), were pooled and purified using a centricon-30 microconcentrator 
column (Millipore) (pre-spinned with 450 µl TE for 8 minutes at 13.000 rpm). PolyA RNA 
(20 µg) (Amersham) and yeast tRNA (20 µg) (Invitrogen) were added to 450 µl TE during 
the second wash step. The purified product was collected, by inverting the column and by 
centrifuging for 1 minutes at 13000 rpm, and finally, resuspended in a total volume of 45 µl 
hybridization solution, containing 7.65 µl 20x SSC and 1.35 µl 10% SDS. 
(Pre-) hybridization
For the hybridization experiments microarrays, on which the NIA 15k mouse cDNA clone 
set(25) was spotted, were purchased from the Leiden Genome Technology Center (LGTC). 
DNA was crosslinked by UV irradiation at 65 mJ/cm2 (Stratalinker mode 1800 UV 
Illuminator, Stratagene). To prevent non-specific hybridization, the slides were incubated 
in 45 µl hybridization solution (400 ng/µl yeast tRNA, 400 ng/µl poly(A) RNA, 400 ng/µl 
herring sperm DNA (Invitrogen), 100 ng/µl mouse Cot1 DNA, 5x Denhardt's solution, 3.2x 
SSC and 0.4% SDS) at 65ºC for 30 minutes. Prior to hybridization, the slides containing the 
pre-hybridization mixture were incubated for 2 minutes at 80ºC to denature the spotted 
DNA. After pre-hybridization, the slides were washed twice in 2x SSC for 5 minutes at room 
temperature and dehydrated with subsequent steps of 5 x 5 minutes 70%, 5 minutes 90% 
and 5 minutes 100% ethanol. For hybridization, the probes were denatured by heating for 2 
minutes at 100ºC, left at room temperature for 15 minutes, centrifuged for 10 minutes, and 
placed under a 24 mm x 60 mm glass coverslip. The slides were incubated overnight at 65ºC in 
a hybridization chamber (Corning, Amsterdam, The Netherlands) and washed the next day in 
2x SSC for 5 minutes at room temperature and dehydrated using graded ethanols.
Microarray design and statistical analysis
The reference array experiments, 0h vs 0h, were hybridized in duplicate, 1h vs 0h and 2h vs 0h 
in triplicate, and 4h vs 0h in quadruplicate. Following hybridization, slides were scanned in 
the Agilent DNA Microarray scanner (Agilent Technologies, Amstelveen, The Netherlands). 
Genepix 3.0 software (Axon Instruments Inc.) was used to quantify the resulting images. 
Subsequently, normalization and gene expression analysis were performed with Rosetta 
Resolver (Rosetta Biosoftware). Due to the overall poor quality of the cDNA spots on the 
microarray, stringent selection criteria were used for inclusion of spots, to minimize the risk 
of false positive signals. A spot was only included if the spot settles the selection criteria in 
all time points. Spots showing an absolute fold change of 2 or spots showing significantly 
regulation (p<0.01) in the reference array, and flagged spots in all arrays were excluded from 
analysis. For further analysis, spots were selected from the remaining list if the signal intensity 
of Cy3 or Cy5 was above a cut off level (0.05), and the absolute fold change was under 50. 
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Analysis of variance (ANOVA) was performed between the remaining spots of the 4 different 
hybridizations. Spots showing significant (p<0.001) differential expression regulation, with 
intensity value above background value, and with a fold change >1.8, for upregulated genes, 
and <0.55, for downregulated genes, were selected for further analysis. To identify the selected 
spots, the PCR-amplified cDNA of each spot (500 ng) was sequenced by the LGTC using 12 
pmol M13 primers in a total volume of 24 µl.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
RNA was isolated from ATDC5 micromasses, cultured for 7 and 14 days, using Trizol LS 
Reagent (Invitrogen), and reverse transcribed into cDNA, using random hexamer primers 
(Amersham). Semiquantitative PCR was performed for beta-2 microglobulin (β2m), collagen 
II, collagen IX, collagen X, and PTHR1 under the following conditions: cDNA was denatured 
at 94ºC for 5 minutes, followed by cycles of 30 s at 94ºC, 30 s at 56ºC, and 30 s at 72ºC, and 
final extension at 72ºC for 10 minutes (table 1). 
Name  F/R Primer     cycli
β2µ  F TGACCGGCTTGTATGCTATC  25
  R CAGTGTGAGCCAGGATATAG 
PTHR1  F TGCTTGCCACTAAGCTTCG  30
  R TCCTAATCTCTGCCTGCACC 
Collagen II F GCCAAGACCTGAAACTCTGG  27
  R GCGATGCTGTTCTTACAGTGG 
Collagen IX F CTGTGTGTGCAGTTGTCTGG  27
  R CCAGTGCTTTTCAAGTGTGC 
Collagen X F GCCTCGAGCCCAAAAGGCGTCTCATATTT 35
  R GGCTCGAGCCCAGGAGCAGTGGATAATG 
Table 1 : RT-PCR primer sets
F: forward primer, R: reverse primer
RNA isolation from KS483 osteoblasts
After 11 day of culture, KS483 cells have formed bone nodules and the cells within the 
nodules start to mineralize the extracellular matrix. This time point was chosen to stimulate 
the cells with 10-7 M PTHrP(1-34). RNA was isolated after 1, 3, and 6 hours using Trizol 
LS Reagent (Invitrogen) and reverse transcribed into cDNA using random hexamer primers 
(Amersham).
Quantitative PCR (qPCR)
To validate the expression patterns of PTHrP target genes, quantitative PCR was performed 
using the BioRad iCycler (Biorad, Veenendaal, The Netherlands). For each gene a set of 
primers was designed (table 2), which spanned at least 1 intron-exon boundary and had an 
optimal annealing temperature of 60˚C, using the Applied Biosystems software program 
Primer Express. cDNA (5 ng) was amplified in triplicate using the qPCR core kit for SYBR 
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green 1 (Eurogentec, Maastricht, The Netherlands), under the following conditions: cDNA 
was denatured for 10 minutes at 95˚C, followed by 40 cycles, consisting of 30 s at 95˚C, 20 
s at 60˚C, and 40 s at 72˚C. From each sample a melting curve was generated to test for the 
absence of primer dimer formation and DNA contamination. Each reaction contained 5 µl 
cDNA (1 ng/µl), 10x reaction buffer, 3 or 4 mM MgCl2 (table 2), 40 µM dNTP's, 300 nM 
primer, 0.75 µl SYBR green, and 0.1 µl HotGoldStar polymerase in a total volume of 25 µl. 
Fold changes, adjusted for the expression of β2m, were calculated and log transformed using 
the comparative method(26).
Name F/R Forward primer    MgCl
β2µ F CACTGACCGGCCTGTATGC  3 mM
 R GAATTCAGTGTGAGCCAGGATATAGA 
RGS2 F GGAAGCCCAAAACTGGCAA  3 mM
 R CTGCCCAGAGCTGCGCT 
SGK F CTCCTCCGCCAAGTCCCT   3 mM
 R TGCCTAGCCAGAAGAACCTTTC 
Ptp4a1 F CCTTGGCAGAGCTCCGGT  3 mM
 R GGAGCCGCATTTTCGGAC 
Upar F CAATGGTGGCCCAGTTCTG  3 mM
 R TCCCAGCACATCTAAGCCTGT 
IER3 F CTCTACCCTCGAGTGGTCCG  4 mM 
 R CTCAGGTGTCACGGCGC 
Stat3 F AGCCCCGGAGACAGTCGA  3 mM
 R AAACACCAACGTGGCATGTG 
Csrp2 F CCACTCGGAATGCCTGTCTG  3 mM
 R GCCACTGTTGTGCTGTCTAAATTTT 
Sf3a2 F CATCAGACTAACTTGGCCCGG  3 mM
 R TCTCAGGGTAGTCAATCTGGAACAG 
Acvr2b F GACGGGCCTGTCGATGAGTA  3 mM
 R TCATGGTCCCAGCACTCCTC 
Gab1 F GACAGAAAAGTCAAGCCGGC  3 mM
 R GGACATGGGAAACCTAGAGGAGT 
LamRI F CAACAACAAGGGAGCTCACTCA  4 mM
 R TCTCAATCTCCTCTGGGTCTCTG 
Dym F AAAGTCCCCCGGCAGCTA  3 mM
 R TGGGCCTTGCATCAGGTACT 
Arpc4 F CGCGATGACTGCCACTCTC  3 mM
 R CAATTTCATCGGCCTGCTTC 
Aurkb F GGACTGCCACGATCATGGA  4 mM
 R CGCACATGGTCTTCCTCCTC 
Uchl5 F TTTTTGCCAAGCAGGTAATTAATAATG 4 mM
 R GCCCCTTCATAGCTGCATCA 
Akr1b8 F CACCTGGAAGTCTCCCCCA  3 mM
 R AATGAAGAGGTCCTCCCGCT 
Table 2 : qPCR primer sets.
F: forward primer, R: reverse primer
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Identification of transcription factor binding sites
To find evolutionary conserved transcription factor binding sites in promoters of target 
genes, sequences surrounding the transcription start site, from –1000 bp to +100 bp, were 
extracted from the NCBI database and were aligned to either the human or rat genome 
using the evolutionary conserved regions (ECR) browser(27). rVista 2.0 was used to predict 
conserved regulatory elements and define transcription factor binding sites, with similarity 
predefined as 0.85 (complete match has a value of 1)(28). Consensus binding sequences, which 
were predicted in 4 or more promoters, were selected. 
Transient transfection
ATDC5 cells were seeded at a density of 10000 cells/cm2 and UMR106 cells were seeded at a 
density of 30000 cells/cm2 in a 24-wells plate. The cells were kept in a humidified atmosphere of 
5% CO2 and 95% O2 at 37ºC. The second day the cells were transiently co-transfected with 1 µg 
of the reporter construct and with either 100 ng HA-Stat3 expression vector (kindly provided 
by T. Hirano, Department of Molecular Oncology, Osaka university, Japan(29)), 100 ng Stat5a, 
100 ng Stat5b expression vector (kindly provided by Warren J. Leonard, National Institutes of 
Health, Bethesda, Maryland, USA(30)) or 100 ng pcDNA3.1 expression construct using Fugene 
6 transfection reagent (Roche, Basel, Switzerland), according to the manufacturers protocol. 
The following reporter constructs were used: a Stat3 specific reporter promoter construct 
(kindly provided by Dr. I. Touw, Erasmus Medical Center, Rotterdam, The Netherlands(31)), 
and a Stat5 specific reporter promoter construct (kindly provided by Peter Storz, University 
of Stuttgart, Stuttgart, Germany(32)). To correct for transfection efficiency, 25 ng CMV renilla 
was included in all transfection experiments. The next morning the medium was changed and 
at the end of the day cells were treated with a dose range of PTHrP(1-34) (10-9, 10-8 and 10-7 
M). After 20 hours luciferase assays were performed using the Dual-Luciferase Reporter assay 
system (Promega) according to the manufacturers protocol. Luciferase activity was measured 
using the Wallac 1450 Microbeta Trilux luminescence counter (Perkin-Elmer, Boston, MA, 
USA). Firefly luciferase activity was corrected for renilla luciferase activity.
Statistics
Values represent mean ± SEM. Differences were examined by analysis of variance (ANOVA) 
followed by the post-hoc least significant difference test (LSD). Results were considered 
significant at p<0.05.
Results
Characterization of ATDC5 micromass cultures
To induce chondrocyte differentiation, ATDC5 cells were cultured as micromasses. Already 
after 7 days a homogeneous cell pellet was formed, containing an alcian blue positive cartilage 
matrix. Both the size of the micromasses and the intensity of the alcian blue staining increased 
further after 14 days of culture (fig. 1A). Histological analysis at 7 days showed rounded 
chondrocytes embedded in an alcian blue positive extracellular matrix (fig.1B). RNA was 
isolated and used for PCR analysis to study the expression of typical cartilage markers (fig. 
1C). Collagen II was expressed at 7 days and tended to decline at 14 days. Markers for pre-
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hypertrophic (collagen IX) and for hypertrophic chondrocytes (collagen X) were present at 
7 days and were increased at 14 days. PTHR1 mRNA did not change in the differentiation 
process (fig. 1C), but the responsiveness of the ATDC5 cells to PTHrP increased with 
differentiation (fig. 2).
Taken together, culturing the ATDC5 cells as micromasses efficiently induced chondrocyte 
differentiation. After 1 week of culture, the cells responded to PTHrP and expressed markers 
of pre-hypertrophic chondrocytes, which are the main target cells for PTHrP in the growth 
plate. For this reason, this time point was chosen for identification of PTHrP target genes.




Figure 1: Phenotypic characterization of ATDC5 micromass cultures.
(A) ATDC5 micromass cultures were cultured for 7 and 14 days and stained for alcian blue. (B) Section of an ATDC5 micromass, 
cultured for 9 days, and stained for alcian blue (C) Expression pattern of coll II, coll IX, coll X, PTHR1, and β2µ mRNAs at day 7 and 
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Identification and selection of PTHrP target genes
ATDC5 cells were cultured as micromasses and stimulated at day 8 with 10-7 M PTHrP for 
1, 2, and 4 hours and cDNA microarray analysis was performed. After applying stringent 
selection criteria, 7843 out of the 15442 spots were taken in the analysis. A list of 31 spots, 
which exhibited significant (p<0.001) differential expression after 1, 2 or 4 hours following 
PTHrP stimulation, was generated. Sequence analysis revealed that 3 genes were present 
in two different spots and 1 gene in 3 spots. The expression patterns for the duplicate and 
triplicate spots were identical. This reduces the number of response genes to 26 (table 3). From 
this list 16 genes were chosen for validation experiments in ATDC5 cells. Exclusion criteria 
were insufficient information on gene identity, for example ESTs, and insufficient information 
for the design of qPCR primer sets, which span intron-exon boundaries. 
The expression patterns of the selected genes were first validated by studying expression 
profiles using qPCR on the same RNA samples subjected to microarray analysis (fig. 3B, D, 
and F). As internal standard β2µ, which was not regulated by PTHrP in microarray analysis 
(data not shown), was used. Four out of 16 genes could not be validated and were discarded 
from further study, leaving 12 genes for more detailed analysis (table 4). In qPCR experiments 
RGS2, Stat3, Csrp2, Upar, and IER3 showed the same expression profile compared to the data 
from microarray analysis (fig. 3B and D). The expression pattern of early upregulated target 
genes SGK and Ptp4a1 were slightly different. SGK was only upregulated after 1 hour and 
Ptp4a1 after 2 and 4 hours, instead of continuously up regulation of both target genes revealed 
by microarray analysis. The downregulated target genes, Sf3a2, Acvr2b, Gab1, LamRI, and 
DYM showed in the qPCR data down regulation at all time points, instead of transient down-
regulation at 1 hour after PTHrP stimulation found by microarray analysis (fig. 3F). The 
expression patterns were confirmed in RNA samples from ATDC5 cells isolated in a new 























Figure 2: Responsiveness of ATDC5 cells to PTHrP during differentiation.
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0h 1h 2h 4h
0h 1h 2h 4h
0h 1h 2h 4h
Figure 3: expression profiles of PTHrP target genes in ATDC5 chondrocytes revealed by microarray analysis and qPCR analy-
sis.
RNA was isolated from ATDC5 micromass cultures at 0h, 1h, 2h and 4h after PTHrP stimulation, amplified and labelled as described. 
Samples were hybridized against 0h. Based on the expression profiles revealed by microarray analysis, the genes were divided over 
3 clusters. (A) Cluster 1 contained 5 immediate early upregulated genes, i.e. RGS2, SGK, Ptp4a1, UPAR, and IER3. The expression 
pattern revealed by qPCR is shown in (B). (C) Cluster 2 contained 2 immediate early upregulated genes, i.e. STAT3 and Csrp2. The 
expression pattern revealed by qPCR is shown in (D). (E) Cluster 3 contained 5 immediate downregulated genes, i.e. Sf3a2, Acvr2b, 
Gab1, LamRI, and DYM. The expression pattern revealed by qPCR is shown in (F).
RGS2 SGK Ptp4a1 Upar IER3
Stat3 Csrp2

















































Validation of PTHrP target genes by qPCR
Among these 12 identified PTHrP target genes (table 3) 7 genes were upregulated and 5 
genes were downregulated. Most of the genes were implicated in signal transduction and 
regulation and were intracellular mediators or receptors. Three genes were already known 
target genes of PTHrP in osteoblasts and 6 genes have previously been found in growth plate 
chondrocytes. Based on the expression patterns, the genes were divided into 3 groups, 2 
groups for upregulated genes and 1 group for downregulated genes (fig. 3A, C, and E). Genes 
in expression pattern 1 were upregulated after 1 hour and genes in expression pattern 2 were 
upregulated after 2 and 4 hours. The genes in expression pattern 3 were downregulated after 
1 hour. Expression pattern 1 contained RGS2, SGK, Upar, IER3, and Ptp4a1; Stat3 and Csrp2 
formed expression pattern 2; and expression pattern 3 contained Sf3a2, Gab1, DYM, LamRI 
and Acvr2b. 
To test whether the response of these target genes was restricted to chondrocytes or whether 
it was part of a more generalised response to PTHrP, the expression patterns were analysed in 
differentiated KS483 osteoblasts using qPCR (fig. 4). For this purpose, RNA was isolated after 
0, 1, 3, and 6 hours after a challenge with PTHrP. The expression patterns of all upregulated 
genes were comparable with the expression patterns found in chondrocytes. The expression 
patterns of the downregulated genes in KS483 osteoblasts were less clear. All genes responded 
to PTHrP. Only Gab1 was downregulated, although this regulation was transiently instead 
of continuously as in ATDC5 cells. Remarkably, Sf3a2 and Dym were upregulated instead of 
downregulated. No consistent pattern of regulation was found for Acvr2b and LamRI.
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Transcription factor binding sites
We subsequently analyzed promoter regions (sequences from -1000 bp to + 100 bp from 
the transcription start site) of target genes to identify common regulatory elements involved 
in their expression regulation. To decrease the number of false positive results, we searched 
for transcription factor binding sites that were conserved in human and rat genomes. The 
promoter regions of RGS2, SGK, Ptp4a1, Stat3, Acvr2b, Gab1, and LamRI were aligned to 
the human genome and the promoter regions of IER3, Upar and Csrp2 to the rat genome. 
Insufficient information was available in the database to align the promoter regions of Sf3a2 
and Dym with the human and the rat genomes, preventing the selection of evolutionary 
conserved binding elements in these genes. Table 5 shows transcription factors of which 
binding sequences have been found in 4 or more promoters of the identified PTHrP target 
genes.
ATF/CREB binding sites were predicted in the promoter regions of 6 out of 7 upregulated 
genes, 4 times in combination with an AP-1 binding site. ATF/CREB binding sites were 
also predicted in 2 downregulated genes, but never in combination with an AP-1 binding 
site. Remarkably, 1 of these genes was Dym, which was upregulated in KS483 osteoblasts. 
Another interesting finding was the identification of Stat transcription factor binding sites, 
predominantly in the promoter regions of upregulated PTHrP target genes. Binding sites for 
the transcription factor ELK1, which is, like ATF/CREB, AP-1, and Stat, involved in immediate 
early responses, were predicted in 7 promoter regions. Binding sites for transcription factor 
E2F and SP1, both of which are facilitating factors involved in gene transcription, were 
distributed over up and downregulated target genes and were predicted in 10 out of 12 and 6 
out of 12 promoter regions, respectively.
0 1 3 6
Figure 4: Expression patterns of PTHrP target genes in KS483 osteoblasts.
The genes were grouped according to expression profiles revealed by microarray analysis in chondrocytes as described in fig. 3. RNA 
was isolated from KS483 osteoblasts, stimulated with PTHrP at day 11, after 0h, 1h, 3h and 6h and qPCR was performed. The expres-
sion of the genes in expression pattern 1 in chondrocytes (A), in expression pattern 2 in chondrocytes (B), and in expression pattern 
3 in chondrocytes (C) were determined by qPCR.

















Reg.1 Name ATF/ AP1 E2F2 SP12 ELK12 Stat12 Stat32 Stat62
  CREB2
up RGS2 X X    X  X
up SGK X X X  X X X X
up Ptp4a1 X(3) X X(2)     
up Upar X X  X  X  
up IER3   X(2) X(2) X(2) X X X(2)
up Stat3 X(2)  X X(2) X(2) X X 
up Csrp2 X  X(4) X X(2)  X(3) X(2)
down Sf3a2   X(3) X X(2) X(2) X 
down Acvr2b   X(2) X(4)    
down Gab1   X     
down LamRI X  X  X   
down Dym X(2)  X(4)  X(2) X(2) X 
Table 5: Transcription factor binding sites.
Conserved transcription factor binding sites predicted 4 times or more in the promoter regions of the PTHrP target genes. X: 
transcription factor binding site is present in promoter region. 1) Reg.: Regulation  2) In case more than 1 site is present in the 
promoter regions the number of hits is indicated between brackets.
Stat regulation by PTHrP
In order to investigate the biological significance of the interactions between PTHrP and Stat 
signalling, transient transfection experiments were performed. In contrast to undifferentiated 
cells, differentiated ATDC5 (and KS483) cells could not be transfected. Since undifferentiated 
ATDC5 cells express very low amounts of the PTHR1, experiments were also performed in 
UMR106 cells, which can easily be tranfected and have higher PTHR1 expression levels. 
In line with the upregulation of Stat3 mRNA revealed by microarray analysis, PTHrP induced 
activity of a Stat3 reporter in both cell types dose dependently with a maximal fold induction 
of 1.4 in ATDC5 cells (fig. 5A) and 2.5 in UMR106 cells (fig. 5B). In the presence of Stat3 
expression vector, luciferase activity of the Stat3 reporter was enhanced in ATDC5 cell, but 
not in UMR106 cells (fig. 5A and B). PTHrP also further increased Stat3 reporter activity in 
the presence of Stat3 expression vector in both cell lines.
To investigate whether the regulation of Stat proteins by PTHrP is part of a more generalized 
interaction between PTHrP and Jak/Stat signalling, we subsequently studied the regulation 
of Stat5a and Stat5b by PTHrP. Comparable to Stat3, the mRNA expression of Stat5a (fig. 6A) 
and Stat5b (fig. 6B) was upregulated after 4 hours of PTHrP treatment in ATDC5 cells by 
qPCR. Transient transfection experiments were performed in ATDC5 cells and in UMR106 
cells, using a Stat5 promoter-reporter construct in the absence of Stat5 expression vector. 
PTHrP inhibited luciferase activity of the Stat5 reporter, with a maximal fold change of 0.5, 
in UMR106 cells (fig. 6D), but had no effect in ATDC5 cells (fig. 6C). This observation is in 
contrast to the increase in mRNA expression of Stat5a and Stat5b. Addition of Stat5a or Stat5b 
enhanced the reporter activity in ATDC5 and in UMR106 cells. In both cell lines, PTHrP 
inhibited Stat5 reporter activity in the presence of Stat5b expression vector, whereas in the 
presence of Stat5a expression vector reporter activity was inhibited in UMR106 cells only.
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Discussion
In the present study, we have identified early response genes of PTHrP in chondrocytes using 
the chondrogenic ATDC5 cell line. Disadvantages of the ATDC5 cell line differentiated under 
standard conditions in monolayer are the formation of a heterogeneous culture and the necessity 
for prolonged culture periods of at least 28 days(15). In monolayer cultures chondrogenesis 
is initiated when multi cell layers appear, suggesting that cell-cell contacts are crucial for 
chondrocyte differentiation. These cell-cell contacts are the initial trigger for mesenchymal 
stem cells (MSCs) to form chondrocytes in embryogenesis. To accelerate the formation of 
cell-cell contacts, we used the micromass culture technique, resembling the condensation of 
MSCs in vivo by formation of a three-dimensional spheroid structure(19;33). Aggregation of 
ATDC5 cells resulted in more homogeneous cultures. Already after 7 days type II collagen 
was abundantly expressed compared to expression after 14 days in monolayer culture(16). Type 
IX and type X collagen were expressed at low levels after 7 days compared to expression after 
14 and 21 days, respectively, in monolayer culture(16). In both cultures the responsiveness of 
























Figure 5: Regulation of the activity of Stat3 protein by PTHrP.
A) ATDC5 cells and B) UMR106 cells were transiently transfected with the stat3 specific promoter-reporter construct and co-trans-
fected with 100 ng pcDNA3.1 or 100 ng stat3 expression vectors and treated with a dose range of PTHrP (0, 10-9, 10-8, 10-7 M). 
Data are expressed as fold induction compared to control after correction for transfection efficiency. Experiments were performed 
in quadruplicate and repeated at least twice. *Significant p<0.05 compared to vehicle stimulation. #Significant p<0.05 compared to 



























micromasses at day 8 with PTHrP. At this time point, the chondrocytes respond to PTHrP 
and have pre-hypertrophic characteristics as demonstrated by the expression of collagen type 
IX. Late-proliferating and pre-hypertrophic cells are the main target cells of PTHrP in the 
growth plate(34). The higher levels of collagen X expression at day 14 of culture suggested that 
more cells have already undergone chondrocyte hypertrophy at this time point.
To identify early response genes of PTHrP the NIA 15k mouse cDNA bank was used. This bank 
was amplified and spotted by the Leiden Genome Technology Center. The quality control of 
custom-made cDNA microarray, compared to commercially available microarrays, is a well-
known problem. The quality of the spots of the microarray used in this study was low, due to 
heterogeneous spot morphologies (“doughnuts”), deposition inconsistencies, and oversized 
spots(35). In addition, identification of the spots was only possible by direct sequencing the 
cDNAs used in the spotting process, because of contamination. This contamination is most 
likely introduced during multiple rounds of replication of the bank by PCR, as previously 
suggested(36). Because of the uncertainty of the identity of the spots, our results could not be 
used for pathway screening or genome wide analysis. By applying very stringent selection 
criteria, the microarray could still be used to identify a subset of PTHrP target genes. The 
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validity of this approach was subsequently shown by qPCR in different cell models and by 
bio-informatics analysis. We were able to classify 12 out of 16 genes as bonafide target genes 
of PTHrP. qPCR analysis is an established method for validation of microarray data. However, 
due to the distinct methodologies and in our case also the relative poor quality of the custom 
made arrays, the overlap was not 100%. Others have also reported this, particularly with 
respect to the fold changes(37-39).
Bio-informatic analysis revealed that RGS2, Upar, and SGK were already identified as PTH 
target genes in osteoblasts(14;40;41). Indeed, in this study RGS2, Upar and SGK were also induced 
in osteoblasts as well as in chondrocytes by PTHrP. Six out of 12 target genes have not been 
demonstrated in growth plate chondrocytes before. The majority of the identified PTHrP 
target genes (10 out of 12) were involved in signal transduction pathways and modulation 
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Figure 6: Regulation of Stat5 mRNA expression and Stat5 protein activity by PTHrP.
RNA was isolated at day 11 from ATDC5 micromass cultures at 0h, 1h, 2h and 4h after PTHrP stimulation and qPCR was performed 
for A) Stat5a and B) Stat5b. C) ATDC5 cells and D) UMR106 cells were transiently transfected with the stat5 specific promoter-re-
porter construct and co-transfected with 100 ng pcDNA3.1, 100 ng Stat5a or 100 ng Stat5b expression vectors and treated with a dose 
range of PTHrP (0, 10-9, 10-8, 10-7 M). Data are expressed as fold induction compared to control after correction for transfection 
efficiency. Experiments were performed in quadruplicate and repeated at least twice. *Significant p<0.05 compared to vehicle stimu-












of these pathways. These include RGS2, SGK, Ptp4a1, Ier3, Stat3, Csrp2, and Gab1. These 
factors are involved in various signal transduction pathways, like AC/PKA, ERK, Jak/Stat and 
PI3-kinase/AKT pathways, suggesting that PTHrP signalling could influence these signalling 
cascades(41-46). In addition, PTHrP could also influence other pathways via regulation of 
expression of receptors, like Upar, Acvr2b, and LamRI.
Quantitative PCR resulted in validation of the upregulated PTHrP target genes identified 
by microarray analysis, in chondrocytes as well in osteoblasts. These data suggest that the 
upregulated genes are part of a more generalized response to PTHrP, which is not restricted 
to chondrocytes. Verification of the downregulated target genes revealed a more cell type 
dependent picture. For instance, two genes, Dym and Sf3a2, were downregulated in 
chondrocytes, but upregulated in osteoblasts. 
The dominant pathway activated by PTHrP is the AC/PKA pathway, which results in 
activation of the transcription factors CREB and/or AP-1(47). Indeed, in various early 
response genes of PTH or PTHrP functional CREB and AP-1 response elements have been 
identified(48). In line with this, promoter analysis revealed CREB transcription factor binding 
sites predominantly in the upregulated genes (6 out of 7), 4 times in combination with an 
AP-1 site. A less consistent picture was found for the downregulated genes. In the promoter 
regions of 2 downregulated genes (LamRI and Dym) CREB transcription factor binding sites 
were predicted. Remarkably, Dym was induced by PTHrP in KS483 osteoblasts. In addition, 
the presence of SP1, E2F and ELK1 were predicted in both up- and downregulated genes. 
Recently, Qin et al used a statistical approach to identify transcription factor binding sites 
used by PTH-signalling in osteoblasts(14) instead of enrichment for evolutionary conserved 
binding sites applied in this paper. Comparable to our study were the predictions of CREB 
and AP-1 transcription factor binding sites predominantly in upregulated genes. Also the 
presence of Sp1 sites in up- and downregulated genes were predicted by both methods. The 
validity of our approach was furthermore underscored by previous data showing the presence 
of a CREB transcription factor binding site in the Stat3 promoter(49). Furthermore, RGS2 is 
induced by cAMP, suggesting a CREB transcription factor binding site in its promoter(50). In 
addition, SP1 binding sites have been described before in the promoter regions of IER3 and 
Csrp2(51;52). 
A remarkable finding in our study was the expression regulation of proteins involved in the 
Jak/Stat signalling cascade, like Stat3 and Csrp2. Csrp2 is a binding partner of Pias1, which 
is an inhibitor of Stat1(42). In addition, a novel observation was the prediction of several Stat 
transcription factor binding sites in the promoter regions of genes induced by PTHrP (6 out 
of 7), often in combination with CREB and AP1 sites. These observations were of biological 
significance, since we also observed that PTHrP induced the activity of a Stat3 reporter 
construct, either in the presence or absence of extra Stat3. This result is comparable with 
another study, in which Stat3 reporter activity was induced by activation of the AC/PKA 
pathway, by increasing the posttranslational activation of Stat3 proteins in rat thyroid cells(53). 
In addition, we showed that the regulation of Stat proteins by PTHrP was not only restricted 
to Stat3, but also included other members of the Jak/Stat family, like Stat5a and Stat5b. Despite 
the induction of Stat5a and Stat5b mRNA, PTHrP inhibited Stat5 reporter activity in the 
absence and presence of exogenous Stat5a and Stat5b. This observation is most likely explained 
by an effect of PTHrP on the posttranslational actions of Stat5a and Stat5b, mediated by the 
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AC/PKA pathway. Indeed, the inhibiting effect on Stat5 activity after activation of the AC/
PKA pathway has been described before in T lymphocytes(54). It was shown that AC/PKA 
signalling inhibited tyrosine phosphorylation of Stat5a and Stat5b, thereby preventing their 
activation. Our results suggest that this mechanism may also be operation in chondrocytes 
and osteoblasts after activation of PTHR1 signalling.
The effects of PTHrP on Stat3 and Stat5 reporters were observed in ATDC5 and UMR106 cells 
with only slight differences. Generally, the responses in ATDC5 cells were lower than observed 
in UMR cells. This is most likely explained by low PTHR1 responses of the undifferentiated 
ATDC5 cells. Due to the excessive formation of cartilage matrix, which prevented efficient 
transfections, the transfection experiment could not be repeated in differentiated ATDC5 
cells and KS483 cells, which express higher levels of PTHR1. The data suggest, however, that 
a crosstalk between PTHR1 and Jak/Stat signalling is a more generalized mechanism. Taken 
together, we provide evidence for interactions between PTHrP and Jak/Stat signalling, not 
only at the level of mRNA expression regulation, but also at the level of posttranslational 
modification, resulting in either activation of Stat3 or repression of Stat5a and Stat5b mediated 
gene transcription. 
The involvement of Jak/Stat proteins in signalling cascades of other growth factors in 
chondrocyte differentiation has been described before. Stat1 and Stat3 are involved in the 
effects of fibroblast growth factor (FGF) on chondrocyte proliferation within the growth 
plate(55). In addition, the Jak/Stat cascade is involved in growth hormone (GH) signalling. 
Stat5b is the most important Stat protein with respect to the actions of GH on growth and 
is responsible for the induction of insulin-like growth factor-1 (IGF-1)(56). Since Jak/Stat 
signalling plays an important role in chondrocyte proliferation, modulation of this pathway 
by PTHrP might be an essential mechanism involved in the actions of PTHrP in keeping the 
growth plate chondrocytes in a proliferation competent state. 
In summary, we have applied new culture conditions to induce chondrogenic differentiation 
of ATDC5 cells. In addition, we have identified 12 PTHrP target genes. Among them were 
several genes involved in distinct signalling pathways operational within the growth plate, 
suggesting the presence of a crosstalk with PTHrP signalling. In addition, we report for the 
first time the presence of a previously not recognized interaction between PTHrP and Jak/Stat 
signalling. 
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Abstract
To gain more insight into the downstream effectors of PTHrP signalling in chondrocytes, we 
performed microarray analysis to identify late PTHrP response genes using the chondrogenic 
ATDC5 cell line. At day 8 of micromass culture ATDC5 cells have pre-hypertrophic-like 
characteristics and at this time point the cells were stimulated with 10-7 M PTHrP for 24h 
and 72h and RNA was isolated. PTHrP treatment inhibited the outgrowth of cartilage matrix 
and decreased the expression of Col10a1 mRNA, which is in line with the inhibitory effects of 
PTHrP on chondrocyte differentiation.
Using cDNA microarray analysis, a list of 9 genes (p< 10-3) was generated, including 3 
upregulated (IGFBP4, Csrp2, and Ecm1) and 6 downregulated (Col9a1, Col2a1, Agc, Hmgn2, 
Calm1, and Mxd4) response genes. Four out of 9 genes (Ecm1, Calm1, Hmgn2, and Mxd4) are 
novel PTHrP response genes and 2 out of 9 (Calm1 and Hmgn2) have not yet been identified 
in cartilage. Four out of 9 (Ecm1, Col2a1, Col9a1, and Agc) genes are components of the extra 
cellular matrix and the remaining genes are involved in signal transduction and transcription 
regulation. 
The response to PTHrP was validated by quantitative PCR, using the same RNA samples as 
labelled in the microarray experiments and RNA samples isolated from a new experiment. In 
addition, we examined whether these genes also reacted to PTHrP in other PTHrP responsive 
models, like KS483 osteoblasts and explanted metatarsals. The expression of late PTHrP 
response genes varied between ATDC5 chondrocytes, KS483 osteoblasts and metatarsals, 
suggesting that the expression of late response genes is dependent on the cellular context of 
the PTHrP responsive cells.
Introduction
Parathyroid hormone (PTH) related peptide (PTHrP) regulates the pace of chondrocyte 
differentiation during endochondral bone formation(1;2). In the growth plate the main target 
cells for PTHrP are late-proliferating and pre-hypertrophic chondrocytes, which express the 
PTH/PTHrP receptor (PTHR1)(1;3). Since both decreased and increased PTHrP signalling lead 
to severe growth plate abnormalities, the expression of PTHrP must be tightly controlled(4-7). 
The protein controlling PTHrP expression in the growth plate is the growth factor Indian 
Hegdehog (IHh), which is expressed by pre-hypertrophic chondrocytes. Vice versa, PTHrP 
regulates the expression of IHh by inhibiting the transition from proliferating chondrocytes 
into hypertrophic chondrocytes, thereby delaying IHh production, which completes the 
negative feedback loop. 
PTHrP not only controls the pace of chondrocyte differentiation in the growth plate, but is 
required for keeping the chondrocytes in the proliferative competent stage as well(8). The effect 
of PTHrP on proliferation is mediated by controlling the expression of cell cycle regulators, 
like cyclin dependent kinase inhibitor p57kip2, as described recently(9). 
Two major pathways are involved in PTHR1 transduction, namely the adenylate cyclase 
(AC)/ protein kinase A (PKA) and the phopholipase C (PLC)/ protein kinase C (PKC) 
pathway. Recently it was shown that the AC/PKA pathway is sufficient for the effects of 
PTHrP on chondrocyte differentiation, suggesting only a minor role for the PLC/PKC 
pathway(10). Signalling via AC/PKA leads to the activation of the transcription factors, cAMP 
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response-element binding protein (CREB) and members of the AP-1 family. These two 
classes of transcription factors are largely responsible for the biological response to PTHrP. In 
concordance with this, a majority of the early target genes of PTHrP contain binding sites for 
CREB and/or AP-1 in their promoters(11-13). Furthermore, phosphorylation by PKA regulates 
the activity of one of the master transcription factors in cartilage formation, Sox9(14). This is 
another illustration that PTHrP can influence chondrocyte differentiation via the AC/PKA 
pathway.
Despite the critical role of PTHrP in endochondral bone formation, downstream targets 
of PTHrP, which transduce its effect on chondrocyte differentiation, are largely unknown. 
For this reason, we have started microarray experiments with the chondrogenic ATDC5 
cell line(15). This cell line is a representative model for studying the actions of PTHrP on 
chondrogenesis. The cells reproducibly differentiate into chondrocytes in 7 days in micromass 
culture. In addition, during this process cells become responsive to PTHrP and in agreement 
with in vivo studies PTHrP inhibits hypertrophic chondrocyte differentiation(16;17). Previously, 
we have identified novel early response genes of PTHrP(18). In this study we focus on the 
identification of late PTHrP response genes, regulated 24 or 72 hours after PTHrP treatment. 
Comparison of the expression patterns of these response genes in osteoblasts and explanted 
metatarsals with ATDC5 cells, demonstrates that the regulation of these genes by PTHrP is 
cell type specific and dependent on the cellular context of the PTHrP responsive cells.
Materials and Methods
Cell culture
ATDC5 cells were grown in Dulbecco’s modified Eagle’s medium /F-12 (DMEM/F12) 
(Invitrogen, Breda, The Netherlands) containing 100 U/ml penicillin (Invitrogen), 100 U/
ml streptomycin (Invitrogen), 10% charcoal stripped foetal calf serum (FCS; Integro BV, 
Zaandam, The Netherlands), 10 µg/ml insulin (Sigma Chemical Co., St Louis, MO, USA), 10 
µg/ml bovine transferrin (Roche, Almere, The Netherlands), and 3 x 10-8 M sodium selenite 
(Roche), in a humidified atmosphere of 5% CO2 and 95% O2 at 37ºC. The micromass culture 
technique was modified from Ahrens et al.(19). Trypsinized cells were resuspended in medium 
at a concentration of 2 x 107 cells/ml, and 3 drops of 10 µl of this cell suspension were placed 
in a well of a standard 12 wells culture plate. The cells were allowed to adhere for 2 hours at 
37ºC and 5% CO2, and then 1 ml medium was added to each well. The medium was replaced 
every other day. 
RNA isolation and amplification
Medium was refreshed after 7 days and the ATDC5 micromasses were challenged with 10-7 M 
PTHrP or vehicle at day 8 of culture (time point 0h) and total RNA was extracted at different 
time points in triplicate using Trizol LS Reagent (Invitrogen), followed by RNA cleanup 
with RNeasy mini kit (Qiagen, Maryland, USA). RNA concentrations were determined by 
measuring the absorbance at 260 nm. Next, RNA samples were pooled and time point 0h was 
chosen as reference sample. Total RNA (3 µg/reaction) was amplified as described before(20), 
with slight modifications. In short, first strand cDNA was synthesized by adding 500 ng T7-
oligodT primer (5’-TCTAGTCGACGGCCAGTGAATTGTAATACGACTCACTATAGGGC
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G(T)21-3’) to 10 µl RNA sample. Samples were incubated for 10 minutes at 70ºC, followed by 
60 minutes at 42ºC in a total volume of 20 µl, containing 5x first strand buffer, 10 mM DTT, 
0.5 mM dNTPs, 2U Rnasin (Promega, Leiden, The Netherlands), and 200U Superscript II RT 
(Invitrogen). Next, second strand cDNA was synthesized for 2 hours at 16ºC in a total volume 
of 150 µl, containing 5x second strand buffer, 0.2 mM dNTPs, 10U DNA Ligase (Invitrogen), 
40U DNA polymerase I (Invitrogen), and 2U Rnase H (Invitrogen). This was followed by 
addition of 2 µl T4 polymerase (5 U/µl) (Invitrogen) and incubation for 5 minutes at 16ºC. 
The double-stranded cDNA reaction was stopped and the remaining RNA in the mixture was 
degraded by addition of 7.5 µl of 1 M NaOH, 2 mM EDTA followed by incubation at 65ºC for 
10 minutes. Samples were purified by phenol/chloroform/isoamylalcohol (25:24:1) extraction. 
The volume of the aqueous phase was increased to 450 µl using H2O. For further purification, 
samples were transferred to a Centricon-100 microconcentrator column (Millipore, 
Amsterdam, The Netherlands) (pre-spinned with 450 µl H2O) and centrifuged for 12 minutes 
at 2500 rpm. After 3 wash steps with 450 µl H2O, cDNA was collected in a total volume of 7 µl 
by inverting the column and by centrifuging for 30 s at 13000 rpm. Subsequently, cDNA was 
transcribed into cRNA using the T7 high yield transcription kit (Epicentre, Madison, USA). 
The cDNA solution was incubated at 42ºC for 3 hours in a total volume of 20 µl, containing 
10x T7 reaction buffer, 7.5 mM ATP, CTP, GTP, and UTP, 10 mM DTT, 2 U Rnasin, and 2 
µl Ampliscribe T7 enzyme solution, followed by sample concentration using centricon-100 
microconcentrator columns. This method was based on the original protocol of Van Gelder et 
al.(21). Finally, cRNA concentration was determined by measuring the absorbance at 260 nm.
Probe labelling
cRNA (1.2 µg) was reverse transcribed with random hexamer primers, and labelled by 
incorporation of cyanine 5-dUTP (Cy5) or cyanine 3-dUTP (Cy3) (NEN, Boston, USA) 
according to the protocols of Ross et al.(22) with slight modifications. In short, cRNA and 8 
µg random primers (Roche) in a total volume of 15 µl was incubated for 10 minutes at 70ºC. 
Subsequently, 6 µl 5x first strand buffer, 3 µl 0.1 M DTT, 0.6 µl low-T dNTPs, 3 µl Cy3 dUTP 
(time point 0h) or Cy5-dUTP (other time points), and 1 µl Superscript II RT (200 U/µl) were 
added, incubated for 10 minutes at room temperature, followed by incubation at 42ºC for 90 
minutes. After 60 minutes fresh Superscript II RT (1 µl) was added. Next, RNA was degraded, 
by addition of 15 µl 0.1 M NaOH and incubation for 10 minutes at 70ºC, after which the 
solution was neutralized by addition of 15 µl 0.1 M HCl. The labelled samples, supplemented 
with 180 µl 10 mM Tris, 1mM EDTA, pH 8 (TE) and 10 µl mouse Cot-1 DNA (10 mg/ml) 
(Invitrogen), were pooled and purified using a centricon-30 microconcentrator column 
(Millipore) (pre-spinned with 450 µl TE for 8 minutes at 13000 rpm). PolyA RNA (20 µg) 
(Amersham) and yeast tRNA (20 µg) (Invitrogen) were added to 450 µl TE during the second 
wash step. The purified product was collected, by inverting the column and by centrifuging 
for 1 minutes at 13000 rpm, and finally, resuspended in a total volume of 45 µl hybridization 
solution, containing 7.65 µl 20x SSC and 1.35 µl 10% SDS. 
(Pre-) hybridization
For the hybridization experiments microarrays, on which the NIA 15k mouse cDNA clone 
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set(23) was spotted, were purchased from the Leiden Genome Technology Center (LGTC). 
DNA was crosslinked by UV irradiation at 65 mJ/cm2 (Stratalinker mode 1800 UV 
Illuminator, Stratagene). To prevent non-specific hybridization, the slides were incubated 
in 45 µl hybridization solution (400 ng/µl yeast tRNA, 400 ng/µl poly(A) RNA, 400 ng/µl 
herring sperm DNA (Invitrogen), 100 ng/µl mouse Cot1 DNA, 5x Denhardt's solution, 3.2x 
SSC and 0.4% SDS) at 65ºC for 30 minutes. Prior to hybridization, the slides containing the 
pre-hybridization mixture were incubated for 2 minutes at 80ºC to denature the spotted 
DNA. After pre-hybridization, the slides were washed twice in 2x SSC for 5 minutes at room 
temperature and dehydrated with subsequent steps of 5 x 5 minutes 70%, 5 minutes 90% 
and 5 minutes 100% ethanol. For hybridization, the probes were denatured by heating for 2 
minutes at 100ºC, left at room temperature for 15 minutes, centrifuged for 10 minutes, and 
placed under a 24 mm x 60 mm glass coverslip. The slides were incubated overnight at 65ºC in 
a hybridization chamber (Corning, Amsterdam, The Netherlands) and washed the next day in 
2x SSC for 5 minutes at room temperature and dehydrated using graded ethanols.
Microarray design and statistical analysis
The reference array experiment, 0h vs 0h, was hybridized in duplicate, 24h vs 0h and 72h vs 0h 
for PTHrP and vehicle treated samples were hybridized in triplicate. Following hybridization, 
slides were scanned in the Agilent DNA Microarray scanner (Agilent Technologies, Amstelveen, 
The Netherlands). Genepix 3.0 software (Axon Instruments Inc.) was used to quantify the 
resulting images. Subsequently, normalization and gene expression analysis were performed 
with Rosetta Resolver (Rosetta Biosoftware, seattle, USA). Due to the overall poor quality 
of the cDNA spots on the microarray, stringent selection criteria were used for inclusion of 
spots, to minimize the risk of false positive signals. A spot was only included in the analysis 
if it passed all of the following selection criteria. 1) Spots should have an absolute fold change 
of less than 2 in the reference array. 2) Spots should show no significantly regulation (p<0.01) 
in the reference array. 3) Only non-flagged spots in any of the arrays were included. 4) The 
signal intensity of Cy3 or Cy5 of the spots should be above a cut off level (0.05).  5) Spots 
should show an absolute fold change less than 50. Next, analysis of variance (ANOVA) was 
performed between the remaining spots of the reference and PTHrP treated hybridizations. 
6) Spots should show significant (p<0.001) differential expression regulation, with intensity 
value above background value. 7) Spots should not be differentially expressed (p<0.01) during 
time in the vehicle treated cultures. To identify the selected spots, the PCR-amplified cDNA of 
each spot (500 ng) was sequenced by the LGTC using 12 pmol M13 primers in a total volume 
of 24 µl.
Histology
Micromasses were fixed for 10 minutes in 10% formalin, subsequently dehydrated using 
graded ethanols, and embedded in paraffin. Sections of 5 micron were deparaffined with 
Paraclear (EarthSafe Technologies Inc, Belle Mead, NJ, USA) and hydrated using graded 
ethanols. Subsequently, the sections were treated for 3 minutes with 3% acetic acid, stained 
with 1% Alcian Blue for 30 minutes, rinsed first with 3% acetic acid and then with bidest. 
Hereafter, the sections were immersed in Nuclear Fast Red for 5 minutes and then rinsed with 
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bidest. Next, the sections were dehydrated using graded ethanols. Finally, the sections were 
embedded in histomount-diluted 1:1 xylene.
RNA isolation from mouse bone explants
Metatarsalsia were isolated from 15-days old Swiss Albino mouse embryos. The mice were 
kept in a light and temperature controlled room (12 hours light, 20-22ºC) with food and 
water available ad libitum. Experiments were approved by the local ethical committee for 
animal experiments. The bone explants were cultured in αMEM with 10% FCS and the next 
day metatarsals were challenged with 10-7 M PTHrP or vehicle in αMEM containing 1% BSA. 
RNA was isolated after 24 and 72 hours from metatarsals, using Trizol LS Reagent (Invitrogen) 
and reverse transcribed into cDNA using random hexamer primers (Amersham).
RNA isolation from KS483 osteoblasts
KS483 mesenchymal progenitor cells were differentiated into osteoblasts as described 
previously(24). At day 11, KS483 cells have formed bone nodules and the cells within the nodules 
start to mineralize the extracellular matrix. This time point was chosen to treat the cells with 
10-7 M PTHrP. RNA was isolated after 24 and 72 hours using Trizol LS Reagent (Invitrogen) 
and reverse transcribed into cDNA using random hexamer primers (Amersham).
Quantitative PCR (qPCR)
To validate the expression patterns of PTHrP response genes, quantitative PCR was performed 
using the BioRad iCycler (Biorad, Veenendaal, The Netherlands). For each gene a set of 
primers was designed (table 1), which spanned at least 1 intron-exon boundary and had an 
optimal annealing temperature of 60˚C, using Beacon designer (United Bioinformatica Inc., 
Calgary, Canada). cDNA (5 ng) was amplified in triplicate using the qPCR core kit for SYBR 
green 1 (Eurogentec, Maastricht, The Netherlands), under the following conditions: cDNA 
was denatured for 10 minutes at 95˚C, followed by 40 cycles, consisting of 15 s at 95˚C, 20 
s at 60˚C, and 40 s at 72˚C. From each sample a melting curve was generated to test for 
the absence of primer dimer formation and DNA contamination. Each reaction contained 
5 µl cDNA (1 ng/µl), 10x reaction buffer, 3 or 4 mM MgCl2 (table 1), 40 µM dNTP's, 300 
nM primer, 0.75 µl SYBR green, and 0.1 µl HotGoldStar polymerase in a total volume of 25 
µl. Fold changes, adjusted for the expression of β2m, were calculated and log transformed 
using the comparative method(25). Significant changes were calculated using the Double Delta 




Effect of PTHrP treatment on ATDC5 micromass cultures
ATDC5 cells were cultured as micromasses for 8 days to stimulate chondrocyte differentiation. 
Previously we have shown that the cells have a pre-hypertrophic phenotype at this stage of 
culture(18). PTHrP treatment at day 8 resulted in inhibition of the outgrowth of cartilage 
matrix 72 hours later (fig. 1A). Histological analysis of the micromasses showed rounded 
chondrocytes embedded in an alcian blue positive extracellular matrix (fig.1B). Treatment 
with PTHrP for 24 and 72 hours did not change the cell structure or the intensity of the alcian 
blue staining in the micromasses. RNA was isolated 24 and 72 hours after PTHrP treatment 
and used for qPCR analysis to study the expression of collagen 10 (Col10a1), a marker for 
hypertrophic chondrocytes. PTHrP decreased Col10a1 mRNA expression after 72 hours of 
treatment (fig. 1C).
Taken together PTHrP treatment at day 8 of culture inhibited new formation of cartilage 
and inhibited the differentiation into hypertrophic Col10a1 expressing chondrocytes. For this 
reason, this time point was chosen for identification of PTHrP response genes.
Name F/R Forward primer   MgCl
β2µ F CACTGACCGGCCTGTATGC  3 mM
 R GAATTCAGTGTGAGCCAGGATATAGA 
IGFBP4 F AACTGTGACCGCAACGGC  4 mM
 R ACGCTGTCCGTCCAGGG 
Csrp2 F CCACTCGGAATGCCTGTCTG  3 mM
 R GCCACTGTTGTGCTGTCTAAATTTT 
Ecm1 F TCGCCCACCTAGCTCCCTATC 4 mM
 R AGCAGCGGACGGTCATATTCTG 
Col2a1 F CTTCGGAGAGTGCTGTCCCATC 4 mM
 R CCCTTGTCACCACGATCACCTC 
Col9a1 F CACTGGGCTGCCTGGTATCC  4 mM 
 R GGCTCCTGTGTCTGGTCTCTTG 
Agc F CGAATGGAACGACGTCCC  3 mM
 R CTGATCTCGTAGCGATCTTTCTTCT 
Calm1 F GTGTCCGTGGTGCCGTTACTC 3 mM
 R TGCGAGCGAAGGAAGGAAGAAC 
Hmgn2 F TCCAAAGCCAGAGCCCAAACC 4 mM
 R GGCATCTCCAGCACCTTCAGC 
Mxd4 F CCCGAACAACAGGTCTTCACAC 4 mM
 R GCACGCTTCAGAAGGCTCAG 
Ap3d F AATGCGGAGGCGGTGAAGTC 4 mM
 R GGGTGGTGGACAGCCAGAAGC 
Brd4 F GGCTCGAAAACTCCAGGATGTG 4 mM
 R TGTCGCTGCTGCTGTCACTAG 
Nme1 F CAGGCAGGGGACCAGCAAC  4 mM
 R GCCTGAAGGAGGTAAGGAATGC 
Nsd1 F CACACAGAACAAGGGCTTCAGG 3 mM
 R CCACAGGACAGCGGACACAG 
Tgfβ1i4 F CTCCCTCCCGCCCTCTCTC  4 mM
 R GGTTCCCAGCAAAGACGACAAG 
Table 1 : qPCR primer sets









































Figure 1: characterization of ATDC5 micromass cultures.
(A) ATDC5 micromass cultures were cultured for 8 days and then treated with vehicle or 10-7 M PTHrP for 0, 24 and 72 hours. 
Cultures were stained with alcian blue. (B) Alcian blue stained sections of ATDC5 micromasses, cultured for 8 days and then treated 
with vehicle or 10-7 M PTHrP for 24 and 72 hours. (C) qPCR analysis of col10a1 mRNA in micromasses cultured for 8 days and then 
treated with 10-7 M PTHrP for 24 and 72 hours. Expression in PTHrP treated cultures was compared to vehicle treated cultures and 
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Selection of PTHrP response genes
ATDC5 cells were cultured as micromasses and treated at day 8 with 10-7 M PTHrP for 24 and 
72 hours and cDNA microarray analysis was performed. After applying stringent selection 
criteria, 8319 out of the 15442 spots were taken in the analysis. A list of 31 spots, which 
exhibited significant (p<0.001) differential expression after 24 or 72 hours following PTHrP 
treatment and did not change in the vehicle treated cultures, was generated (table 2). From 
this list 14 genes were chosen for validation experiments in ATDC5 cells. Exclusion criteria 
were insufficient information on gene identity, for example ESTs, or insufficient information 
for the design of qPCR primer sets, which span intron-exon boundaries. 
Validation of PTHrP response genes in ATDC5 cells by qPCR
The expression patterns of the selected genes were first validated by studying expression 
profiles using qPCR in the same RNA samples subjected to microarray analysis (fig. 2B, D, 
F and H) and in RNA samples from ATDC5 cells isolated in a new independent experiment 
(data not shown). Beta-2-microglobulin (β2µ) was used as internal standard, as it was not 
regulated by PTHrP in microarray analysis (data not shown). Five out of 14 genes could not 
be validated in the second RNA panel and were discarded from further study, leaving 9 genes 
for more detailed analysis (table 3). Among these 9 identified PTHrP response genes, 3 genes 
were upregulated and 6 genes were downregulated. Five genes were already known response 
genes of PTHrP and 7 genes have previously been found in growth plate chondrocytes (table 
3). Four out of 9 response genes were extracellular matrix proteins, namely Ecm1, Col2a1, 
Col9a1 and Agc. The other response genes were implicated in protein binding and were 
involved in the regulation of signalling and transcription. 
Based on the expression patterns, the genes were divided into 4 groups, 2 groups for 
upregulated genes and 2 groups for downregulated genes (fig. 2A, C, E and G). The expression 
of the genes in expression pattern 1 peaked at 24 hours while the gene in expression pattern 2 
was continuously upregulated. The gene in expression pattern 3 was only downregulated after 
72 hours. In expression pattern 4 the genes were continuously downregulated. Expression 
Reg.1 Abbr.2 Name     Function    rp3  gp4
up IGFBP4 Insulin-like growth factor 
  binding protein 4    Negative modulator of IGF-1 activity yes  yes
up Csrp2 Cystein and glycine-rich protein 2  Binding partner of protein inhibitor 
       of activated STAT1 (PIAS1)  yes  yes
up Ecm1 Extracellular matrix protein 1   Negative regulator of endochondral
       bone formation   no  yes
down Col9a1 Collagen, type IX, alpha 1   Extracellular matrix protein  yes  yes
down Col2a1 Collagen, type II, alpha 1   Extracellular matrix protein  yes  yes
down Agc Aggrecan     Extracellular matrix protein  yes  yes
down Calm1 Calmodulin 1    Principal mediator of the calcium signal no  no
down Hmgn2 High mobility group nucleosome
  binding protein 2    Nucleosome binding protein  no  no
down Mxd4 Max dimerization protein 4   Member of Myc/Max/Mad network  no  yes
Table 3 : List of validated PTHrP target genes.
1) Reg. = regulation
2) Abbr. = abbreviation
3) rp = previously been implicated in PTHrP signaling





































































































































pattern 1 contained Csrp2 and IGFBP4 and expression pattern 2 contained Ecm1. Col9a1 
formed expression pattern 3. In expression pattern 4 were Col2a1, Agc, Calm1, Hmgn2, and 
Mxd4. 
In qPCR experiments all genes, except for Ecm1, showed the same expression profile compared 
to the data from microarray analysis (fig. 2). Ecm1 showed the same expression pattern as the 
genes in expression profile 1 (fig. 2B and D), upregulation at 24 hours followed by a slight 
decrease of mRNA expression after 72 hours, instead of continuously upregulation revealed 
by microarray analysis. 
Validation of PTHrP response genes in metatarsals by qPCR
To test whether the identified response genes also respond to PTHrP in chondrocytes ex vivo, 
metatarsals from 15-day old mouse embryos were treated with 10-7 M PTHrP for 24 and 
72 hours and qPCR analysis was performed. Metatarsals from 15-day old mouse embryos 
consist of undifferentiated cartilage surrounded by a perichondrium in which osteoblast and 
osteoclast precursors are present. They differentiate normally during a 1 week culture period 
into a mineralized bone explant(26). In response to PTHrP the expression of Col10a1 decreased 
after 24 hours, indicating a biological response to PTHrP (fig. 3A). All genes except 1, Calm1, 
responded to PTHrP in the metatarsal model. However, there were remarkable differences, 
both in the temporal regulation and in the direction of regulation, in the response to PTHrP 
when compared to the response in ATDC5 cells (compare fig. 3 with fig. 2). For instance, all 
downregulated genes in the ATDC5 cultures were upregulated in the metatarsal model. In 
addition, the peak in expression of the upregulated genes, IGFBP4, Csrp2, and Ecm1 differed 
between the two models. In metatarsals the peak expression of IGFBP4, Csrp2, and Ecm1 was 
after 72 hours compared to the peak expression in ATDC5 cells after 24 hours.
Validation of PTHrP response genes in KS483 osteoblasts by qPCR
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they were part of a more generalised response to PTHrP, the expression patterns were analysed 
in differentiated KS483 osteoblasts using qPCR (fig. 4). For this purpose, RNA was isolated 
after 24 and 72 hours after a challenge with 10-7 M PTHrP. The expression patterns of the 
typical chondrocyte markers Agc, Col2a1 and Col9a1 were not established in this osteoblast 
culture system. The expression of 3 out of 6 response genes changed after PTHrP treatment in 
the KS483 culture system, including IGFBP4, Ecm1, and Mxd4. The expression regulation of 
IGFBP4 and Ecm1 was comparable to the regulation in metatarsals and was different in peak 
expression compared to the ATDC5 cells. Mxd4 mRNA expression increased in response to 
PTHrP in osteoblasts, instead of a decrease in expression in ATDC5 chondrocytes, however 
the expression was comparable to the PTHrP response in metatarsals. Csrp2, Calm1, and 
Hmgn2 were not significantly regulated by PTHrP in KS483 osteoblasts. 
Discussion
In the present study, we have identified late response genes of PTHrP in chondrocytes using 
the chondrogenic ATDC5 cell line. ATDC5 cells were cultured as micromasses to induce 
chondrocyte differentiation. After 1 week this resulted in a homogeneously differentiated cell 
culture, which contained chondrocytes with pre-hypertrophic-like characteristics. Previously, 
we have shown high expression of PTHR1 in these cells(18). Because late-proliferating and 
pre-hypertrophic cells are the main target cells of PTHrP in the growth plate(2), we decided to 
stimulate the micromasses at day 8 with PTHrP for 24 and 72 hours, to identify late PTHrP 
0h 24h 72h



























Figure2: expression profiles of PTHrP response genes in ATDC5 chondrocytes revealed by microarray analysis and qPCR ana-
lysis.
RNA was isolated from ATDC5 micromass cultures, at 0, 24 and 72 hours after PTHrP (10-7 M) stimulation, amplified and labelled 
as described. Samples were hybridized against 0 hours in duplicate or triplicate (for details see materials and methods). In the left 
panel the expression profiles revealed by microarray analysis are shown (A, C, E, and G). In the right panel the corresponding patterns 
revealed by qPCR are shown (B, D, F, and H). Every sample was run in triplicate.
(A and B) Expression profile 1 contained 2 upregulated genes, i.e. IGFBP4 and Csrp2. (C and D) Expression profile 2 contained 1 
upregulated gene, i.e. Ecm1. (E and F) Expression profile 3 contained 1 downregulated gene, i.e. Col9a1. (G and H) Expression profile 
4 contained 5 downregulated genes, i.e. Col2a1, Agc, Calm1, Hmgn2, and Mxd4. Expression in PTHrP treated cultures was compared 









































































































































Figure 3: expression patterns of PTHrP response genes in 15-day old metatarsals.
RNA was isolated from 15-day old metatarsals and treated with 10-7 M PTHrP for 24 and 72 hours, and qPCR was performed. Every 
sample was run in triplicate. (A) PTHrP treatment decreased Col10a1 mRNA expression as expected. (B) Expression regulation of 
genes from expression pattern 1, as revealed by microarray analysis in ATDC5 cells, in explanted metatarsals. (C) Expression regula-
tion of genes from expression pattern 2, as revealed by microarray analysis in ATDC5 cells, in explanted metatarsals. (D) Expression 
regulation of genes from expression pattern 3, as revealed by microarray analysis in ATDC5 cells, in explanted metatarsals. (E) Ex-
pression regulation of genes from expression pattern 4, as revealed by microarray analysis in ATDC5 cells, in explanted metatarsals. 
Expression in PTHrP treated cultures was compared to vehicle treated cultures and expressed as log fold change. *Significant vs 









response genes. A challenge with PTHrP resulted in a biological response at 72 hours, as shown 
by downregulation of the hypertrophic marker Col10a1 and inhibition of the outgrowth of the 
cartilage matrix, but did not result in a change of cell structure within the micromasses. This is 
in agreement with current evidence that PTHrP does not inhibit formation of chondrocytes 
per se, but inhibits their differentiation into hypertrophic cells.
To identify late response genes of PTHrP we used the NIA 15k mouse cDNA bank, which was 
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amplified and spotted by the Leiden Genome Technology Center. Compared to commercially 
available microarrays, the quality control of custom made cDNA microarray is a well known 
problem. The quality of the spots of the microarray used in this study was low, due to 
heterogeneous spot morphologies (“doughnuts”), deposition inconsistencies, and oversized 
spots as described previously(18;27). In addition, identification of the spots was only possible 
by direct sequencing the cDNAs used in the spotting process, because of contamination. This 
contamination is most likely introduced during multiple rounds of replication of the bank 
by PCR, as previously suggested(28). Pathway screening or genome wide analysis could not 
be used in this study, because of the uncertainty of the identity of the spots. However, the 
microarray could still be used to identify PTHrP response genes by applying very stringent 
selection criteria. Using qPCR in different cell models and bio-informatics analysis we showed 
the validity of this approach. We were able to classify 9 out of 14 genes as bonafide response 
genes of PTHrP. However, due to the distinct methodologies and in our case also the relative 
poor quality of the custom made arrays, the overlap was not 100%. Others have also reported 
this, particularly with respect to the fold changes(29-31).
Bio-informatic analysis revealed that 4 genes, Ecm1, Calm1, Hmgn2 and Mxd4, have not 
yet been described as response genes of PTHrP. IGFBP4 was already identified as PTHrP 
response gene in osteoblasts(32) and the typical chondrocyte markers, Agc, Col2a1, and 
Col9a1, in chondrocytes(17). In addition, Csrp2 has previously been identified as an early 
target gene of PTHrP in chondrocytes as well as in osteoblasts in our previous study(18). Two 
out of 9 late response genes, Calm1 and Hmgn2, have not been demonstrated in growth plate 
chondrocytes before. Furthermore, 4 out 9 genes (Ecm1, Col2a1, Col9a1, and Agc) were 















































































4C Figure 4: expression patterns of PTHrP response genes in 
KS483 osteoblasts.
RNA was isolated from KS483 osteoblasts, treated with 10-7 
M PTHrP at day 11 for 24 and 72 hours and qPCR was per-
formed. Every sample was run in triplicate. (A) Expression 
regulation of genes from expression pattern 1, as revealed by 
microarray analysis in ATDC5 cells, in KS483 osteoblasts. (B) 
Expression regulation of genes from expression pattern 2, as 
revealed by microarray analysis in ATDC5 cells, in KS483 os-
teoblasts. (C) Expression regulation of genes from expression 
pattern 4, as revealed by microarray analysis in ATDC5 cells, 
in KS483 osteoblasts. Expression in PTHrP treated cultures 
was compared to vehicle treated cultures and expressed as log 
fold change. Typical cartilage markers were not studied. *Sig-
nificant vs vehicle treated samples (p<0.05).
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4 out of 9 late response genes (Csrp2, Hmgn2, Calm1 and Mxd4) were involved in signal 
transduction and regulation, compared to 10 out of 12 early response genes(18). Although we 
had only a small list of response genes, this is in agreement with the notion that the majority 
of early target genes are implicated in signal transduction and regulation and that the majority 
of late response genes code for structural proteins belonging to the extracellular matrix(29;33). 
The remaining late response gene, IGFBP4, is involved in protein binding and modulation of 
signal transduction. 
Detailed analysis on the role of some of our targets in chondrocyte differentiation is currently 
lacking. For example, an interesting feature of the transcription factor Hmgn2 is the presence 
of a HMG domain. Remarkably, the three major transcription factors involved in chondrocyte 
differentiation, Sox9, Sox6, and L-Sox5, contain a HMG box. The HMG domain containing 
protein family can be divided in two subfamilies, the first one containing the subclass of 
Sox proteins and Hmgn2 belongs to the second subfamily(34). Together with other as yet 
unidentified HMG-box containing proteins, the Sox transcription factors form a complex, 
which binds to several consensus HMG binding sites in the collagen 2 promoter(35;36). Hmgn2 
may be one of these unknown binding proteins. Thus besides regulation of Sox9 activity by 
phosphorylation, PTHrP may also influence the expression of putative binding partners of 
Sox9. Remarkably, Hmgn2 is downregulated in ATDC5 and upregulated in metatarsals, but 
not regulated in osteoblasts, suggesting chondrocyte specific regulation of Hmgn2 expression 
by PTHrP.
Another response gene of PTHrP involved in protein binding and transcription regulation 
was Mxd4, a member of the Mad gene family. Mxd4 heterodimerizes with Max forming a 
transcriptional repression complex. Mxd4 competes for Max binding with Myc, which 
heterodimerizes with Max forming a transcriptional activation complex. Through regulation 
of Mxd4 expression, PTHrP could influence the activity of c-Myc, which plays an important 
role in cell proliferation and prevents the differentiation of cultured chondrocytes into 
hypertrophic chondrocytes(37;38). Regulation of c-Myc activity might be one of the mechanisms 
by which PTHrP keeps the chondrocytes in a proliferative competent stage. 
The remaining proteins involved in protein binding and signalling regulation were IGFBP4, 
Csrp2, and Calm1. PTHrP may play a role in changing intracellular Ca2+ levels by regulating 
Calm1 expression, which appears to be limited to the ATDC5 cells(39). The expression 
regulation of Csrp2, a binding partner of Pias1, which inhibits Stat1, could indicate a 
possible crosstalk between PTHrP signalling and FGF or Growth Hormone (GH) signalling 
cascades as mentioned before(18;40). Both factors use Jak/Stat signalling to exert their effects 
on chondrocyte proliferation and differentiation. In addition, our data indicates a crosstalk 
between PTHrP and the IGF signalling cascade as well. IGFBP4 is shown to exert inhibitory 
effects on IGF1-promoted growth(41;42). Via upregulation of IGFBP4, PTHrP might be able to 
counteract IGF1-activity. 
A remarkable finding in this study was the decrease of Agc mRNA expression in ATDC5 
chondrocytes and an increase of Agc mRNA expression in explanted metatarsals after PTHrP 
treatment. In contrast to the metatarsals, which contain chondrocytes at various stages of 
differentiation as well as other cell types like osteoblasts and –clasts, the cultures of the ATDC5 
cells are more homogenous. It may well be that regulation of Agc by PTHrP is dependent 
on the developmental and differentiation stage of the chondrocyte. This is supported by 
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observations in rat costal chondrocytes in which PTHrP either induced, slightly repressed or 
had no effect on Agc mRNA expression depending on the gestational age of the cells(43).
Previously we have shown that the majority of early PTHrP effects were part of a more 
generalised response, not only restricted to chondrocytes(18). To address whether this was also 
the case for late PTHrP responses, the expression regulation of these genes by PTHrP were 
also established in KS483 osteoblasts and in explanted metatarsals, which consist of different 
cell types, like chondrocytes and osteoblast and osteoclast precursors in the perichondrium. 
In both systems differences were found in gene expression compared to the expression in 
ATDC5 chondrocytes in response to PTHrP. Most of the upregulated genes showed a 
temporal change in expression in metatarsals and osteoblasts. In addition, the direction of 
the expression of downregulated genes was changed or the expression was not regulated in 
osteoblasts and metatarsals. This suggest that between early and late effects mechanisms must 
be operational that translate the PTHrP responses from a more generalised effect, as seen in 
the immediate early response, into a cell type and cellular context dependent effect, as seen 
in the late response. Results of other studies also indicate such a mechanism(29;33). The factors 
involved in this process are not known. 
In summary, we have identified 9 late PTHrP response genes, including 4 novel target genes, 
Ecm1, Calm1, Hmgn2, and Mxd4. Among them were structural proteins, binding proteins 
and regulators of signalling. The expression of the late PTHrP response genes varied between 
cell types, suggesting a functional mechanism, translating the PTHrP responses from a more 
generalised early response, into a cell type and cellular context dependent late response.
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Several mathematical models exist to calculate data derived from qPCR analysis. However, 
a model providing computations for expression ratios and p-values in experiments in which 
all samples are run in triplicate in a single qPCR experiment, well organized in a single 
spreadsheet, is not available. 
Results
We have developed the double delta model (DDM) to calculate p-values and confidence 
bands in single qPCR experiments in which reference and target samples are run in 
triplicate. In this model, which is derived from the 2-∆∆Ct method, the variances of the gene 
of interest as well as the variances of the reference are taken into account.
Conclusions
This model is particularly useful when working with many samples, because the calculations 
of the ratios and the calculations of the p-values are well organized in a single spreadsheet. 
Because the DDM does not include corrections for qPCR efficiency, it can only be used 
when the amplification efficiencies of the target and reference gene are close to 1. The DDM 
may also be applied to other data sets, in which experimental values are correlated with 
reference values. 
Background
The quantitative Polymerase Chain Reaction (qPCR) is a powerful method to quantify 
gene expression (for review see(1)). Two different methods to analyze qPCR data are mainly 
used. The standard curve method is performed in circumstances where it is necessary 
to determine the absolute transcript copy number(2). This method is also called absolute 
quantification and is usually performed by relating the PCR signal to a standard curve. In 
most situations, however, relative quantification will suffice. This is for example the case in 
experimental designs in which one would like to examine the effect of a drug or treatment 
on the expression of a given gene. Many mathematical models exist to calculate the mean 
normalized gene expression(3-6). In these methods, the expression of the gene of interest is 
determined in control and treated samples and related to the expression of a reference gene, 
which is measured in the same samples. This reference gene is often a house-keeping gene, 
of which the expression is presumed not to be affected by the treatment. 
An appropriate method for calculating expression ratios in data derived from a single qPCR 
experiment, in which the samples of the gene of interest and the reference gene are run 
in triplicate, is the 2-∆∆Ct method. The derivations and assumptions have been described 
elsewhere(5). Since different efficiencies will generate errors when using this method, the 
amplification efficiencies of the target and reference gene must be close to 1. This is often 
the case for amplicons designed to be less than 150 bp and for which the PCR conditions 
are properly optimized. However, this method does not include calculations of p-values and 
confidence bands. 
A suitable model for calculating expression ratios and p-values in a single qPCR experiment, 
in which all samples are run in triplicate, is the relative expression software tool (REST). 
This tool is based on the correction for PCR efficiencies and the mean Ct-value deviation 
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between sample and control group(6). In addition, REST also includes statistical analysis by 
using the pair-wise fixed reallocation randomization test. However, a disadvantage of the 
REST tool is the requirement of a new spreadsheet for the calculations of each sample in 
experiments in which the expression of 1 gene is determined in many different samples. This 
is a lot of work and could be confusing. Examples of such experiments are time series, dose 
range series or series using different stimuli.
In this letter we propose a novel statistical model, the double delta model (DDM). For 
calculations of expression ratios, p-values and confidence intervals, using qPCR data 
derived from a single qPCR experiment in which all samples are run in triplicate. This 
model is based on the 2-∆∆Ct method(5). Like the 2-∆∆Ct method, the variances of the Ct-values 
of the gene of interest as well as the variances of the Ct-values of the reference gene are 
taken into account. This model does not include corrections for amplification efficiencies, 
so we want to emphasize that this model can only be used when these values are close to 1. 
This model is especially useful for calculating differences in gene expression in experiments 
with many samples. The computations of the ratios and p-values can be calculated in a 
single spreadsheet, making it well organized and easy to produce graphs. 
Implementation
Here, we present a short derivation of the required formulas and show how to implement 
them as an Excel spreadsheet (table 1). Let ypcr be a probe concentration, where p indicates 
the type of probe (reference or not), c indicates the condition, and r indicates a repetition. 
Let Xpcr= log2Ypcr . We assume that x is approximately normally distributed. This is more 
realistic than assuming a normal distribution for the concentrations, which are inherently 
positive and can vary over an enormous range. We also assume that the normal distribution 
has the same variance for all combinations of p and c.
The mean of all Xpcr for any combination of p and c will be indicated by 
mpc =       Xpcr/npc ,
where npc is the number of observations. The DDM computes the contrast
d = (m22-m21)-(m12-m11) = m22 -m21-m12 + m11 .
For explanation of symbols, see result section and table 1. The variance in each group can be 
estimated as 
vp =      (Xpcr - mpc)
2 / npc-1 .
These can be combined to estimate the pooled variance as 
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where
DF =             npc-1 
Let sepc indicate the standard error of mpc. It is given by sepc =      v/npc  . In other words: the 
variance of mpc is v/npc. From elementary mathematical statistics it shows that the variance 
of a sum or difference of independent variables is equal to the sum of the variances. We thus 
find: 
var(d) = v(1/n11 + 1/n12 + 1/n21 + 1/n22),
and
se(d) =      v(1/n11 + 1/n12 + 1/n21 + 1/n22) 
Under the assumption of normality, d/    se(d) has a t-distribution with degrees of freedom 
(DF). This allows the computation of confidence bands and p-values. The confidence limits 
(CL) are computed as: d ± t(0.05;DF)*se(d), where t(0.05;DF) is the critical value of the t-
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 1: Example of the double delta model (DDM).
1) ref. = reference and GOI = gene of interest. 2) Stim. = stimulation. 3) var = variance. SSQ = sum of squares. DF = degrees of free-
dom. SE = standard error. CL = confidence limit. 4) Symbols used in the mathematical equations and corresponding with the name 
in column C. xabc = Ct-value of group (a), stimulation (b), and type (c). mab/vab/nab = mean/variance/counts of group (a) and 
stimulation (b). 
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Results
We want to illustrate this model with an example in which the effect of treatment with 
a drug is examined on the expression of a particular gene at several time points. RNA is 
isolated from untreated (time point of stimulation) and treated specimens and prepared for 
qPCR analysis. Samples are run in triplicate in a single qPCR experiment and Ct-values are 
calculated for the gene of interest and the reference gene (see column E, F, G, and H table 1). 
Using the DDM we show that the drug has a significant effect on gene expression after 1 (p = 
0.002) and after 2 hours (p = 0.002) (table 1 and fig. 1).  
The computations can conveniently be organized as an Excel spreadsheet, as shown in table 
1. The numbers in one data set are contained in one column (here columns E, F, G, and H). 
The upper rows (2– 13) hold the individual measurements (Ct-values). Samples (groups) are 
indicated in column A. Stimulation, where appropriate, is indicated in column B. Column 
C gives a name to each number in columns E, F, G, and H, while column D shows the 
correspondence with symbols in the mathematical equations. Column I shows the Excel 
formulas. This is done here for illustration purposes; in practical use this column (and 
perhaps also the fourth, containing the symbols) could probably be deleted. The middle 
rows (15–26) contain the calculations of mean, variance and sample size for each of the four 
groups. The lower block (rows 28–38) contains the pooled results and the final statistics, 
labelled as “contrast”. The present spreadsheet assumes a maximum group size of 3. It is 
not difficult to add extra rows for larger sizes. Smaller group sizes or missing data are no 
problem: one simply leaves spreadsheet cells empty; the calculations are organized in such a 
way that they automatically handle missing data. In addition, it is not difficult to add extra 
columns for additional data sets. Figure 1 shows the graph with the mean expression of a 
gene of interest (GOI) at 0 (data1), 1 (data2), 2 (data3) and 4 (data4) hours after stimulation, 
compared to the mean expression at time point 0, described in table 1.  

























Figure 1. Expression of gene of interest. 
The mean expression of the gene of interest (GOI) is shown as 2log fold change compared to 0, time point of stimulation (data1, 





Several mathematical methods exist to calculate data derived from qPCR analysis(3-6). 
However, a model providing calculations for expression ratios and p-values in experiments 
in which all samples are run in triplicate in a single qPCR experiment, well organized in 
1 spreadsheet, is not available. Therefore, we have developed a novel statistical model, the 
double delta model (DDM) to calculate p-values and confidence bands using data derived 
from a single qPCR experiment. The DDM is particularly useful when working with many 
samples. In addition, the DDM is also applicable to other data sets, in which experimental 
values are correlated with reference values. Examples are experiments, in which enzymatic 
activity is corrected for cell number or DNA concentration and transient transfection assays, 
in which luciferase activity is corrected for the transfection efficiency. 
Availability
The double delta model is freely available on request from the corresponding author.
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A network of endocrine and paracrine factors regulates the process of chondrocyte proliferation 
and differentiation in the growth plate. One of the key regulators involved in this process is 
Parathyroid Hormone (PTH) related peptide (PTHrP). This has been underlined by several 
studies, in human and mice, in which type 1 PTH/PTHrP receptor (PTHR1) signalling is 
interrupted or augmented(1-11). The exact working mechanism of PTHrP signalling, alone 
or in combination with other growth factors or systemic hormones, in endochondral bone 
formation is not completely understood. In this thesis, we further addressed the actions of 
PTHrP in the complex network of endocrine and paracrine regulation of endochondral bone 
formation. 
The first major result described in this thesis was that the heterogeneity of Blomstrand 
Osteochondrodysplasia (BOCD) is caused by the impact of a mutation in the PTHR1 gene on 
the receptor function. In addition, we demonstrated that the PTHR1 adaptor proteins, Na+/
H+ exchanger regulatory factor 1 (Nherf1) and Nherf2, are expressed during endochondral 
bone formation and that they may play a role in matrix mineralization during osteoblast and 
chondrocyte differentiation. Furthermore, we identified novel early and late PTHrP target 
genes using cDNA microarray and quantitative PCR (qPCR) analysis. Finally, we showed for 
the first time interaction between PTHrP and the janus kinase (Jak)/signal transducer and 
activator of transcription (Stat) pathway. 
In this chapter, these major findings will be summarized and critically reviewed.
Genotype-phenotype correlation in Blomstrand 
Osteochondrodysplasia
BOCD is a lethal osteochondrodysplasia characterized by severe skeletal malformations, 
due to accelerated endochondral bone formation(12-19). It is caused by disruption of PTHR1 
signalling(2;7-9). BOCD can be divided into two types, type I and type II, depending on the 
severity of the skeletal abnormalities, with type I as the most severe phenotype(12). The 
molecular basis for this heterogenic clinical presentation is unknown and, therefore, we have 
addressed the underlying causative factors in chapter 2. For this purpose, we performed 
mutation analysis in 2 families with type I BOCD and in 3 families with the less severe form, 
type II BOCD. The latter included 1 case that has not been described before. 
Theoretically, there are two possible explanations of the variation in severity of the skeletal 
abnormalities. First, it is possible that the milder presentation of type II BOCD patients is 
caused by the genetic background. Support for this explanation comes from two sources. We 
have identified in two of the type II BOCD families the P132L mutation, which has already 
been found before in another family with type II BOCD. These families lived in the same 
region of England and originated from the same ethnic population(7;8). In addition, it has 
been shown that the presentation of the phenotype of PTHR1 knockout mice depends on the 
genetic background(1). For example, C57BL/6 mice die at mid-gestation, while Black Swiss 
mice die perinatally. 
An alternative explanation is that the clinical severity depends on the degree of inactivation 
of the PTHR1. We have presented a novel family of different genetic origin, with another 
PTHR1 mutation causing type II BOCD, providing evidence that type II BOCD does not 
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depend on the genetic composition. Both mutations resulted in partial inactivation of the 
receptor with some residual activity. This is in contrast with the mutations identified in type I 
BOCD. These mutations, including the R104X described in chapter 2, resulted in a complete 
inactivation of the PTHR1(2;9). Therefore, we concluded that type I BOCD resulted from a 
complete inactivation of the PTHR1, whereas a near complete inactivation of the PTHR1, 
resulting in low levels of residual activity, caused the relatively milder presentation observed 
in type II BOCD. 
This phenomenon is not unique for BOCD. Gradations in the severity of a disease are 
also found in another syndrome arising from mutations in the PTHR1, namely Jansen’s 
metaphyseal chondrodysplasia (JMC)(20). This type of osteochondrodysplasia is caused by a 
constitutively activating mutation in the PTHR1 gene(4;6;11;21). The T140P mutation caused the 
classical form of JMC(11). Another mutation at the same amino acid position, T140R, resulted 
in ligand independent cAMP formation, which was less pronounced than observed with the 
T140P mutations(21). This became clinically evident in a less severe presentation of JMC(21). 
Heterogeneity in clinical manifestations due to the nature of the mutation is not only found 
in diseases arising from the PTHR1 gene. Several types of chondrodysplasia, including 
hypochondroplasia, achondrodysplasia and thanatophoric dysplasia (from less severe to most 
severe phenotype) arise from heterozygous mutations in the same gene, namely the Fibroblast 
Growth Factor (FGF) Receptor 3 (FGFR3)(22). In these diseases a strong correlation between 
genotype and phenotype has been found(23). 
Genotype-phenotype correlations have also been reported for campomelic dysplasia, a disease 
characterized by skeletal and also extra-skeletal abnormalities(24). This disease is caused by 
mutations in the Sox9 gene, the main transcription factor for chondrocyte development. 
Both homozygous and heterozygous mutations have been described(25;26). It has been stated 
that mutations, resulting in residual transactivation capacity of the transcription factor, may 
account for a milder phenotype and longer survival of patients(25).
Taken together, these data indicate that the impact of a mutation on the capacity of the receptor 
to activate downstream signalling pathways, critically determines the clinical presentation.
Regulation of PTHR1 signalling
In chapter 2 we showed that either the type or position of mutations in the PTHR1 resulted 
in distinct clinical features, due to complete or partial inactivation of the PTHR1. Partial 
inactivation resulted in residual activity of the PTHR1 and depending on the impact of 
the mutations, this residual activity could vary. This is also pronounced in patients with an 
activating mutation in the FGFR3, which can cause hypochondroplasia, achondrodysplasia 
and thanatophoric dysplasia(11;22). 
Two pathways are activated by FGFR signalling in chondrocytes, the Jak/Stat pathway and 
the extracellular signal regulated kinase (ERK) pathway(27;28). FGF is a potent inhibitor 
of chondrocyte proliferation and hypertrophic differentiation(29). The dominant pathway 
after FGFR signalling influencing chondrocyte proliferation is the Jak/Stat pathway. FGFR 
signalling results in the activation of Stat1. Subsequently, Stat1 induces the expression of the 
cell cycle inhibitor p21waf1/cip1, thereby inhibiting chondrocyte proliferation(29-31). 
The ERK pathway appears to be more important in the inhibition of hypertrophic 
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differentiation. Transgenic mice that express a constitutively active mutant of ERK kinase 
(Mek1) in chondrocytes, displayed incomplete hypertrophy of chondrocytes, but showed 
no effect on chondrocyte proliferation(32). Therefore, it has been hypothesized that FGFR 
signalling inhibits chondrocyte differentiation through the ERK pathway. Thus, the balance 
between the Jak/Stat pathway and the ERK pathway may adjust the effects of FGFR signalling 
on chondrocyte proliferation and differentiation(33). Diverse mutations in the FGFR3 may 
have distinct impacts on the activity of the two main signalling pathways, which may result in 
the heterogeneity of the clinical presentation of chondrodysplasia.
Signalling through two pathways is also important in PTHR1 signalling(3;34). Mouse knockout 
models have been generated to identify the functions of the two pathways that are activated by 
PTHR1 signalling in chondrocyte proliferation and differentiation. The two pathways are the 
adenylate (AC)/protein kinase A (PKA) and the phospholipase C beta (PLCβ)/protein kinase C 
(PKC) signalling pathway(3;34). Recently, it has been shown that chondrocyte specific knockout 
mice, carrying a mutation in the Gαs and thereby disrupting AC/PKA signalling, displayed a 
phenotype comparable to the PTHrP knockout mice(34;35). These mice had severe growth plate 
defects with reduction of the proliferative zone and accelerated chondrocyte differentiation. 
The opposite was demonstrated in mice carrying a mutant form of the PTHR1 (DSEL mice), 
which specifically interrupted signalling via the PLCβ/PKC pathway and signalled normally 
via the AC/PKA pathway(3). These mice showed an increase in chondrocyte proliferation 
and a decrease in chondrocyte differentiation. These results indicated that the AC/PKA is 
the dominant pathway after PTHR1 signalling in stimulating chondrocyte proliferation and 
inhibiting chondrocyte differentiation. In addition, these results showed that chondrocyte 
differentiation is stimulated by the activation of the PLCβ/PKC pathway. Thus, the two 
pathways had opposite effects on chondrocyte proliferation and differentiation. In addition, 
these results showed that a disbalance between these pathways after PTHR1 activation can 
result in altered chondrocyte proliferation and differentiation and can cause heterogeneity of 
diseases, which are caused by mutations in the PTHR1.
The phenotype of the DSEL mice, in which PTHR1 signalling via the PLCβ/PKC pathway 
was specifically interrupted, was remarkably similar to the phenotype displayed by a 
consanguineous family with a rare growth disorder, the Eiken syndrome(3;36). Eiken syndrome 
is caused by a homozygous mutation in the PTHR1 gene, resulting in a truncated PTHR1(5). 
The truncated protein only missed a small part of the C-terminus. Because of the comparable 
phenotype of the mice model, it is hypothesized that PTHR1 signalling through the PLCβ/
PKC pathway is disrupted. Eiken patients were considered normal at birth, but after a few 
months they developed a skeletal dysplasia, characterized by delayed ossification, principally 
of the epiphyses, the pelvis, the hands and the feet. Taken together, this indicates that the 
role of the PLCβ/PKC pathway becomes more pronounced after birth, while the AC/PKA 
pathway is the dominant pathway during prenatal growth, which has also been suggested 
previously(3;34). 
Normal development of the growth plate requires a balanced signalling between the two main 
signalling pathways of PTHR1. This balance could be influenced by adapter proteins, like the 
PDZ domains containing proteins, Nherf1 and Nherf2. Nherf1 and Nherf2 were first found 
in renal tubuli as regulators of ion channels(37). Further experiments revealed that the Nherf 
proteins not only bind to ion channels, but also to transcription factors, signalling molecules, 
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structural proteins and receptors(38;39). The binding of Nherf1 and Nherf2 to the PTHR1 and 
PLCβ is best studied in renal tubuli(38). 
In chapter 3 we showed that both Nherf1 and Nherf2 mRNAs were expressed in several organs 
using in situ hybridizations, which is in line with other studies(40;41). In addition, we demonstrated 
Nherf1 and Nherf2 mRNA expression during endochondral bone formation by growth plate 
chondrocytes and osteoblasts in the bone collar. To establish whether Nherf1 and Nherf2 
play a role in osteoblast and chondrocyte differentiation, Nherf1 and Nherf2 overexpressing 
KS483 cell lines were generated. Nherf1 and Nherf2 overexpression had distinct effects on 
the differentiation of osteoblasts and chondrocytes. While Nherf1 overexpression inhibited 
terminal osteoblast differentiation, Nherf2 overexpression stimulated terminal osteoblast and 
chondrocyte differentiation using matrix mineralization as a read out. The negative actions 
of Nherf1 in bone formation have been shown before in Nherf1 knockout mice(41). Some, but 
not all female Nherf1 knockout mice were dwarfs and they displayed severe osteoporosis and 
bone fractures. This is most likely a secondary effect. Nherf1 regulates phosphate transport by 
binding to the sodium/phosphate co-transporter type IIa (Npt2a)(41). In addition, Nherf1 null 
mice showed mild hypophosphatemia, which probably affected bone formation. However, 
our data suggests that the bone phenotype may also be explained partly by direct effects on 
osteoblastic matrix mineralization. Others have reported distinct functions for Nherf1 and 
Nherf2 in renal tubuli in the regulation of the Npt2(41-43). The different functions for Nherf1 
and Nherf2 might be explained by the recruitment of different molecules to form a membrane/
submembrane bound complex, displaying diverse actions(40;44-46). 
In chapter 3 we also showed that Nherf1 and Nherf2 overexpression did not change the 
actions of PTHR1 signalling on osteoblast en chondrocyte differentiation. We demonstrated, 
however, overexpression of Nherf1 and Nherf2 mRNA and it is likely that the Nherf1 and 
Nherf2 proteins are overexpressed as well, because both overexpressing cell lines displayed 
altered biological responses on osteoblast differentiation. Functional overexpression will 
probably induce a shift in the balance of PTHR1 signalling, since it has previously been 
shown that Nherf redirects PTHR1 signalling from the AC/PKA to PLCβ/PKC pathway in 
renal tubuli(38). An explanation for the fact that we did not demonstrate an effect of Nherf1 
or Nherf2 overexpression on PTHR1 signalling, could be inefficient coupling of Nherf1 and 
Nherf2 to the PTHR1 in osteoblasts and chondrocytes, in contrast to renal kidney cells. 
In addition, levels of PLCβ could be too low to affect the dominant AC/PKA pathway. The 
measurements of the activation of the AC/PKA pathway and the PLCβ/PKC pathway are 
currently underway.
Microarray and qPCR analysis
In chapter 4 and 5 we identified PTHrP target genes by performing microarray analysis. The 
microarrays, on which the NIA 15k mouse cDNA clone set(47) was spotted, were custom-
made. The quality of the spots of the cDNA microarray was low, due to heterogeneous spot 
morphologies (“doughnuts”), deposition inconsistencies, and oversized spots. In addition, the 
quality control of cDNA microarrays is a well-known problem(48;49). 
Halgren et al. reported a very high error rate of nearly 38% in the spots on cDNA microarrays(50). 
The spots did not contain the cDNAs expected, because of contamination. Also in our study, 
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all spots containing the regulated cDNAs were sequenced and even a larger error rate was 
found. Approximately 55% of the cDNAs were not the cDNAs expected (unpublished data). 
The contamination is most likely introduced during multiple rounds of replication of the 
bank by PCR, as previously suggested(50;51). Because of the uncertainty of the identity of the 
spots cDNA microarray analysis is not the ideal technique for pathway screening or genome 
wide analysis. For this purpose, commercially available oligonucleotide microarrays are much 
more reliable. cDNA microarray analysis is, however, a suitable technique for the identification 
of a subset of target genes, but only by applying very stringent selection criteria, by sequencing 
the regulated cDNAs, and by validation of regulated genes. 
Since the cDNA microarray is used extensively in nearly all areas of biomedical research, 
investigators should always be aware of any indications that there may be serious unreliability 
in the microarray data. In addition, a major focus of microarray data appears to be centred 
on the statistical treatment of microarray data, such as image analysis, normalization, and 
background subtraction. However, more attention should be given to artefacts generated by 
amplification of the cDNAs and investigators should be especially cautious when interpreting 
data obtained from cDNA microarrays. 
Microarray data, especially derived from cDNA microarrays, should be validated before 
jumping to conclusions. Bio-informatic analysis and techniques like Northern blot and qPCR 
analysis are mainly used for this purpose(52;53). In our study we used bio-informatic analysis 
and qPCR analysis in different cell models and we thereby showed the validity of a part of the 
microarray data. However, due to the distinct methodologies and the relative poor quality of 
the custom cDNA microarrays, the overlap was not 100%, which is in line with other studies(52-
54). In our study the overlap in expression pattern between microarray and qPCR analysis was 
57%. The expression pattern of the remaining genes differed only slightly between microarray 
analysis and qPCR analysis. In contrast to the expression patterns between microarray and 
qPCR analysis, which were comparable, the fold changes were dissimilar. A decrease, as well 
as an increase in fold change were demonstrated, which has also been reported by others(52-54). 
cDNA microarray analysis is not a quantitative method in contrast to qPCR and Northern 
blot. Therefore, direction of changes, but not fold changes, can be determined with cDNA 
microarray analysis. 
While the technical approach of qPCR is straightforward, the statistical analysis of qPCR 
data is less clear. A model providing computations for expression ratios and p-values in 
experiments in which all samples are run in triplicate in a single qPCR experiment, well 
organized in a single spreadsheet, is not available. For this purpose, we generated the double 
delta model (DDM), which is described in chapter 6. This model is derived from the 2-∆∆Ct 
method and the variance of the gene of interest as well as the variance of the reference is taken 
into account(55). The DDM is particularly useful when working with many samples, because 
the calculations of the ratios and the calculations of the p-values are well organized in a single 
spreadsheet. Because the DDM does not include corrections for qPCR efficiency, it can only 
be used when the amplification efficiencies of the target and reference gene are close to 1. The 





To unravel how PTHrP exerts its effects on growth plate chondrocytes, we have identified 
early and late PTHrP target genes, using cDNA microarray analysis. By applying very 
stringent criteria for data generation and by performing validation studies we have produced 
a small list of early (12) and late (9) PTHrP response genes. The list of early PTHrP response 
genes included 7 upregulated (RGS2, SGK, Upar, IER3, Ptp4a1, Stat3, and Csrp2) and 5 
downregulated (Sf3a2, Gab1, DYM, LamRI and Acvr2b) genes and the list of late response 
genes included 3 upregulated (IGFBP4, Csrp2, and Ecm1) and 6 downregulated (Col9a1, 
Col2a1, Agc, Hmgn2, Calm1, and Mxd4) genes. The majority of the early PTHrP response 
genes, 83%, were involved in signal transduction and regulation, compared to only 44% of the 
late PTHrP target genes. In addition, none of the early PTHrP response genes were structural 
proteins, compared to 44% of the late target genes. This is in agreement with the notion that 
the majority of early target genes are implicated in signal transduction and regulation and 
that most of late response genes code for structural proteins belonging to the extracellular 
matrix(54;56).
In chapter 4 we showed that the majority of early PTHrP effects were part of a more generalized 
response, not only restricted to chondrocytes, but also present in osteoblasts. In chapter 5 we 
demonstrated that the expression of most of the late response genes showed temporal and 
directional changes between the different cell models. This indicates that for studying the 
actions of PTHrP, the early response genes are most relevant. The late targets of PTHrP are 
not only manipulated by PTHrP treatment, but have also endured other influences, which 
are dependent of the cell type and environmental effects. This suggest that between early and 
late effects mechanisms must be operational that translate the PTHrP responses from a more 
generalized effect into a cell type and cellular context dependent effect. Results of other studies 
also indicate such a mechanism(54;56). The factors involved in this process are not known.
Transcription factor binding sites in promoters of PTHrP target 
genes
To identify common conserved regulatory elements involved in the expression regulation of 
early PTHrP target genes, we analyzed their promoter regions. We found several conserved 
transcription factor binding sites in various early target genes. Among these transcription 
factor binding sites were cAMP response elements (CRE) and AP-1 response elements. CREs 
can be bound by CRE binding proteins (CREB). CREB and AP-1 are the main transcription 
factors activated by the AC/PKA pathway after PTHR1 signalling(3;57). Remarkably, 6 out 7 of 
the upregulated genes in chondrocytes contained CREB transcription factor binding sites, 4 
times in combination with an AP-1 response element, and only 2 out of 5 of the down regulated 
genes in chondrocytes contained CREB transcription factor binding sites. In addition, these 
2 downregulated target genes were upregulated in osteoblasts. Comparable to our study 
were the predictions of CREB and AP-1 transcription factor binding sites predominantly 
in upregulated genes in a study by Qin et al.(58). They used a statistical approach to identify 
transcription factor binding sites used by PTH-signalling in osteoblasts instead of enrichment 
for evolutionary conserved binding sites applied in this paper. This suggests that CREB and 
AP-1 are predominantly involved in upregulation of transcription of PTHrP target genes. 
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Among downregulated genes by CREB after PTHR1 signalling is the transcription factor 
for osteoblast differentiation and hypertrophic chondrocyte differentiation, the runt related 
transcription factor 2 (Runx2)(59;60). The suppression of Runx2 transcription is primarily 
regulated through the AC/PKA signalling pathway(61). This effect is only partially mediated via 
CREB, suggesting that other transcription factors are involved in the negative regulation of 
Runx2 transcription and probably also in the transcription of other downregulated genes(61).
PTHrP and the interactions with other paracrine and endocrine 
signals
Endochondral bone formation is under the control of endocrine (systemic hormones) 
and paracrine (growth factors) factors(29;62-64). From the systemic hormones, the dominant 
regulator of endochondral bone formation is Growth Hormone (GH)(65). GH can act directly 
on the growth plate, via its receptor, which is expressed by growth plate chondrocytes(66). 
In addition, GH influences chondrocyte proliferation and differentiation indirectly via the 
induction of Insulin-like Growth Factor 1 (IGF-1)(67-69). It is likely that GH also controls the 
expression of other locally produced growth factors, for instance components of the Indian 
Hedgehog (IHh)/PTHrP negative feedback loop(62). In this thesis we provide evidence for the 
opposite, namely, the regulation of GH actions by PTHrP. Thus, the interaction between GH 
and PTHrP might be reciprocal. 
Besides GH, another important regulator of chondrocyte differentiation in the postnatal 
growth plate is estrogen. Its main actions are inducing the growth spurt at the beginning 
of puberty and stimulation of growth plate fusion at the end of puberty(70;71). While we 
demonstrated possible interactions between PTHrP and GH, no indications for interactions 
between PTHrP and estrogens were found in our limited data set.
In chapter 4 we demonstrated for the first time a crosstalk between PTHrP and members of 
the Jak/Stat family. PTHrP induced the mRNA expression of Stat3, Stat5a, Stat5b, and Csrp2. 
Csrp2 is a binding partner of PIAS1, which is an inhibitor of Stat1(72). In addition, several 
conserved Stat transcription factor binding sites were predicted in the early PTHrP response 
genes. Furthermore, PTHrP influenced posttranslational activation of Stat3, Stat5a, and Stat5b. 
Interestingly, activation of Stat3 was increased, while the activation of Stat5a and Stat5b was 
decreased. Both the increased activity of Stat3 and the decreased activity of Stat5a and Stat5b 
after AC\PKA signalling have already been demonstrated before in other cell types(73;74). 
Stat5b is the most important Stat protein in GH signalling, with respect to longitudinal 
growth(75;76). GH induces IGF-1 expression through Stat5b and IGF-1 stimulates chondrocyte 
proliferation and differentiation(69;77). By inhibiting Stat5b activity, PTHrP may diminish the 
positive actions of GH on chondrocyte proliferation and differentiation. Thus, we found that 
paracrine factors, in our study PTHrP, may influence the actions of endocrine signals, in 
our study GH. Our experiments were not set up to investigate whether endocrine signals 
influenced the actions of paracrine factors. This suggests that if indeed endocrine signals exert 
their effects by modulating paracrine factors, like PTHrP, it is not a one-way direction, but a 
reciprocal interaction.
Most Stat proteins are also involved in FGFR signalling. The negative regulation of 
chondrocyte proliferation by FGFR signalling is mediated through Stat1, by inducing the 
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expression of cell cycle inhibitor p21waf1/cip1(30;31). Stat1 activation is inhibited by PIAS1, which 
is a binding partner of Csrp2(72). By inducing the expression of Csrp2 (chapter 4 and 5), 
PTHrP could alleviate the inhibitory actions of PIAS1 on Stat1 and thereby increasing the 
negative regulation of chondrocyte proliferation. The inhibitory actions of FGFR signalling 
on chondrocyte differentiation is mediated through the ERK pathway(32). No indications for 
interactions between PTHrP and the ERK pathway were found in our limited data set.
The role of PTHrP in the growth plate is regulating the transition of proliferating into 
hypertrophic chondrocytes and thereby keeping the chondrocytes in a proliferative competent 
stage(78). It has been shown that p57, a member of the CIP/KIP family of inhibitors of cyclin-
dependent kinases, is one of the major mechanism used by PTHrP to maintain chondrocyte 
proliferating and delay their differentiation(79;80). Studies with transgenic mice demonstrated 
that the level of PTHrP is very important in normal endochondral bone formation. Both mice 
with ablation of the PTHrP gene or ectopic expression of PTHrP showed severe dwarfism(35;81). 
The expression of PTHrP is tightly controlled. This is accomplished by IHh(62).
In this study we provide evidence that the biological actions of PTHrP might also be controlled 
by other regulators of endochondral bone formation. PTHrP may influence the signalling 
pathways of FGF and GH, thereby probably counteracting its positive effect on chondrocyte 
proliferation, but possibly enhancing its negative effect on chondrocyte differentiation (fig. 
1). PTHrP might affect the actions of FGF signalling on chondrocyte proliferation and the 
actions of GH signalling on both chondrocyte proliferation and differentiation, through 
influencing Jak/Stat signalling. Through inhibition of the activity of Stat5b by PTHrP, IGF-1 
expression may be diminished, presumably resulting in a decrease of chondrocyte proliferation 
and differentiation. In addition, by inducing Csrp2 expression, PTHrP is potentially able to 
alleviate the inhibition of PIAS1 on Stat1 activity. This may result in a decrease of chondrocyte 
proliferation. Experiments to establish whether Stat1 is directly activated by PTHR1 signalling 
are currently underway. In addition, conflicting data have been reported about Stat3 
phosphorylation after FGF activation. Hart et al. found that FGFR signalling could activate 
Stat3 in the fibroblast cell line NIH3T3, however, another study using rat chondrosarcoma cells 
(RCS), revealed that FGF treatment had no effect on Stat3 phosphorylation(30;82). Therefore, 
the role of Stat3 after FGF activation in this model is unclear.
The transition of proliferating chondrocytes into hypertrophic chondrocytes is under the 
control of the IHh/PTHrP negative feedback loop(62). It has been proposed that FGF and BMP 
signalling affects the negative feedback loop. They show opposite effects on the expression 
of IHh, on chondrocyte proliferation and on terminal differentiation(29;63). These actions are 
believed to be independent of the IHh/PTHrP pathway(29). By showing that PTHrP influenced 
the Jak/Stat pathway, which signalling molecules are intracellular mediators of FGF signalling, 
we provide evidence that a cross talk between PTHrP and FGF signalling may exist. 
Final remarks
PTHrP is an essential growth factor in the regulation of growth plate chondrocyte development. 
It works, however, in a complex environment of other growth factors and endocrine signals, 
which can influence either their own or each others expression and activity. Thus, the overall 
effect of the actions of systemic hormones and locally acting growth factors on chondrocyte 
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proliferation and differentiation is the result of the activation of signalling pathways and the 
interactions between them. The occurrence and intensity of specific signalling responses 
depend upon many factors that may be controlled directly or indirectly by the environment 
of the chondrocyte. These may include the level of receptor expression, the abundance 
of adaptor or scaffolding proteins, for instance Nherf, or the expression and activity of 
downstream kinases and their substrates. In addition, interactions with adjacent cells or with 
the extracellular matrix could also influence the response to systemic hormones or growth 
factors.
In the past, most studies have focussed on the actions of a single gene. With the rapid 
advancements in technology, a growing number of studies are using techniques to determine 
a wide range of target genes. Among these techniques is genome wide analysis, but another 
increasing field of interest is the field of bioinformatics and the use of computer models. By 
using these techniques, the connections between the target genes will lead to new insights. 
FGFs PTHrP GH










Figure 1: positive and negative actions of PTHrP on chondrocyte proliferation and differentiation. 
PTHrP exerts its positive effects on chondrocyte proliferation through the suppression of p57 expression. We hypothesize that PTHrP 
may also have negative effects on chondrocyte proliferation, through influencing the signalling pathways of FGF and GH and may 
enhance its negative effect on chondrocyte differentiation, through influencing the GH signalling pathway. PTHrP is potentially able 
to alleviate the inhibition of PIAS1 on Stat1 activity by inducing the expression of Csrp2. The negative actions of Stat1 on chondrocyte 
proliferation after FGF activation may be enhanced through inhibition of p21. GH induces IGF-1 expression through Stat5b activa-
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Longitudinal growth is the key characteristic that distinguishes children from adults. Growth 
is regulated in the growth plates, which are layers of cartilage located at the ends of the long 
bones. The cartilage cells are called chondrocytes and go through a coordinated program 
of proliferation, maturation, hypertrophic differentiation, apoptosis and replacement by 
bone. This process is called endochondral bone formation. A complex network of hormones 
(endocrine regulators) is involved in this process. The mechanism of actions of these hormones 
is not completely understood. A possible mechanism of action is the interaction of systemic 
hormones with locally produced growth factors (paracrine regulators), like the Parathyroid 
Hormone (PTH) related Peptide (PTHrP) and its receptor, the type 1 PTH/PTHrP receptor 
(PTHR1). PTHrP and PTHR1 are among the key regulators in the process of endochondral 
bone formation. The working mechanism of PTHrP signalling, alone or in combination with 
other growth factors or systemic hormones, in endochondral bone formation is not completely 
understood. In this thesis, we have further addressed the actions of PTHrP in the complex 
network of endocrine and paracrine regulation of endochondral bone formation.
Disruption of PTHR1 signalling, caused by a loss of function mutation in the PTHR1 gene, 
results in the human in Blomstrand Osteochondrodysplasia (BOCD). BOCD can be divided 
into two types, depending on the severity of the skeletal abnormalities, with type 1 as the most 
severe form. The molecular basis for the heterogenic presentation is unknown. In chapter 
2 the underlying causative factor of this heterogeneity in clinical presentation of BOCD is 
addressed. We performed mutation analysis in 2 families with type I BOCD and in 3 families 
with the less severe form, type II BOCD. The latter group includes 1 case that has not been 
described before. In one of the type I BOCD cases a nonsense mutation (R104X) was found, 
resulting in a truncated PTHR1, while in the second type I BOCD case no receptor mutation 
was identified. A splicing defect (intronM4+27C>T) was demonstrated in one of the type II 
BOCD cases. In the other 2 families with type II BOCD a previously identified missense P132L 
mutation was found. Functional analysis demonstrated a near complete inactivation of the 
PTHR1 with low residual activity in the type II BOCD cases. In combination with published 
data , we concluded that a complete inactivation of the PTHR1 causes type I BOCD, whereas 
the relatively milder presentation of type II BOCD is caused by low levels of residual activity 
due to a near complete inactivation of the PTHR1.
In chapter 3 we investigated the role of the adaptor proteins for the PTHR1, the PDZ 
domain containing proteins Na+/H+ exchanger regulatory factor 1 (Nherf1) and Nherf2, 
in endochondral bone formation and PTHR1 signalling. Using in situ hybridization we 
showed that Nherf1 and Nherf2 mRNAs are expressed during endochondral bone formation 
by osteoblasts in the bone collar and by chondrocytes in the growth plate. In addition, 
overexpression of Nherf1 and Nherf2 in KS483 mesenchymal progenitor cells resulted in 
opposite effects on terminal osteoblast differentiation. Nherf1 overexpression inhibited, while 
Nherf2 overexpression stimulated matrix mineralization. Cartilage matrix mineralization 
was increased in the Nherf2, but not in the Nherf1 overexpressing cell line. Overexpression 
of Nherf1 or Nherf2 had no effect on the production of early chondrocyte markers, the 
glycosaminoglycans (GAGs). PTHrP inhibited osteoblastic matrix mineralization and GAG 
production in chondrocytes. Overexpression of Nherf1 or Nherf2 did not change the effect 
of PTHrP treatment on osteoblast and chondrocyte differentiation. We concluded that the 
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distinct actions of Nherf1 and Nherf2 are probably due to the recruitment of different target 
molecules, like transcription factors, receptors and signalling molecules.
We used the chondrogenic ATDC5 cell line and performed cDNA microarray analysis to 
identify early PTHrP response genes in chondrocytes and to recognize interactions with other 
regulatory factors in chapter 4. For this purpose, ATDC5 cells were treated for 1, 2, and 4 
hours with PTHrP. By applying very stringent criteria for data generation and by performing 
validation studies we have produced a small list of early PTHrP response genes, including 7 
upregulated (RGS2, SGK, Upar, IER3, Ptp4a1, Stat3, and Csrp2) and 5 downregulated (Sf3a2, 
Gab1, DYM, LamRI and Acvr2b) genes. The majority of these genes were implicated in signal 
transduction and regulation. The early response genes were part of a generalized response to 
PTHrP, since they were also identified as PTHrP response genes in osteoblasts. The majority of 
the upregulated early response genes contained CREB and AP-1 transcription factor binding 
sites in their promoter regions, suggesting that CREB and AP-1 are predominantly involved 
in upregulation of transcription of PTHrP target genes. Among the early response genes 
were mediators of the Janus Kinase (Jak)/Signal transducer and activator of transcription 
(Stat) pathway. In addition, several Stat transcription factor binding sites were predicted 
in the promoter regions of the early response genes. Furthermore, in transient transfection 
assays we showed that PTHrP positively regulated the posttranslational activity of Stat3 and 
negatively regulated the posttranslational activity of Stat5a and Stat5b. This data is suggestive 
for a previously not recognized interaction between PTHrP and Jak/Stat signalling.
In chapter 5 the identification of late PTHrP target genes using the ATDC5 cell line and 
cDNA microarray analysis is described. For the identification of late PTHrP target genes the 
ATDC5 cells were treated for 24 and 72 hours with PTHrP. By applying very stringent criteria 
for data generation and by performing validation studies we have produced a small list of 
late PTHrP target genes. The list of late response genes included 3 upregulated (IGFBP4, 
Csrp2, and Ecm1) and 6 downregulated (Col9a1, Col2a1, Agc, Hmgn2, Calm1, and Mxd4) 
genes. The majority of the late response genes code for structural proteins belonging to the 
extracellular matrix. The expression of late PTHrP response genes varied between different 
cell types, suggesting that the expression of late response genes is dependent on the cellular 
context of the PTHrP responsive cells.
The early and late response genes were validated by quantitative PCR (qPCR) analysis. While 
the technical approach of qPCR is straightforward, the statistical analysis of qPCR data is less 
clear. We developed the Double Delta Model (DDM) to calculate p-values and confidence 
bands in data derived from qPCR analysis, which is described in chapter 6.
In chapter 7 the major findings of this thesis are summarized and critically reviewed in relation 
to current literature. These findings include the discussion of the quality of cDNA microarrays 
and the interactions of PTHrP with other regulators of endochondral bone formation.
Samenvatting (Summary in Dutch)
Lengtegroei is één van de belangrijkste verschillen tussen kinderen en volwassenen. De 
groei wordt gereguleerd in de groeischijven. De groeischijven bevinden zich aan de distale 
uiteinden van de pijpbeenderen en bestaan uit kraakbeen. De cellen in de groeischijf worden 
kraakbeencellen of chondrocyten genoemd. Deze chondrocyten doorlopen een gecontroleerd 
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programma van celdeling (proliferatie), maturatie, differentiatie en geprogrammeerde celdood 
(apoptose). Dit proces eindigt met de vervanging van het kraakbeen door bot en wordt 
endochondrale botvorming genoemd. Een complex netwerk van hormonen (endocriene 
regulatoren) is betrokken bij de regulatie van dit proces. Hoe deze regulatie precies verloopt 
is nog niet helemaal duidelijk. Een mogelijk mechanisme zou kunnen zijn, dat hormonen 
de activiteit van locaal geproduceerde groeifactoren (paracriene regulatoren) beïnvloeden, 
bijvoorbeeld door het reguleren van het “Parathyroid Hormone (PTH) related Peptide” 
(PTHrP) en de bijbehorende type 1 PTH/PTHrP receptor (PTHR1). PTHrP and PTHR1 
behoren tot de groep van belangrijkste regulatoren binnen het proces van de endochondrale 
botvorming. Het mechanisme waarmee PTHrP endochondrale botvorming reguleert, alleen 
of in combinatie met hormonen, is nog niet helemaal duidelijk. In dit proefschrift hebben we 
de werking van PTHrP binnen het complexe netwerk van endocriene en paracriene regulatie 
van de endochondrale botvorming verder uitgediept.
Een homozygote inactiverende mutatie in het PTHR1 gen, waardoor een onderbreking ontstaat 
in de signaalroute van de PTHR1, leidt in de mens tot Blomstrand Osteochondrodysplasia 
(BOCD). Afhankelijk van de ernst van de afwijkingen in het skelet wordt deze ziekte in 
twee types verdeeld, waarbij type I de meest ernstige vorm is. De moleculaire basis voor 
deze heterogene presentatie is niet bekend. In hoofdstuk 2 hebben we dit onderzocht met 
behulp van mutatie analyse in 2 families met type I BOCD en in 3 families met de minder 
ernstige vorm, type II BOCD. Deze laatste groep bevat een familie, die in hoofdstuk 2 voor 
het eerst wordt beschreven. In één van de type I BOCD families werd een nonsense mutatie 
(R104X) gevonden, wat resulteerde in een “getrunkeerd” PTHR1 eiwit. In de tweede type 
I BOCD familie werd geen mutatie in het PTHR1 gen geïdentificeerd. Een splicingsfout 
(intronM4+27C>T) werd gevonden in één van de type II BOCD families. De andere twee 
families met type II BOCD hadden de P132L missense mutatie in het PTHR1 gen. Deze 
mutatie is al eerder beschreven. Functionele analyse liet in de type II BOCD families een 
bijna complete inactivatie van de PTHR1 met lage restactiviteit zien. In combinatie met reeds 
gepubliceerde data hebben we geconcludeerd dat een complete inactivatie van de PTHR1 
leidt tot type I BOCD en dat type II BOCD veroorzaakt wordt door een lage restactiviteit van 
de receptor, wat komt door een niet geheel complete inactivatie van de PTHR1.
In hoofdstuk 3 hebben we de rol van de adaptor eiwitten voor de PTHR1, de PDZ domein 
bevattende eiwitten “Na+/H+ exchanger regulatory factor 1” (Nherf1) en Nherf2, in 
endochondrale botvorming en in PTHR1 signalering onderzocht. Met behulp van in situ 
hybridisatie hebben we laten zien dat de Nherf1 en Nherf2 mRNAs tot expressie worden 
gebracht gedurende endochondrale botvorming, in de bot aanmakende cellen (osteoblasten) 
in de botkoker en in de chondrocyten in de groeischijf. Daarnaast hebben we laten zien dat 
overexpressie van Nherf1 en Nherf2 in KS483 mesenchymale voorlopercellen resulteerde in 
tegenovergestelde effecten in terminale osteoblast differentiatie. Nherf1 overexpressie remde 
de matrix mineralisatie, terwijl Nherf2 overexpressie deze stimuleerde. De mineralisatie van 
de kraakbeenmatrix was eveneens toegenomen door overexpressie van Nherf2, maar niet 
door overexpressie van Nherf1. Overexpressie van Nherf1 of Nherf2 veranderde de productie 
van de vroege chondrocyte markers, de glycosaminoglycanen (GAGs), niet. PTHrP remde de 
mineralisatie van de botmatrix en remde de GAG productie door chondrocyten. Overexpressie 
van Nherf1 of Nherf2 veranderde dit effect van PTHrP op osteoblast en chondrocyte 
Chapter 8
150
differentiatie niet. De afwijkende effecten van Nherf1 en Nherf2 worden mogelijk veroorzaakt 
door de interactie met verschillende target moleculen, zoals transcriptie factoren, receptoren 
en signaal moleculen. 
In hoofdstuk 4 hebben we gebruikt gemaakt van ATDC5 cellen, die te beschouwen zijn als 
voorlopercellen van chondrocyten, en cDNA microarray analyse om vroege PTHrP respons 
genen in chondrocyten te identificeren en om interacties met andere regulatiefactoren 
te vinden. Voor het identificeren van vroege PTHrP respons genen, zijn de ATDC5 cellen 
voor 1, 2 en 4 uur gestimuleerd met PTHrP. Door gebruik te maken van zeer strenge selectie 
criteria en door het doen van validatie studies hebben we een kleine lijst met vroege PTHrP 
respons genen kunnen maken. Deze lijst bestond uit 7 opgereguleerde (RGS2, SGK, Upar, 
IER3, Ptp4a1, Stat3 en Csrpe) en 5 downgereguleerde (Sf3a2, Gab1, DYM, LamRI en Acvr2b) 
genen. Het grootste deel van deze genen is betrokken bij de regulatie van signaaltransductie. 
De vroege respons genen maken deel uit van een meer algemene PTHrP respons, omdat deze 
genen ook in osteoblasten zijn gevonden als vroege PTHrP respons genen. In de promoter 
regionen van de meeste opgereguleerde vroege PTHrP respons genen hebben we CREB en 
AP-1 transcriptiefactor bindingsplaatsen gevonden. Dit suggereert dat CREB en AP-1 bovenal 
betrokken zijn bij de opregulatie van transcriptie van PTHrP respons genen. De groep 
van vroege respons genen bevatte eveneens genen die betrokken zijn bij de “Janus Kinase” 
(Jak)/”Signal transducer and activator of transcription” (Stat) signaalroute. Ook werden 
verschillende Stat transcriptie factor bindings domeinen voorspeld in de promoter regionen 
van de vroege respons genen. Daarnaast hebben we laten zien, door gebruik te maken van 
transiente transfectie analyses, dat PTHrP de posttranslationele activiteit van Stat3 positief 
beïnvloedde en dat PTHrP de posttranslationele activiteit van Stat5a en Stat5b negatief 
beïnvloedde. Deze bevindingen zijn suggestief voor een niet eerder gevonden interactie 
tussen PTHrP en Jak/Stat signalering.
In hoofdstuk 5 hebben we late PTHrP respons genen geïdentificeerd, door gebruik te maken 
van ATDC5 chondrocyte voorlopercellen en cDNA microarray analyse. Om late PTHrP 
respons genen te identificeren, zijn de ATDC5 cellen voor 24 en 72 uur gestimuleerd met 
PTHrP. Door gebruik te maken van zeer strenge selectie criteria en door het doen van validatie 
studies hebben we een kleine lijst met late PTHrP respons genen kunnen maken. Deze lijst 
bestond uit 3 opgereguleerde (IGFBP4, Csrp2 en Ecm1) en 6 downgereguleerde (Col9a1, 
Col2a1, Agc, Hmgn2, Calm1 en Mxd4) genen. Het grootste deel van de late repons genen 
codeerde voor structurele eiwitten behorende tot de extracellulaire matrix. De expressie van 
de late PTHrP respons genen verschilde tussen celtypes, wat suggereerde dat de expressie van 
late response genen afhankelijk is van de cellulaire context van de PTHrP responsieve cellen.
De vroege en late PTHrP repons genen zijn gevalideerd met behulp van kwantitative PCR 
(qPCR) analyse. De technische procedure van qPCR is duidelijk. De statistische analyse van 
qPCR data daarentegen is minder duidelijk. Om p-waarden en betrouwbaarheids intervallen 
te berekenen in data van qPCR analyse, hebben we het “Double Delta Model” (DDM) 
ontwikkeld. Dit is beschreven in hoofdstuk 6.
Tenslotte zijn in hoofdstuk 7 de belangrijkste bevinden van dit proefschrift samengevat en 
bediscussieerd in het licht van de bestaande literatuur. Deze bevindingen omvatten onder 
andere de discussie over de kwaliteit van de cDNA microarrays en de interacties van PTHrP 
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